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Abstract
Pekka Rapeli, Cognitive function in opioid substitution treated patients. Associa-
tions with drug treatment variables. National Institute for Health and Welfare. Re-
search 130. 174 pages. Helsinki, Finland 2014.
ISBN 978-952-302-223-2 (printed); ISBN 978-952-302-224-9 (online publication)
Opioid-substitution treatment (OST) with the long-acting opioid agonist bu-
prenorphine or methadone has proven to be the most effective treatment for opi-
oid-dependence. The duration of treatment is typically years or even decades. 
Thus, the psychosocial rehabilitation of patients needs to be initiated simultane-
ously with drug treatment. Rehabilitation may include education, participation in 
employment programs, or getting a driver’s license. Patients, their signiﬁcant oth-
ers, or the treatment team are often perplexed by the goal-setting of rehabilitation. 
It is not uncommon for them to think that an opioid-substitution drug as such 
would negatively affect mental capacities and therefore the rehabilitation goals 
need to be set low. On the basis of ﬁndings made in this thesis, a more optimistic 
view about the cognitive competence of OST patients is better founded.
In this thesis, cognitive performance of OST patients was examined by at-
tention, working memory, and episodic memory tests. The participants also com-
pleted a memory complaint questionnaire. Patients who had recently entered OST 
were examined three times within the ﬁrst year in the OST. Normal control par-
ticipants did the tests at similar intervals. Fourteen buprenorphine and 12 metha-
done patients and 14 normal controls were examined at each time points (T1, T2, 
and T3). The largest study examined drug treatment variables as predictors of cog-
nitive performance by using data from 104 patients. The ﬁnal study was a case se-
ries examining driving ﬁtness using data from 22 patients. 
Methadone patients performed worse in many attention-related reaction time 
tasks in relation to normal controls or buprenorphine patients. In each OST drug 
group, approximately 10% of the attention performance could be predicted by 
drug treatment variables. In working memory both drug groups were impaired rel-
ative to controls in most tests. Improvement of working memory function in one 
test among buprenorphine patients between T2 and T3 was an exception. In the 
regression analysis, use of benzodiazepine (BZD) medication predicted impaired 
working memory performance. In episodic memory tests both drug groups lagged 
behind controls, although not all differences were statistically signiﬁcant. Treat-
ment with more than one other psychoactive drug (than opioid or BZD) and fre-
quent substance abuse during the past month predicted about 20% of verbal epi-
sodic memory performance. Subjective memory problems were common in OST 
patients. In an on-road driving test all except one of 22 OST patients were found 
to be ﬁt to drive a car. 
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The close to normal cognitive performance in stable OST patients supports 
the idea of efﬁcient compensation of the neural burden that is related to their pre-
vious opioid abuse history. This compensation may not be as efﬁcient among those 
with recent frequent substance use or with concurrent psychoactive polypharma-
cy. The results of these studies bring relevant new information for patients and pre-
scribers when choosing between different pharmacological and non-pharmaco-
logical treatment options. Also, the results may encourage OST patients for setting 
education and employment goals with normal cognitive demands. 
Keywords: opioid use disorder, neurocognition, opioid agonist therapy
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Tiivistelmä
Pekka Rapeli, Cognitive function in opioid substitution treated patients. Associa-
tions with drug treatment variables [Kognitiiviset toiminnot opioidiriippuvuuden 
korvaushoitopotilailla: Yhteydet lääkemuuttujiin]. Terveyden ja hyvinvoinnin lai-
tos. Tutkimus 130. 174 sivua. Helsinki, Finland 2014.
ISBN 978-952-302-223-2 (painettu); ISBN 978-952-302-224-9 (verkkojulkaisu)
Opioidiriippuvuuden korvaushoidossa on tällä hetkellä n. 2400 suomalaista henki-
löä. Aivojen opioidireseptoreita pitkäaikaisesti aktivoiva korvaushoitolääkitys bup-
renorﬁinilla tai metadonilla ei aiheuta päihtymystä, mutta vähentää merkittäväs-
ti opioidien väärinkäyttöä. Korvaushoito onkin todettu tehokkaimmaksi tavaksi 
hoitaa opioidiriippuvuutta.   Tyypillisesti hoito kestää vuosia tai vuosikymmeniä 
ja potilaiden psykososiaalinen kuntoutus on syytä aloittaa samanaikaisesti lääke-
hoidon kanssa. Kuntoutukseen voi kuulua koulutuksen täydentäminen, työllisty-
minen ja ajokortin hankkiminen.   Potilailla ja heidän asioitaan hoitavilla tahoilla 
on usein epätietoisuutta kuntoutuksen mahdollisuuksista. Ajatellaan esimerkiksi, 
että korvaushoitolääkitys heikentää tiedonkäsittelyn suoriutumisedellytyksiä ja ta-
voitetasoa on siksi laskettava.   Tämän väitöskirjan tulosten perusteella melko op-
timistinen arvio korvaushoitopotilaiden tiedonkäsittelystä on paremmin perustel-
tavissa.  
Tässä väitöskirjassa tutkittiin korvaushoitopotilaiden kognitiivista suoriutu-
mista eli tiedonkäsittelyä tarkkaavuutta, työmuistia ja tapahtumamuistia arvioi-
villa testitehtävillä. Lisäksi osallistujat arvioivat omaa kokemustaan muististaan eli 
subjektiivista muistia. Hoidon äskettäin aloittaneiden potilaiden suoriutumista ar-
vioitiin kolme kertaa ensimmäisen hoitovuoden aikana. Verrokkiryhmänä käytet-
tiin normaaliväestöä edustavia verrokkeja. Kaikkiin seurantapisteisiin osallistui 14 
buprenorﬁinilla ja 12 metadonilla hoidettua potilasta ja 14 verrokkia. Laajimmas-
sa tutkimuksessa selvitettiin, kuinka hyvin lääkemuuttujat ennustavat vähintään 
puoli vuotta hoidossa olleiden potilaiden kognitiivista suoriutumista (n=104). Vii-
meisimmässä tutkimuksessa arvioitiin 22:n korvaushoidossa olevan potilaan ajo-
kykyä.  
Metadonipotilaat suoriutuvat verrokkeja ja buprenorﬁinipotilaita heikommin 
useissa tarkkaavuuttaa arvioivissa reaktioaikatehtävissä. Regressionanalyysissa, jo-
ka tehtiin erikseen molemmille potilasryhmille, lääkemuuttujat ennustivat kum-
massakin ryhmässä n. 10 % vireystilaa arvioivien reaktioaikojen vaihtelusta. Työ-
muistitehtävissä molemmat potilasryhmät suoriutuivat verrokkeja heikommin 
useimmissa testipisteissä. Buprenorﬁiinipotilailla havaittiin seurannan aikana toi-
sessa työmuistitehtävässä tilastollisesti merkitsevää suoriutumisen kohentumis-
ta. Bentsodiatsepiinilääkityksen käyttö ennusti heikkoa työmuistisuoriutumis-
ta. Muistitehtävissä havaittiin molempien potilasryhmien suoriutuvan verrokkeja 
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heikommin, mutta suoriutumisen erot eivät aina yltäneet tilastollisesti merkitse-
viksi. Viimeisen kuukauden aikainen keskimäärin vähintään kolmena päivänä vii-
koittain tapahtuva päihteidenkäyttö sekä runsas muu psyykenlääkitys kuin opioi-
di- tai bentsodiatsepiinilääkitys ennustivat n. 20 % kielellisen muistin vaihtelusta. 
Potilaat kokivat subjektiivisen muistinsa selvästi verrokkeja heikommaksi. Ajoko-
keessa kaikki paitsi yksi potilas 22:sta todettiin kykeneväksi ajamaan henkilöautoa. 
Potilailla havaittu lähelle normaalia yltävä suoriutuminen tukee käsitystä, 
jonka mukaan ihmisen keskushermostolla on hyvä kyky korvata opioidien väärin-
käyttöhistoriaan liittyviä tiedonkäsittelytoimintojen haittavaikutuksia. Niillä po-
tilailla, joilla viimeaikainen päihteidenkäyttö tai samanaikainen muu ajankohtai-
nen keskushermostolääkitys on runsasta, tiedonkäsittelypuutosten korvaaminen ei 
näyttäisi onnistuvan yhtä hyvin. Tuloksilla arvioidaan olevan merkitystä, kun po-
tilaat ja hoitotahot pohtivat lääkkeellisiä ja ei-lääkkeellisiä hoitovaihtoehtoja. Tu-
lokset voivat myös kannustaa potilaita pyrkimään tiedonkäsittelyvaatimuksiltaan 
normaaleihin koulutuksiin ja työpaikkoihin.   
Avainsanat: opioidiriippuvuus, korvaushoito, kognitiivinen suoriutuminen
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1 Introduction
Opioid dependence means, in general, uncontrolled use of opioids despite negative 
consequences. Opioid abuse is a worldwide problem affecting 0.4% of the popula-
tion over 15 years (“UNODC, World Drug Report ”, 2013). Globally, heroin is still 
largely the most abused opioid. However, prevalence of abuse of prescription drugs 
such as buprenorphine, methadone, or oxycodone has surpassed heroin abuse in 
many countries. For instance, according to the latest Finnish statistics, about two 
thirds of those patients seeking treatment for opioid abuse are using mainly phar-
maceutical opioids, with about half using buprenorphine (Subutex) intravenous-
ly (Varjonen, Tanhua, Forsell, & Perälä, 2012). Typically individuals who seek treat-
ment for opioid dependence have a long history of substance abuse that started 
with other substances of abuse (Ross et al., 2005). Prescription opioids are often 
used along with other drugs or alcohol (Fischer et al., 2005). Thus, these individ-
uals are in fact polysubstance abusers. In some rare cases, abuse of opioid drugs 
started as normal medical use of opioid drugs for pain relief, which then turned in-
to abuse. Surveys have shown that among those who are given prescription opioids 
for chronic pain the prevalence of opioid abuse is between 2–6 % (Fields, 2011). 
Opioid abuse is notorious for its high mortality rate, which is at least three 
times, and in some cases up to 50 times higher, than in the general population 
(Bargagli et al., 2006). Eventually most opioid abusers want a safer life without un-
controlled use of opioids. However, long-term abstinence from opioid-depend-
ence is not easily achieved. Patients entering non-opioid treatment for opioid-de-
pendence usually resume their opioid abuse (Kakko, Svanborg, Kreek, & Heilig, 
2003). Instead, when opioid-dependent patients are admitted for opioid-substitu-
tion treatment (OST), also known as opioid maintenance treatment, in which they 
are given a slow-releasing opioid agonist orally, such as buprenorphine or metha-
done, treatment retention is high; many users stop illicit opioid use (Kakko et al., 
2007). During OST, mortality of opioid-dependent individuals reduces steeply, but 
it rises again steeply if treatment is stopped (Cornish, Macleod, Strang, Vickerman, 
& Hickman, 2010; Degenhardt et al., 2009). It has been shown that OST is many 
times more cost-effective than no treatment (Connock et al., 2007). Consequent-
ly, most countries around the world have adopted OST as a treatment for opioid-
dependence. 
Some opioid-dependent patients, however, experience cognitive function 
problems during OST. In one survey half of OST patients complained about recent 
attention and memory problems while in another survey a third complaint about 
“troubles thinking clearly” or “confusion”(Dursteler-MacFarland et al., 2010; Dy-
er & White, 1997). This should be taken seriously as drug-dependent patients ex-
periencing difﬁculties with concentrating and remembering have a poor treatment 
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Cognitive function in opioid substitution treated patients 
prognosis (Fiorentine, Nakashima, & Anglin, 1999; Gossop, Stewart, & Marsden, 
2003). Thus, it is important to objectively study cognitive function of OST patients 
and its correlates. 
In addiction studies, cognitive functioning is often conceptualized as control 
of behavior or simply as cognitive control (Cheetham, Allen, Yuecel, & Lubman, 
2010; Garavan & Weierstall, 2012). In this thesis cognitive function refers to cog-
nitive functioning in real-life and cognitive performance refers to the performance 
in standardized neuropsychological tests. Cognitive function (for example mem-
ory functioning) correlates well with cognitive performance (memory test score), 
but these are not equivalent. 
1.1 Substance use disorders
1.1.1 Addiction defined: diminshed control and behavioral  
changes
In order to deﬁne addiction it is relevant to ﬁrst consult with the addicted indi-
viduals themselves. One of the few studies adopting this approach achieved the 
following written deﬁnitions from a highly experienced sample of abstinent male 
inmates (Walters & Gilbert, 2000). The most cited deﬁnition was “diminished con-
trol over substance use”, followed by “need for survival”, “urge or craving”, “depend-
ence, psychological”, and “immediate gratiﬁcation”. In sum, an individual with a 
serious substance use problem commonly experiences diminished control over 
needs and urges. 
In the ﬁeld of medicine, addiction is considered a psychiatric diagnosis and re-
ferred to as dependence. Current deﬁnitions for dependence are given in the Inter-
national Classiﬁcation of Diseases, 10th version (ICD-10) or in the Diagnostic and 
Statistical Manual of the American Psychiatric Association, 4th version (DSM-IV) 
(Saunders, 2006). The common element in both classiﬁcations includes meeting 
three or more dependence sub-criteria that occur within a speciﬁed time frame: 
These include: (1) tolerance to the effects of substance abuse for achieving intoxi-
cation, or markedly diminished effects with continued use; (2) withdrawal symp-
toms that are speciﬁc to the substance being used; (3) impaired control over sub-
stance abuse; (4) neglect of important activities; (5) time spent in substance-related 
activity; (6) continued use despite adverse physical or psychological consequenc-
es; and (7) compulsive use or strong desire to use the substance. The last criterion 
is not included in the DSM-IV, and there are also other small differences between 
these deﬁnitions. However, both diagnostic deﬁnitions are highly reliable (Hasin, 
Hatzenbuehler, Keyes, & Ogburn, 2006). The recently launched DSM-V psychiatric 
diagnostics uses the term “substance use disorder” rather than “dependence” and 
‘abuse’ (Regier, Kuhl, & Kupfer, 2013). In this thesis ‘drug addiction’ and ‘substance 
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1 Introduction
use disorder’ (abbreviated as SUD) are used synonymously and ‘dependence’ refers 
to addiction as a psychiatric diagnosis according to the DSM-IV.  
While medical deﬁnition of addiction is very important for scientiﬁc stud-
ies some of the abnormalities which are commonly related to addiction may ex-
ist before any development of addictive behavior, although these tend to become 
worse when addiction develops. These include individual ‘motivational system’ ab-
normalities like propensity to anxiety, depression, or impulsivity (West, 2006). Al-
so, there are social conditions in which addiction is seen as normal behavior. These 
include conditions that lack of other sources of contentment than easily available 
substances of abuse or reduce individual sense of self-worth, and thus reduce de-
sire for self-protection or reﬂection (Davies, 1992; West, 2006). 
Although scientiﬁc deﬁnitions of addiction are likely to remain somewhat 
fuzzy due to ongoing evolution of human social life, the idea that prolonged drug 
use brings about major changes in the brain is now well evidenced. Brain chang-
es can be molecular, cellular, structural, or functional, and they may be manifested 
by brain metabolism, receptor function, gene experession or behavioral responses 
to various cues (Leshner, 1997). Therefore, the rest of the introduction section will 
deal with neurobehavioral changes in addiction. 
1.1.2 Addiction neurocircuitry is a cascade of neurobehavioral 
changes
It has been postulated that vulnerability towards development of a SUD among 
many individuals stems from an initially abnormal processing of reward in the 
brain (Blum, Liu, Shriner, & Gold, 2011). In concert with this idea a well-known 
neurobiological model of addiction describes it as a spiraling addiction cycle in 
which binge-like substance use dominates ﬁrst and the brain reward system is over 
activated (Koob & Le Moal, 2008b). The repeated higher-than-normal reward, 
however, does not come without a cost. In order to reach a homeostatic balance, 
the brains stress systems (HPA axis and extrahypotothalamic stress system) are also 
activated (Koob & Le Moal, 2001). Initially HPA axis activity paradoxically intensi-
ﬁes reward, and increases impulsive substance use,  but then more widespread ac-
tivation of brain stress systems starts to decrease reward (Koob & Le Moal, 2008a). 
This second phase of addiction cycle is dominated by withdrawal symptoms and 
negative affect such as anhedonia or dysphoria. These are only temporarily relieved 
by substance use periods (Koob & Volkow, 2010) In the third phase of addiction cy-
cle compulsive preoccupation with drug use and craving for drug reward (or antic-
ipation of drug relief) dominate (Koob Le Moal 2008a). Although hard to measure 
precisely, it is widely asserted that while the initiation of drug use can be related to 
unfavorable social and cultural factors the later phases of addiction cycle are more 
related to neurobiological vulnerabilities (Koob & Le Moal, 2006).
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Cognitive function in opioid substitution treated patients 
Many ﬁndings support the conclusion that frequent use of addictive drugs 
produces profound changes in brain pathways, and these persist long after the de-
pendent person stops abusing drugs. The brain changes are thought to be common 
for all the major drugs of abuse, and they have been summarized as a cascade of 
discrete but linked neuro-adaptions called addiction neurocircuitry. Five neural cir-
cuits are shown to be engaged sequentially, starting from reward processing in the 
mesolimbic dopamine system, extending ﬁnally to brain stress systems in the ex-
tended AMG (Koob & Volkow, 2010). The experimentally supported neuro-com-
putational model of addiction circuitry currently lists 19 distinct neural locations 
and includes the major excitatory and inhibitory neurotransmitters (glutamate 
and GABA), monoamines (DA, NA, and 5-HT), ACh, and the corticotropin-releas-
ing factor system (Noori, Spanagel, & Hansson, 2012). In more behavioral terms, 
cumulative evidence has linked the transition to drug addiction with the “repro-
gramming” of neuronal circuits that process important behavioral functions:
1. Reward and motivation engaging ﬁrst the mesolimbic DA system originating in 
the ventral tegmental area and then neurotransmitters DA and opioid peptides 
in nucleus accumbens (shell and core) and dorsal striatum (Koob & Volkow, 
2010; Luescher & Malenka, 2011);
 2. Conditioning and habit-formation that has been linked to the activity in the ven-
tral striatum, and thalamus circuits with output to the PFC (Depoy et al., 2013; 
Koob & Volkow, 2010; Le Moal & Koob, 2007);
3. Cognitive control (working memory, episodic memory, inhibitory control, and 
executive function) linked to dorsolateral, anterior, and inferior PFC, parietal 
cortex, and the hippocampal circuits (Koob & Volkow, 2010; Krmpotich et al., 
2013); 
 4. Interoception and self-awareness associated with a proposed salience network 
which activates when the individual is integrating highly processed sensory data 
with visceral, autonomic, and hedonic “markers,” (Seeley et al., 2007). The sali-
ence network gives the individual intuitive knowledge so that she/he can decide 
what to do (or not to do). The brain networks for interoception and salience 
processing include widely distributed midbrain areas such as insula, ventrome-
dial and orbitofrontal cortex, anterior cingulate cortex, parts of the extended 
AMG and periaqueductal gray. At rest, there is overlapping activity between the 
salience network and the well-known ‘resting state’ or default mode networks 
(Cauda et al., 2013);
5. Stress reactivity, emotional pain, and arousal linked to the extended AMG and 
brain stress systems. Extended AMG represents a macrostructure composed of 
several basal forebrain structures: the bed nucleus of the stria terminalis, cen-
tral medial AMG, and a transition zone in the posterior part of the medial nu-
cleus accumbens. 
As shown in Figure 1, it can by hypothesized that the cognitive control sys-
tem loses its relative strength over other regulatory neural circuits. Instead, recip-
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3. Cognitive control 
PFC, parietal cortex, and HPC
5. Stress reactivity, negative 
aﬀect, and arousal 
Extended AMG and brain 
stress systems
4. Interoception self-
awareness, and salience
Frontoinsular cortex, 
OFC, and ACC2. Conditioning and 
habit-formation
Ventral striatal and 
thalamic systems
1. Reward and motivation
Mesolimbic DA system, 
VTA, and NaC
Strengthened eﬀect
Reduced eﬀect
FIGURE 1. Neural cascade of behavioral dysfunction in addiction.
ACC = anterior congulate cortex; AMG = amygdala; DA = dopamine; HPC = hippocampus; NAc = nu-
cleus accumbens; OFC = orbitofrontal cortex; PFC = prefrontal cortex; VTA = ventral tegmental area. 
?
?
rocal connections between many other neural systems are hypothesized to become 
stronger.
1.1.3 Opioid abuse induces widespread neurotoxicity in the brain 
A substance is considered neurotoxic if it causes any adverse effect on the struc-
ture or function of the central and/or peripheral nervous system (Erinoff, 1995). 
Neurotoxicity may be reversible or permanent; masked by temporary compensato-
ry mechanisms; or show lifetime temporal and within-species variability (Wallace, 
2005). Opioid dependence has been associated with increased cell death through 
activating mitochondrial and death-receptor apoptotic pathways, causing altera-
tion in the dendrites, abnormal neurogenesis, neuro-degeneration, and dysfunc-
tional connectivity (J. X. Liu et al., 2009; Shen, Wang, Wang, & Lou, 2012; Upad-
hyay et al., 2010). 
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BAs with the highest
opioid-related brain changes
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approximate
location of BAs
FIGURE 2A. Schematic presentation of lateral cortical areas linked to opioid-dependence.
FIGURE 2B. Schematic presentation of medial cortical areas linked to opioid-dependence.
13
Shaded areas indicate
BAs with the highest
opioid-related brain changes
Numbers indicate
approximate
location of BAs
(Modified from Wikipedia: http://en.wikipedia.org/wiki/Brodmann_area (Access date 
15.11.2013)
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Brain structure comparisons between opioid-dependent patients and normal 
controls typically show signs of cerebral atrophy with increased size of the lateral 
ventricles and increased width of the sylvian ﬁssures (Borne, Riascos, Cuellar, Var-
gas, & Rojas, 2005; Kivisaari et al., 2004; Pezawas et al., 1998). Some atrophy ﬁnd-
ings like those in the cerebellum or thalamus have been associated with concom-
itant polysubstance and alcohol use (Aasly, Storsaeter, Nilsen, Smevik, & Rinck, 
1993; Anderson, Rabi, Lukas, & Teicher, 2010). More speciﬁcally ‘pure’ opioid-de-
pendent patients have shown decreased gray matter density in the bilateral PFC 
cortex (BA 6, 8, 9, 10, 11, 46, and 47), the bilateral insular cortex (BA 13), the bi-
lateral anterior cingulate (BA 24, 32), the bilateral temporal cortex (BA 20, 21 and 
38), the left fusiform cortex (BA 37), and the right uncus (BA 28) (H. H. Liu et al., 
2009; Lyoo et al., 2006; X. Wang et al., 2012; Yuan et al., 2009). Figures 2a and 2b 
show the cortical Brodman areas with the highest opioid-related neuropathology. 
In subcortical areas, decreased AMG volumes have been reported in one study 
(Upadhyay et al., 2010). White matter integrity deﬁcits have been found predom-
inantly in the right PFC, right temporal cortex, and right parietal, cingulate, cor-
pus callosum, and thalamic radiation; and some of these deﬁcits correlate with the 
duration of opioid abuse, indicating probable neurotoxicity (Li et al., 2013; Liu et 
al., 2008; Qiu et al., 2013). There is evidence that among those with a ten-year or 
so history of opioid dependence, the white matter deﬁcit is even more diffuse, ex-
tending from myelin damage to axon damage (Bora et al., 2012; Qiu et al., 2013). 
In fact, it is not clear if any brain area is fully protected against widespread cellu-
lar or microvascular damage found in polysubstance using opioid-dependent pa-
tients (Buttner, Rohrmoser, Mall, Penning, & Weis, 2006; Ferrer-Alcon, La Harpe, 
& Garcia-Sevilla, 2004; Ferrer-Alcon, La Harpe, Guimon, & Garcia-Sevilla, 2003) . 
The cellular route to neuropathology includes mitochondrial dysfunction, 
oxidative stress, damage to the neuroﬁlaments of the cytoskeleton, and dendrit-
ic spines (Cunha-Oliveira, Rego, & Oliueira, 2008; Ferrer-Alcon et al., 2004; Fer-
rer-Alcon et al., 2003; T. E. Robinson & Kolb, 2004). Animal studies have shown 
that chronic opioid use increases the expression of apoptosis-related proteins and 
impairs memory performance (Tramullas, Martinez-Cue, & Hurle, 2007, 2008). 
Neuron loss is increased by a concomitant decrease of hippocampal neurogenesis 
(Cunha-Oliveira et al., 2008). Chronic opioid use as such creates immunosuppres-
sion (Roy et al., 2011). As opioids are often used intravenously with dirty needles, 
hepatitis C or human immunodeﬁciency virus (HIV) infections are not uncom-
mon among opioid abusers. Also, bacterial infections in skin or soft-tissues, endo-
carditis, pulmonary, or sexually transmitted infections are common. For instance, 
chronic hepatitis C has been associated with cognitive impairment (Hilsabeck et 
al., 2010). Endocrine changes of opioid abusing patients include both hypothalam-
ic-pituitary-gonadal and hypothalamic-pituitary-adrenal system (Brennan, 2013). 
Lower than normal sex hormone level can be seen in both sexes, and this may affect 
up to 90% of chronic opioid users (Katz & Mazer, 2009). Also, lower than normal 
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cortisol levels are found in opioid abusers (Abs et al., 2000). Optimal cortisol lev-
el is important for several cognitive functions (Kukolja, Thiel, Wolf, & Fink, 2008; 
Van Houdenhove, Van den Eede, & Luyten, 2009). Activation of mu opioid recep-
tor increase sweet preference and this may lead to high sugar intake, and eventu-
ally to reduced glycemic control. In fact, delayed and increased insulin response to 
glucose loads and increased fasting insulin levels have been found in both hero-
in addicts and methadone patients (Mysels & Sullivan, 2010). Transient brain dys-
function and cognitive impairment is common in hypo- or hyperglycemic con-
ditions (Weston, 2012), while long-term brain dysfunction is possible (Mattson, 
2012; Suh, Hamby, & Swanson, 2007). Some of the cellular and synaptic adapta-
tions leading to the development of opioid tolerance and dependence may then 
lead to further adaptations “downstream” from the actual opioid synapses. This 
could regulate two or more synapses in series through a domino effect involving at 
least glutamate, GABA, and NA synapses (Williams, Christie, & Manzoni, 2001). 
1.1.4 The human brain may counterbalance opioid-abuse related 
neurotoxicity by neuroprotective adaptations
The neurotoxic changes decribed in the previous chapter indicate that cognitive 
performance deﬁcits could be seen in opioid-dependent patients. For instance, 
working memory impairment in methadone-treated opioid dependent patients 
has been associated with altered white matter integrity in the left superior fascic-
ulus that connects the superior temporal gyrus (BA 41) with the dorsolater PFC, 
and memory impairment with white matter deﬁcits in the left para-hippocam-
pal area of the cingulum (BA 30) (W.-C. Lin et al., 2012). However, with neuropa-
thology, cognitive deﬁcits are not always found. Thus, it is likely that some of the 
neural adaptations in chronic opioid users could be compensatory and neuropro-
tective rather than neurotoxic (Weber et al., 2006). The hypothesized interplay be-
tween neuropathology and compensatory mechanisms related to opioid abuse is 
described in Figure 3. Notably, there is evidence that the adenosine A1 receptor and 
glial activity could prevent glutamate-induced excitotoxicity in the CNS (Castil-
lo, Leon, Ballesteros-Yanez, Albasanz, & Martin, 2010; Lauro et al., 2010; Lauro et 
al., 2008). The role of these changes in cognitive functioning among opioid abus-
ers is, however, not well-known although there is preliminary evidence support-
ing compensatory mechanisms for preserving working memory function (Marvel, 
Faulkner, Strain, Mintzer, & Desmond, 2012). Also, there is some evidence that opi-
oid agonism in delta receptors can be neuroprotective against hypoxia (Benarroch, 
2012). It is not known if buprenorphine or methadone use would have this effect, 
although mild delta agonist action is possible.
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FIGURE 3. Opioid abuse related neural changes and cognitive function.
11.5 Neurotoxicity of a substance does not equal a neuropsycho-
logical deficit related to its use
As outlined in the previous chapter, the neurotoxic potential of substance abuse 
may be high, but may be functionally well compensated for and not observed in 
neuropsychological testing. Furthermore, when neuropsychological deﬁcits are 
found in SUD patients some of these may be premorbid. For instance, a longitu-
dinal study including alcohol dependent patients instead of opioid-dependent pa-
tients showed that premorbid general cognitive performance deﬁcit predicted fail-
ure to recover from dependence by the age of 40 years (Penick et al., 2010). Table 1 
shows an overview of ﬁndings of premorbid cognitive deﬁcits among individuals 
who develop SUD and are likely to seek help for it. In this table and the following 
tables, domains of cognitive performance are classiﬁed according to factor analysis 
studies and theoretical accounts based on them (Ardila & Bernal, 2007; Fals-Stew-
art & Bates, 2003; Friedman et al., 2006; Jurado & Rosselli, 2007; Tulsky & Price, 
2003). In the tables of the Introduction section, attention and working memory 
are grouped together even though they are later dealt with separately. This is based 
on the fact that some cognitive tests, such as the Digit Span, seem to tap both con-
structs equally, indicating an overlap of the constructs (Postle, 2006). 
As shown in the Table 1, so far, there is no evidence for a higher than nor-
mal prevalence of premorbid learning and memory or motor performance deﬁcit 
among those seeking treatment for SUD. Notably, among non-treatment seeking 
individuals with SUD, cognitive performance deﬁcits are likely to be minor if any. 
For instance, a recent large (n=8992) prospective cohort study found that in the 
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TABLE 1. Premorbid cognitive deﬁcits among individuals with SUD
attention or working memory Attention score obtained from five attention tests 
(Tapert, Baratta, Abrantes, & Brown, 2002)
Motor performance ?
Processing  speed ?
Executive function Response inhibition measure from the Stop task 
(Nigg et al., 2006; Wong, Brower, Nigg, & Zucker, 2010)
Verbal ?
Visuoperceptual Mazes subtests from the Wechsler Preschool and Primary 
Scale of Intelligence. 
(Pechtel, Woodman, & Lyons-Ruth, 2012)
Verbal learning and memory ?
Visual learning and memory ?
Overall cognitive performance Standardized sum measure of four reasoning test including 
verbal, logical, spatial, and technical knowledge subtests 
(Gale, Batty, Tynelius, Deary, & Rasmussen, 2010)
Combination of premorbid cognitive and neurological measures
(Penick et al., 2010)
middle-aged general population, illicit lifetime drug use shows actually positive as-
sociation with general cognitive functioning (Dregan & Gulliford, 2012). However, 
this association was not seen for current use and there was a tendency for more se-
rious drug use disorder (lifetime drug dependence) to be associated slightly nega-
tively with general cognitive performance. 
1.2 Opioids and cognitive function disorders
1.2.1 The opioid receptor family includes four known members 
Opiates that can be derived from the poppy plant include opium, morphine, and 
codeine, to name the most well-known. The term “opiate” is also used for the semi-
synthetic drug heroin that is produced from poppy compounds. The term “opi-
oids” has broader meaning, referring to endogenous opioids, opiates, and other 
semisynthetic and synthetic compounds with similar (morphine-like) properties 
(Trescot, Datta, Lee, & Hansen, 2008). 
The scientiﬁc basis for the effects of opioids was established in the 1970s, when 
opioid receptors were found in the human CNS and in peripheral tissues. On the 
basis of their pharmacological proﬁles, opioid receptors are classiﬁed as mu, delta, 
kappa or nociceptin (also known as the orphanin-FQ) receptors (Corbett, Hender-
son, McKnight, & Paterson, 2006). Opioid receptors belong to the G protein-cou-
pled group of receptors like the majority of known neurotransmitters and hor-
mones. Opioid receptors in the brain are activated both by endogenously produced 
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opioid peptides and by exogenously administered opioid compounds (Waldhoer, 
Bartlett, & Whistler, 2004)
Opioids are not considered neurotransmitters because their activity cycle is 
different to that of a neurotransmitter. For instance, opioids lack a re-uptake mech-
anism and their release requires greater stimulation than that of neurotransmitters 
(Kandel, Schwartz, & Jessell, 2000). However, in some cases, opioids are co-released 
with a neurotransmitter and act like a neurotransmitter. Furthermore, opioid re-
ceptor activity is able to modify the function of a neurotransmitter and neurohor-
mone systems (Fichna, Janecka, Costentin, & Do Rego, 2007). Opioid agonists are 
able to inhibit the main CNS neurotransmitter systems (ACh, glutamate, GABA, 
DA, 5-HT, and NA) (Corbett et al., 2006). However, opioids may also excite neuro-
transmitter release via disinhibition (Benarroch, 2012). 
1.2.2 Endogenous opioids modulate cognitive function
Endogenous opioids are supposed to have only minor effects on cognitive func-
tion under normal conditions (Carlsson & Carlsson, 2002). However, when an in-
dividual is exposed to situations with high relevance for survival or reproduction, 
or to serious stress, opioids play an important role by eliciting pleasure or pain and 
modulating cognitive function (Guarna, Ghelardini, Galeotti, Stefano, & Bianchi, 
2005). For instance, endogenous opioids may promote forgetting pain producing 
experiences, and thus help survival under threat (Guarna et al., 2005). In support 
of this, one study found that when drug-naïve individuals were exposed to verbal 
and visual material causing high negative emotional arousal, those receiving a dose 
of non-speciﬁc opioid antagonist naltrexone before the exposure performed better 
than those receiving a placebo on a memory test related to the emotional material 
(Katzen-Perez, Jacobs, Lincoln, & Ellis, 2001). In contrast, when the same individ-
uals were exposed to emotionally neutral stimuli, those receiving naltrexone per-
formed worse than those receiving placebo. In another study, the mu opioid recep-
tor agonist naloxone was given as pretreatment before (stressful) electroconvulsive 
therapy and resulted in better attention task performance and verbal memory in 
comparison to placebo (Prudic, Fitzsimons, Nobler, & Sackeim, 1999). 
1.2.3 Cognitive deficits are pronounced in opioid-dependent  
patients seeking treatment 
Neuropsychological studies reveal quite general cognitive deﬁcits during opioid 
abuse. Table 2 shows cognitive performance ﬁndings from four selected well-con-
trolled studies of opioid abusing individuals. As shown by the table, cognitive def-
icits have been found in verbal performance, visuoperceptual performance, at-
tention/working memory, verbal learning and memory, executive function, and 
overall executive function. Other domains have not shown deﬁcits or not been ex-
plored. Of note here is the fact that the Stevens et al. study is one of the few studies 
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that included a non-treatment seeking sample. Also, many of the well-known earli-
er studies have pooled methadone-treated and active opioid-abusers into the same 
group, and therefore the results of these studies are not reviewed here. 
TABLE 2. Cognitive performance of among individuals with active opioid abuse in relation to 
normal controls
Study
(Guerra, Sole, 
Cami, & Tobena, 
1987)
(Montoya, Hess, 
Covi, Fudala, & 
Johnson, 1994)
(Soyka et al., 2011) (Stevens, Peschk, & 
Schwarz, 2007)
Study 
characteristics
Heroin users test-
ed before entering 
treatment  
(n = 93).
Compared against 
normal controls 
(n = 30).
Heroin using opioid-
dependent patients 
tested when entering 
treatment, most of 
them using recent-
ly cocaine or alcohol 
(n =162).
Compared against 
norms from the gen-
eral populations.
Opioid-dependent 
patients allowed to 
self-administer her-
oin maximum three 
times a day in a out-
patient clinic 
(n = 20).
Compared against 
normal controls
(n = 25).
Community sample 
of polydrug abusing 
males with opiate 
dependence test-
ed when positive for 
opioid and almost all 
to some other illicit 
drug too
(n = 25).
Compared against 
normal non-drug 
using controls
(n = 26).
Tests and findings
Attention or 
working 
memory
? Digit Span;
?Toulouse-Pieron 
cancellation test
? 4/5 attention tests 
from the ART-90
? Delayed matching 
to sample RT
? Implicit sequence 
learning
Motor perfor-
mance
Processing 
speed
Verbal ? WAIS-R Vocabulary 
score
? Multiple choice 
Word Comprehen-
sion Test
Visuopercep-
tual
? Raven matrices ? Figural reasoning
Visual learning 
and memory
Executive func-
tion
?  Verbal 
fluency test
? Trail Making Test B 
Overall cog-
nitive perfor-
mance
? Shipley Institute 
of Living Scale, total 
score.
ART-90 = Act and React Test System 90; ? = no significant diﬀerence between patients and normal 
controls: ? = patients impaired in relation to normal controls.  
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1.3 Opioid substitution treatment drugs
1.3.1 The scientific basis of opioid substitution treatment: long 
action of methadone and buprenorphine 
In the latter part of the 1940s, some good experiences of using long-acting meth-
adone as a morphine or heroin withdrawal drug were documented (Harris Isbell 
& Vogel, 1949). With the idea of “metabolic disease” and “neurologic susceptibili-
ty” in mind, the Rockefeller Institute team in New York started trials in 1964 with 
methadone to produce a “narcotic blockade”. Results of the initial success of these 
trials were published the following year (Dole & Nyswander, 1965). Since then the 
development of Methadone Maintenance Treatment programs has led to well-es-
tablished knowledge on the dosing procedures needed for successful treatment 
(Green, Kellogg, & Kreek, 2004). In most cases, an oral methadone dose from 80–
120 mg is sufﬁcient to reach the desired effects of the drug, that is, to relieve opi-
oid craving, suppress opioid withdrawal effects for 24–36 hours, block the effects 
of administered heroin, and develop tolerance to the narcotic or analgesic effects of 
methadone (Joseph, Stancliff, & Langrod, 2000). 
Methadone is a full mu opioid receptor agonist and may cause a fatal respira-
tory depression if a signiﬁcantly higher than usual dose is administered or the dose 
is injected. Therefore, buprenorphine, which is safer because of its partial mu ago-
nist effect, has been increasingly used in OST programs (Vadivelu & Hines, 2004). 
Buprenorphine, which absorbs well if given sublingually, has an even longer effect 
than methadone (M. Greenwald et al., 2007). Unfortunately, if buprenorphine is 
abused intravenously in combination with other psychoactive substances, it may 
be hazardous. Therefore, a combined buprenorphine/naloxone preparation with 
a reduced intravenous abuse potential has been developed to replace buprenor-
phine in OST programs (Stoller, Bigelow, Walsh, & Strain, 2001). This compound 
contains the mu agonist buprenorphine and the antagonist naloxone in a 4:1 ra-
tio. When the compound is used sublingually, the naloxone is not absorbed. Thus, 
it has similar pharmacokinetic properties as buprenorphine used alone (Comer, 
Walker, & Collins, 2005; Harris, Mendelson, Lin, Upton, & Jones, 2004). However, 
when the compound is used intravenously, the naloxone is activated and this re-
duces the abuse potential (Alho, Sinclair, Vuori, & Holopainen, 2007). 
1.3.2 Milestones of opioid-substitution treatment in Finland
After the Second World War methadone had become available in Finland as a pre-
scription medicine for severe pain with special permission from the prescription 
regulators. In 1973 few physicians were given permission to use methadone for in-
dividual opioid-dependent patients (Fabritius & Granström, 1999). In the early 
1990s two physicians had started to prescribe buprenorphine for opioid-depend-
ent patients, which led to restrictions being imposed on their prescription rights 
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(Selin, Hakkarainen, Partanen, Tammi, & Tigerstedt, 2013). However, these ﬁrst 
treatments led to pressure for broader treatment availability. The ﬁrst ofﬁcial reg-
ulations of OST with methadone or buprenorphine (Subutex) for a restricted pe-
riod for each patient were given in 1997 (Simojoki, 2013). This initiated the slow 
spread of the treatment. However, as the advantages of OST programs become bet-
ter known, restrictions on the treatment length were soon abolished. At the be-
ginning of the 2000s, the Ministry of Social and Welfare wanted to speed up the 
spread of OST and criteria for OST were lowered. The current legislation issued by 
means of a decree in 2008 implied a signiﬁcant change in the policy. OST is now 
the ﬁrst choice treatment for opioid-dependence (Selin et al., 2013). Currently the 
buprenorphine/naloxone compound (Suboxone) is the most used drug therapy for 
opioid-dependence in Finland, with methadone used slightly less (Simojoki, 2013). 
Buprenorphine as a monotherapy is rarely used due its high demand in the illic-
it drug market. 
1.4 Opioid substitution treatment drugs and 
cognitive function
1.4.1 Opioid-naive individuals show cognitive deficits when given 
buprenorphine or methadone
In order to have functional relevance to cognitive function, a drug needs to reach 
a threshold for clinical effects. In the case of G protein coupled receptor antago-
nists, such as opioid antagonists, at least 60% of receptor occupancy seems to be a 
threshold for noticeable cognitive effects (Grimwood & Hartig, 2009; Hirst et al., 
2008). Opioid antagonist naloxone is able to occupy at least 80% of mu opioid re-
ceptors, and to a lesser degree, also kappa, delta, and nociceptin/orphanin recep-
tors (Kim et al., 1997; Melichar, Nutt, & Malizia, 2003; Nicholson, Paterson, Men-
zies, Corbett, & McKnight, 1998; D. X. Wang, Sun, & Sadee, 2007). As basal opioid 
receptor tone is likely to have only a small, if any, effect on cognitive function in 
normal conditions, mixed results have been obtained after non-selective opioid an-
tagonist naloxone administration: improvement, impairment, or no effect (Arn-
sten et al., 1983; Martin del Campo, McMurray, Besser, & Grossman, 1992; Prudic 
et al., 1999; Volavka, Dornbush, Mallya, & Cho, 1979; Wolkowitz & Tinklenberg, 
1985). 
The effects of opioid agonist administration on cognitive function are likely to 
be dependent on other receptor-binding parameters than the magnitude of recep-
tor occupancy. High efﬁcacy mu opioid receptor drugs like methadone show be-
havioral effects associated with the mu receptor in spite of very low receptor occu-
pancy. In contrast to this, a low-efﬁcacy mu agonist drug like buprenorphine needs 
high mu receptor occupancy to achieve the same behavioral effects (Grimwood & 
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Hartig, 2009). In addition, cognitive effects of the drugs are highly dependent on 
receptor location and density in the CNS. 
When given intravenously to healthy opioid-naïve individuals, the prototypi-
cal mu opioid agonist drug morphine produces motor, attention/working memory, 
or visuospatial impairments in a dose-dependent manner. However, oral admin-
istration produces less cognitive effects (Stout & Farrell, 2003; Zacny & Gutierrez, 
2003). For instance, one study found that an orally administered standard pain 
treatment dose of morphine (10 mg) produced a small negative effect on working 
memory but had no effect on episodic memory (Friswell et al., 2008).
Other opioid receptor agonist drugs are known to affect cognitive function, 
although the issue has not been studied well. In one study, the highly selective kap-
pa agonist Salvinorin A produced dose-dependent verbal memory deﬁcits, while 
in another study it failed to affect working memory (MacLean, Johnson, Reissig, 
Prisinzano, & Grifﬁths, 2013; Ranganathan et al., 2012). In both of these studies 
the participants had prior recreational experience with psychoactive Salvinorin A, 
but were without psychiatric diagnoses. Delta opioid agonists have been attribut-
ed with the enhancement of inhibitory control, while nociceptin/orphanin-FQ ag-
onists have been attributed with a negative effect on long-term memory (Befort et 
al., 2011; Reiss, Prinssen, Wichmann, Kieffer, & Ouagazzal, 2012). However, only 
animal studies have so far been reported. 
Table 3 shows the main pharmacological properties of buprenorphine and 
methadone and the related cognitive ﬁndings for both compounds on drug-naïve 
individuals. As can be noted from the Table, the cognitive effects of buprenorphine 
or methadone are not easily predicted from the ﬁndings for the single opioid re-
ceptor function of these drugs. This is because both compounds affect several opi-
oid receptor types, and these may produce opposite cognitive effects. Of note here 
are the differences between buprenorphine and methadone on the mu and kap-
pa receptor functions. Buprenorphine is a partial agonist for the mu receptor and 
an antagonist for the kappa receptor, while methadone is a full agonist for both re-
ceptors. The negative effect of methadone on memory function may reportedly 
be based on mu-receptor agonism-induced inhibition of ACh release in the NAc, 
HPC, and PFC (Hepner, Homewood, & Taylor, 2002). Thus, buprenorphine may 
not have as strong a negative effect on memory as methadone. In addition, it has 
been suggested that kappa antagonism of buprenorphine has a positive effect on 
cognitive functioning via restoration of optimal dopaminergic tone, while meth-
adone as a dopaminergic inhibitor may not have a similar property (Spiga, Lintas, 
& Diana, 2008). However, if an individual uses opioids chronically, the pharmacol-
ogy of buprenorphine and methadone becomes more complex than in short-term 
administration (Trescot et al., 2008).
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TABLE 3. Pharmacology of buprenorphine and methadone in relation to cognitive perfor-
mance in normal conditions
Cognitive eﬀects of the 
drug when given to 
healthy individuals
Opioid receptor activity Opioid receptor activity
Buprenorphine Intravenous administra-
tion produces dose de-
pendent negative eﬀect 
on attention/working 
memory, motor function, 
processing speed, and 
general cognitive func-
tion.
Mu: partial agonist with 
partial eﬃcacy, which is 
compensated by high re-
ceptor aﬃnity and occu-
pancy.
Delta: mixed agonist an-
tagonist action possi-
ble. Eﬃcacy is not well 
known.
Kappa: antagonist activ-
ity. Eﬃcacy in drug-na-
ïve humans is not well 
known.
Nociceptin/Orphanin-FQ: 
agonist activity. Eﬃca-
cy not well-known. Inter-
action with mu activi-
ty likely. 
Three active metabolites 
which may have contra-
dictory activity on the 
opioid receptors. How-
ever, metabolites show 
low concentration in the 
brain.
No significant   eﬀects on 
other neurotransmitter 
systems if not abused.
Methadone Negative eﬀect on at-
tention. Other cognitive 
functions not studied in 
healthy individuals.
Mu: agonist  with high ef-
ficacy despite low recep-
tor occupancy
Delta: agonist which may 
result in reduction of opi-
oid tolerance
Kappa:  agonist with low 
eﬃcacy
Nociceptin/Orphanin-FQ: 
no known activity
Major metabolites in-
active
Weak glutamate NMDA 
receptor antagonist and 
monoamine reuptake in-
hibitor
Buprenorphine: (Brown, Holtzman, Kim, & Kharasch, 2011; Davids & Gastpar, 2004; Englberger, 
Kogel, Friderichs, Strassburger, & Germann, 2006; Jensen et al., 2008; Negus et al., 2002; S. E. 
Robinson, 2002; Smith, 2011; Walsh & Eissenberg, 2003; Zacny, Conley, & Galinkin, 1997; Zacny, 
Conley, Young, et al., 1997) Methadone: (M. P. Davis & Walsh, 2001; Kapur, Hutson, Chibber, Luk, 
& Selby, 2011; Neil, 1984; Raynor et al., 1994; Zacny, 1995) Cognitive eﬀects of opioid receptors 
activity: (Friswell et al., 2008; Kuzmin, Madjid, Johansson, Terenius, & Ogren, 2009; MacLean et al., 
2013; Pradhan, Befort, Nozaki, Gaveriaux-Ruﬀ, & Kieﬀer, 2011; Stout & Farrell, 2003; Zacny, 1995).
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1.4.2 No studies have compared short-term cognitive eﬀects of 
buprenorphine vs. methadone in opioid-dependent patients
In their seminal study examining methadone as a withdrawal drug, Isbell and his 
collaborators had examined already in the 1940s the short-term cognitive effects 
of methadone in opioid-dependent patients. A deterioration of performance was 
seen in the Otis test, a timed multiple-choice intelligence test with both verbal and 
non-verbal items. The methadone dose varied in these experiments, ranging from 
a high 180 mg to an ultrahigh 800 mg (H. Isbell, Wikler, Eisenman, Daingerﬁeld, 
& Frank, 1948). Surprisingly, later studies have not compared the short-term cog-
nitive effects of buprenorphine and methadone. Instead, to my knowledge there 
are only a few separate studies examining one drug. The results of two well-con-
trolled studies are summarized in Table 4. As shown by the Table a dose-effect af-
ter short-term buprenorphine treatment was seen in the recognition memory of 
a word list. No dose-effect was seen in attention/working memory or processing 
speed measures. Moreover, in the methadone study of Curran et al. (2001) verbal 
memory was the only impaired cognitive domain. A 100% daily stabilization dose 
of methadone was associated with impaired delayed story recall performance as 
compared to a placebo or a 50% methadone dose. Attention performance as meas-
ured by a RT task improved after 100% or 50% of daily methadone dose in com-
parison to a placebo. In motor performance or processing speed, no methadone ef-
fects were found.
1.4.3 Studies of cognitive performance in stable OST patients 
have shown mixed results 
Dole and other pioneers of OST were aware of the studies of Isbell et al., reviewed 
in the previous section, which indicated an overall cognitive deﬁcit due to meth-
adone. Therefore, several neuropsychological studies were conducted using ear-
ly patient samples. The results of these studies showed no overall cognitive deﬁcits 
or slowing of RT that could be attributed to methadone (N.B.  Gordon & Appel, 
1995). Methadone doses in these studies were in the middle ranges, with a mean 
of 100 mg. Unfortunately, timing of the testing that followed the administration of 
the dose was not clearly speciﬁed. 
Although early studies did not yield evidence of cognitive deﬁcits among 
stable MMT patients, later studies have shown substantial cognitive impairment 
among them. The often-cited study by Darke et al (Darke, Sims, McDonald, & 
Wickes, 2000) showed that stabilized patients who were given a mean 79 mg of 
methadone showed substantial cognitive deﬁcits in all major domains: attention, 
processing speed, verbal and visuoperceptal performance, memory, and executive 
function (Darke et al., 2000). 
Table 5 summarizes the ﬁndings of three selected well-controlled studies, in-
cluding for both buprenorphine and methadone patients in stable OST and com-
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BUPRENORPHINE METHADONE
Study
(Mintzer, Correia, & Strain, 2004) (Curran, Kleckham, Bearn, Strang, 
& Wanigaratne, 2001)
Study design Participants Study design Participants
Study 
characteristics
Experimental   
double-blind 
cross-over study 
in inpatient set-
tings
No other medica-
tions were given 
(M.Z. Mintzer, per-
sonal communi-
cation, March 2, 
2007)
Opioid-dependent 
patients
(n = 8) 
with unknown
opioid use histo-
ry were given bu-
prenorphine/na-
loxone 8/2 mg 
– 32/8 mg for 
7–10 days before 
tests.
Time of the test 
(1, 6 or 12 h after 
the dose) had no 
eﬀect on the re-
sults and there-
fore test points 
were collapsed 
(except memory).
Experimental  
double-blind 
study in inpatient 
settings
Non-specified 
number of the 
participants were 
given BZD doses. 
No other medica-
tions were given.
Opioid-depend-
ent outpatients 
(n =20)
were given a dai-
ly dose of metha-
done for relieving 
withdrawal symp-
toms (M = 33 ± 
11 mg) for 3 or 5 
days period. Then 
there were given 
normal dose, 
50 %, or placebo.
Tested 3 h after 
the dose.
Tests and  findings
Attention or 
working memory
? Trail Making A
? n – back
? Digit recall
? Faster simpe RTs after 50 % or 100 % 
of daily methadone dose
? Digit cancellation test
Motor perfor-
mance
? Finger tapping speed.
Processing speed ? Digit Symbol ? Digit-Symbol 
Verbal
Visuoperceptual
Verbal or visu-
al learning and 
memory 
? Verbal recognition memory for the 
32 mg condition. 
Test done 1 h from the dose
? Delayed story recall after full with-
drawal methadone dose  in relation to 
placebo or 50 % methadone dose
Executive func-
tion
? Trail Making B
Overall cognitive 
performance
? = no dose eﬀect; ? = Improved performance after a higher dose.     ? = Impaired performance after 
a higher dose. 
TABLE 4.  Cognitive performance of opioid-dependent patients after short-term administration of 
buprenorphine or methadone in relation to dose
paring them separately against normal controls. As seen in the table, methadone 
patients seem to show slightly more deﬁcits and executive function than buprenor-
phine patients. Meta-analyses, however, are lacking. 
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TABLE 5. Results from the selected studies comparing cognitive performance in buprenorphine- 
or methadone-treated opioid-dependent patients in stable treatment against normal controls
Study
(Soyka et al., 2008) (Baewert et al., 2007) (Pirastu et al., 2006)
Study design Participants Study design Participants Study design Participants
Study 
characteristisc
Randomized 
sample of 
OST outpa-
tients test-
ed at baseline 
and then after 
two weeks and 
eigth weeks. 
Controls test-
ed once.  No 
diﬀerences be-
tween patient 
groups on non-
specified addi-
tional medica-
tions. 
Test time after 
dose n/a
BN = 29(T1) or 
22(T2), dose 
n/a.
METH = 30(T1) 
or 24 (T2), dose 
n/a
NC = 24
Non-rand-
omized sam-
ple of OST out-
patients with 
no other medi-
cations or illicit 
use on any sub-
stance
Tested 1.5 and 
20 h after dosea
BN = 20 pa-
tients, mean 
dose 13 ±4 mg
METH = 20 pa-
tients mean 
dose 53 ±22 
mg
NC = 20
Non-rand-
omized sample 
of OST outpa-
tients.
with no oth-
er medications 
known to aﬀect 
cognition 
Test time after 
dose n/a 
BN = 18 pa-
tients, mean 
dose 9 ±1 mg
METH = 30 
patients
mean dose 66 
±7 mg 
NC = 21
Duration of 
OST at test
Minimum 2 
weeks (T1)
Minimum 8 
weeks (T2)
Minimum 2 months   Minimum of 
12 months
Tests and findings
Attention or 
working 
memory
?
d2 test
Digit Span
BN < NC
d2 test (accu-
racy)
BN/METH (combined) < NC in 
two; and 
NC < BN/METH(combined)  < 
in one  
subtest of the Act and React Test 
System –ART-2020
Processing  
speed
BN < NC
METH < NC
Trail Making 
Test A
Verbal
Visuopercep-
tual
Patients and controls matched
on visual matrices test of the 
ART-2020
Verbal learning 
and memory
?
Auditory Verbal 
Learning Test
BN < NC
METH < NC
Auditory Verbal 
Learning Test 
(sum of learn-
ing trials)
Visual learning 
and memory
BN < NC
METH < NC
Benton Visual Retention Test
Executive 
function
?
verbal fluency
BN < NC
METH < NC
Trail Making 
Test B
verbal fluency
METH < NC
Wisconsin Card Sorting Test (per-
sevative errors)
METH < NC 
Iowa Gambling Task (net score)
Overall 
cognitive 
performance
BN < NC
METH < NC
WAIS-R total score
Note. BN = buprenorphine; METH = methadone; NC = normal control. ? = no significant diﬀerence between patients 
and normal controls; < = inferior than or less than; n/a = not available.
aResults in the Table show performance that combines both test times.
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1.4.4 Studies examining drug treatment variables as correlates of 
cognitive performance in OST have yielded few consistent findings
1.4.4.1 Opioid drug treatment variables as correlates of cognitive  
performance
Opioid drug dose is often the only drug treatment variable that is included in the 
analyses of correlates of cognitive performance. In speciﬁc cognitive tests, mild to 
moderate dose correlations have been reported in several studies. For instance, one 
study reported a statistically signiﬁcant correlation (.37) between methadone dose 
and trials needed for correct visual recognition (Grevert, Masover, & Goldstein, 
1977). Another study found slightly higher correlations between methadone dose 
and slow performance in two attention measures (.48 and .43) (Loeber, Kniest, 
Diehl, Mann, & Croissant, 2008). However, when more rigorous statistical meth-
ods have been used, such as covariance or regression analyses, the relationship be-
tween methadone dose and cognitive performance has turned out to be very low 
and statistically non-signiﬁcant (Prosser et al., 2008; Soyka et al., 2008; Specka et 
al., 2000). Low correlations in the expected direction may be related to the fact that 
methadone’s effects on behavior are highly variable and non-linearly affected by 
the dose and receptor occupancy (Grimwood & Hartig, 2009; Hume et al., 2007; 
Leimanis, Best, Atayee, & Pesce, 2012). Buprenorphine, however, occupies mu opi-
oid receptors in a linear fashion in up to at least 16 mg doses in opioid-dependent 
patients (Becerra et al., 2013; M. K. Greenwald et al., 2003). Studies that examined 
this issue, however, have reported no correlation between buprenorphine dose and 
cognitive performance in opioid-dependent patients in spite of the dose-depend-
ent cognitive effect on drug-naïve individuals (Table 3) (Lintzeris, Mitchell, Bond, 
Nestor, & Strang, 2007; Loeber et al., 2008; Shmygalev et al., 2011). The study of 
Mintzer et al. reviewed in Table 4 is an exception. The highest clinical dose of 32 
mg buprenorphine was shown to be negatively associated with one memory meas-
ure (Mintzer et al., 2004). 
Other opioid drug treatment variables that could have an effect on cognitive 
performance are time from the administration of the dose and drug treatment du-
ration. The most comprehensive study examining peak dose vs. trough dose effects 
on OST patients is that of Baewert et al., which was reviewed in Table 5. Although 
some ﬁndings were found the authors concluded that OST patients do not differ 
signiﬁcantly at peak vs. trough level in the majority of the attention tests (Baewert 
et al., 2007). The ﬁndings of a regression analysis study by Loeber et al. are harder 
to interpret. They found that the duration of OST predicted poor scores in the at-
tention test (Loeber et al., 2012), with the authors suggesting that this may relate to 
the neurotoxicity of long-term opioid-dependence. 
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1.4.4.2 Other drug treatment variables as correlates of cognitive perfor-
mance
Psychiatric comorbidity is high among OST patients. The most common non-sub-
stance-use psychiatric disorders are depressive, anxiety, and personality disorders; 
while psychotic disorders more common than in general population; and neu-
ropsychiatric disorders are too often overlooked (Carpentier, Knapen, van Gogh, 
Buitelaar, & De Jong, 2012; Lieb et al., 2010; Strain, 2002). Thus treatment with 
other psychoactive drugs is common in OST programs, although there are ma-
jor differences between treatment providers in their drug policy. In one of the few 
studies taking several clinically relevant variables into account, drug treatment, 
substance abuse, and personality pathology variables were entered into regression 
analysis predicting composite cognitive performance (Prosser et al., 2008). Sum of 
personality pathology was the only signiﬁcant predictor of overall cognitive per-
formance.  In another study (Henry et al., 2012) concerning methadone-treated 
patients self-rated anxiety or depression measures did not correlate with memo-
ry measures although results indicated clinically signiﬁcant level of current anxiety 
and depression symptom.  In a more recent study comorbid depressive symptoms, 
however, predicted worse performance in one attention test (Loeber et al., 2012). 
Regarding neuropsychiatric variables Brooks et al. have reported that OST patients 
with ADHD or conduct disorder perform worse in tests measuring attention and 
psychomotor function than patients without these conditions (Brooks, Vosburg, 
Evans, & Levin, 2006). 
Drug interactions are likely between OST drugs and many commonly used 
psychiatric drugs (McCance-Katz, Sullivan, & Nallani, 2010), yet these are seldom 
taken into account in the analyses of cognitive performance. The studies of Lintz-
eris et al are an exception in this respect. In the ﬁrst study patients treated with bu-
prenorphine or methadone, with a history of BZD use but who had been not used 
BZDs  with the last two weeks, were given 10 mg or 20 mg of diazepam, which had 
a negative effect on many attention tests done at peak dose approximately one hour 
after the dose (Lintzeris, Mitchell, Bond, Nestor, & Strang, 2006). Thus, having a 
BZD drug seems to increase the peak effects of opioid drugs. In the second study 
higher than clinically normal diazepam dose of 40 mg was associated with de-
creased performance in attention and processing speed tests (simple RT and Dig-
it Symbol, respecitively) for both methadone and buprenorphine patients (Lintz-
eris et al., 2007). These effects were independent of the opioid dose administered. 
1.4.4.3 Other variables as correlates of cognitive performance
Other possible correlates of cognitive performance include demographic var-
iables such as age, sex, or education as well as substance abuse variables. Some 
of aging-related neurodegenerative processs are accelerated in opioid-dependent 
patients (Nandhu, Naijil, Smijin, Jayanarayanan, & Paulose, 2010; Reece, 2012a, 
2012b), which can make negative age-associated correlations with cognition steep-
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er among OST patients. Sex of the opioid-dependent patients may correlate with 
cognitive performance because human endogenous opioid system and opioid re-
sponses show slight differences between sexes (Dahan, Kest, Waxman, & Sarton, 
2008; Mogil, 2012). Correlations between cognitive performance and demograph-
ic factors are usually low and abolish when several variables are controlled. How-
ever, a recent study found that female sex predicted better in one test of attention 
and one test of memory (Loeber et al., 2012); but the authors consider this ﬁnding 
being related to sample bias.
A surprising ﬁnding is the fact the current or lifetime illicit drug use data, like 
drug screen results typically shows no effect or only small effect on cognitive func-
tioning in OST patients (Prosser et al., 2008; Rounsaville, Novelly, Kleber, & Jones, 
1981; Shmygalev et al., 2011; Specka et al., 2000).  However, a recent study which 
analysed speciﬁc cognitive domains, found several substance use history variables 
as predictors for attention, memory and executive function (Loeber et al., 2012). 
1.4.5 Few studies have examined the longitudinal changes of cog-
nitive performance during OST 
In the study by Grevert et al. (1977), memory performance was tested before meth-
adone treatment and then one and three months after treatment initiation. No dif-
ferences between patients and matched controls at baseline or later were found. 
Gordon et al. (1995) reported re-testing of overall cognitive performance of meth-
adone-treated patients using the WAIS intelligence test after a mean interval of 9 
years and 10 months. The majority of patients studied (25/30) showed improved 
performance. With this re-testing interval, a practice effect is not likely. The study 
of Gruber et al. (2006) found a statistically signiﬁcant improvement in the process-
ing speed, verbal list learning, and delayed visual memory in methadone patients 
between measurements at baseline and after two months of treatment (Gruber et 
al., 2006). However, the study lacked a control group, and a practice effect due to 
repeated testing within a short test interval cannot be ruled out. The need for more 
longitudinal studies is obvious. For instance, there are no longitudinal studies con-
cerning buprenorphine-treated patients. 
1.4.6 There is no consensus about driving fitness in OST patients 
Safe driving depends on a driver’s abilities and the way those abilities are used, that 
is, on performance and behavior (Lee, 2008). However, when the driving ﬁtness of 
an individual is assessed, the main focus is on driving performance. When an in-
dividual has a valid driver’s license, can handle a vehicle, and has no known major 
sensory or cognitive deﬁcits affecting driving, then by deﬁnition she/he is consid-
ered ﬁt to drive. Yet, in the case of OST patients the issue of driving ﬁtness seems 
to be hard to decide. 
39THL – Research 130 • 2014
1 Introduction
The ﬁrst studies dealing with driving ﬁtness in OST patients were based on the 
driving records of MMT patients, which already gave inconsistent ﬁndings. While 
one study concluded that methadone treatment is not a risk for driving (N.B. Gor-
don, 1976), another study published alarming ﬁgures about the driving safety of 
OST patient (Edwards & Quartaro, 1978). In a sample of 100 patients from a sin-
gle clinic in the United States, 87% of the patients drove a car. Most of them (82%) 
admitted driving while under the inﬂuence of the drug. Road trafﬁc accidents 
were common among them. A third of accidents occurred when the patients felt 
that they were under the inﬂuence of the drug. While the ﬁndings of Edwards and 
Quartaro, for example, have raised concerns among clinicians, it has taken many 
years for a series of well-controlled experimental studies focusing on the driving 
ﬁtness of OST patients to be reported (Chesher, Lemon, Gomel, & Murphy, 1995). 
In these studies Australian patients who had been on the same dose of methadone 
(mean 85 mg) for at least six months were tested  with driving-related cognitive 
tests before and 1 h after the dose. A second group of patients, who were not in 
a stabile phase yet, were tested when they were receiving an increase in their dose 
of methadone of 10 mg per day. A third patient group was tested while they were 
starting OST. Also, normal controls and abstinent ex-opioid users did the same 
tests. In order to ascertain that the test battery would be sensitive to the negative ef-
fects of the psychoactive substance, each group was also tested after doses of alco-
hol (mean blood alcohol concentration 0.064g %) or diazepam (15 mg). The test 
battery proved to be sensitive to the effects of alcohol and diazepam. Instead, there 
was no evidence for an effect of the acute dose of methadone on any of the patient 
groups. The authors concluded that patients in the methadone treatment program 
should be considered as non-impaired in their ability to drive a motor vehicle. 
In the same year that the Australian studies were reported, a series of German 
studies were also reported (Friedel & Berghaus, 1995). Surprisingly, the conclusion 
of the German studies was very different: “Heroin addicts treated with methadone 
are generally not ﬁt to drive. A positive evaluation might be possible in exceptional 
cases when there are special circumstances justifying it”. This conclusion was based 
mainly on the level of psychiatric comorbidity and especially personality disorders 
and lack of self-control in the trafﬁc. Also, some problems in cognitive driving-re-
lated tasks were noticed in the experiments made in the German patient samples. 
During the ﬁrst decade of the current millenium, many well-controlled stud-
ies concerning driving performance in OST patients have been published. Howev-
er, a recent review dismissed the idea that a recommendation of driving ﬁtness of 
OST patients could be determined on the basis of research ﬁndings (Strand, Fjeld, 
Arnestad, & Mørland, 2010). Several shortcomings in the studies so far were not-
ed. These include a lack of actual driving performance tests, great variability in the 
driving-related cognitive tests employed, and not analyzing the effects of other pre-
scription drugs commonly used by the patients.
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The major aim of this series of studies was to compare cognitive performance be-
tween OST patients and normal controls and to analyze drug treatment variables 
as correlates of performance. More speciﬁcally the aims of the studies were as fol-
lows:
1. Compare cognitive performance in OST patients in early treatment (study I);
2. Analyze cognitive performance in OST patients over time. This was done in two 
parts: 2. 
a) Longitudinal change of memory performance during the half year of OST 
(study II); and
b) Longitudinal change of cognitive performance during the ﬁrst year of OST 
(study III);
3. Analyze drug treatment variables as correlates of cognitive performance of OST 
patients. This was done in two parts:
a) Drug treatment variables as predictors of cognitive performance in OST pa-
tients (study IV)
b) Comparison of patients treated with opioid drug only (Additional analyses, 
unpublished); and
4. Examine driving ﬁtness of OST patients (study V).
The main hypotheses concerning drug treatment were as follows: First, we hy-
pothesized that because buprenorphine is a partial mu opioid receptor agonist and 
kappa antagonist, and may have less interaction effects with BZDs than metha-
done patients, patients treated with buprenorphine would show less cognitive def-
icits than those with methadone. Second, we hypothesized that memory consol-
idation would be impaired in OST patients treated along with a BZD drug. This 
hypotheses was based on experimental ﬁndings showing that mu opioid receptor 
agonists and BZDs both negatively affect memory consolidation (Curran, 1999; 
Guarna et al., 2004; Izquierdo & Medina, 1991). Third, we hypothesized that pa-
tients treated with buprenorphine would show greater cognitive improvement in 
long-term treatment in comparison to methadone-treated ones. This, hypothesis 
was based on the ﬁndings that buprenorphine may have cognition restoring ef-
fects that methadone is lacking (Spiga et al., 2008). Fourth, we hypothesized that 
there would be negative associations between opioid agonist dose and cognitive 
performance, BZD dose and cognitive performance, and the number of psycho-
active drugs (other than opioid or BZD) and cognitive performance in opioid-de-
pendent patients treated either with buprenorphine or methadone. Patients treat-
ed with several psychoactive drugs typically perform worse in cognitive tests than 
patients treated with a single drug (Meador, 1998; Starr et al., 2004).
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3.1 Study participants
The inclusion criteria for all participants were age between 18–50 years.  We ex-
cluded participants with current uncontrolled polysubstance abuse, acute alco-
hol abuse, or acute axis I psychiatric morbidity according to DSM-IV, other than 
substance abuse disorders. We also excluded participants with severe brain injury, 
chronic neurological disease, and history of other than substance-induced psycho-
ses, epileptic seizures, human immunodeﬁciency virus (HIV) infection, pregnan-
cy, or primary cognitive deﬁcit. All included OST patients were voluntarily admit-
ted for ﬁrst-time OST. All samples were natural and non-randomized.
In study I, the additional inclusion criteria for OST patients were starting of 
OST during the last six weeks and treatment with either buprenorphine/nalox-
one or methadone. Seventeen buprenorphine/naloxone-treated patients, 16 meth-
adone-treated ones, and 17 normal controls were tested. In study II, additional in-
clusion criteria for OST patients were BZD dependence or abuse diagnosis, start of 
OST with methadone, buprenorphine, or buprenorphine/naloxone during the last 
two months, and attendance at retesting between 6 and 9 months (T2) after OST 
admission. Normal controls were tested according to similar time intervals. Based 
on these criteria, 15 buprenorphine/naloxone- or buprenorphine-treated patients, 
13 methadone-treated patients and 15 normal control participants were tested 
twice. In study III, fourteen buprenorphine- or buprenorphine/naloxone-treated 
and 12 methadone-treated patients were three times tested with cognitive tests: 
within two months (T1), 6–9 months (T2), and 12–17 months (T3) from the start 
of OST. Fourteen normal controls were examined at similar intervals. In part II of 
the study the patient sample was extended to include 36 patients at T2 and T3 (18 
patients in both drug groups). In study IV the sample included 104 OST patients 
who had been in treatment for a minimum of six months and who were treated 
either with buprenorphine or methadone (n=52 in both drug groups). Thirty of 
them came from the longitudinal sample used in the previous studies. In study V 
the sample included 22 OST patients who had been in treatment for a minimum 
for one year and had a valid driver’s license. 
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3.2 Study ethics and funding
The studies were approved by the independent Hospital District of Helsinki and 
Uusimaa Ethical Committee (permission 90/2001), the A-Clinic Foundation, and 
the Helsinki City Bureau of Social and Welfare, all studies were conducted in ac-
cordance with the 1964 Declaration of Helsinki.
3.3 Study designs and measures
Studies I to IV used a non-randomized, quasi-experimental study design. This was 
because randomization of the participants into different opioid drug treatment 
groups was not possible as drug choices were done in the clinics according to clin-
ical guidelines. Study V describes a case series although a post-hoc group compar-
ison between drug treatment groups is included. Cognitive measures and driving 
performance were considered as outcome variables and other measures as back-
ground variables. Although verbal intelligence is a cognitive measure, it was how-
ever treated as a proxy for cognitive baseline, and thus used as a background var-
iable. 
3.3.1 Cognitive and other outcome measures: rationale and de-
scriptions 
Attention, working memory, and episodic memory were chosen as the cognitive 
variables of interest. All of these have practical relevance and tests for them are 
suitable for longitudinal testing. Attention is the spotlighting system of the hu-
man mind that is governed by external cues as well as internal states. The atten-
tion system of the brain is anatomically separate, though not fully independent, 
from the data processing systems that perform operations on speciﬁc inputs even 
when attention is oriented elsewhere (Posner & Petersen, 1990). Working memory 
is a system that stores and manipulates ‘spotted’ or otherwise selected items. Thus, 
working memory refers to the limited capacity short-term store that temporari-
ly maintains information, which is lost without rehearsal (Baddeley, 2003). Work-
ing memory function is considered a gateway for problem-solving in new situa-
tions that partly overlaps with ﬂuid intelligence and executive function. Episodic 
memory, often called simply memory, is central to human life since almost every-
thing in mental life is based on memory, except for the thin slice of the present time 
in which attention and working memory operate; but seldom without interaction 
with long-term memory stores. Episodic memory of events is the central form of 
long-term memory together with semantic and procedural long-term memory. In 
psychology, memory of events, however, is split into sensory-speciﬁc forms like 
verbal, visual, and tactual memory. This is based on the ﬁndings of brain lesion 
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studies showing that the size of the lesion and its location brings about memory 
disorders in one sensory modality with intact performance in another. It is still viv-
idly discussed what kind of memory functions should be called working memory, 
short-term memory, episodic, or long-term memory (Cowan, 2008; Henke, 2010; 
Squire, 2004). Yet, in various patient groups it is possible to ﬁnd cases with pre-
served working memory and impaired episodic memory functions as well as the 
opposite (Frisk & Milner, 1990). Driving ﬁtness of OST patients was assessed be-
cause there is no consensus about this issue and it is associated with cognitive per-
formance and drug treatment variables. 
Attention tests included the Alertness and Go/NoGo- tasks from the Test for At-
tentional Performance (TAP) using computer software and an RT key-pad. (Zim-
mermann & Fimm, 1995). In the Alertness task, visual RT was assessed with and 
without preceding auditory warning signal. The ‘without signal’ condition of the 
Alertness test is a simple RT task, and is thought to reﬂect tonic alertness (Sturm 
et al., 1999). The ‘with signal’ condition is thought to reﬂect both tonic and phasic 
alertness. The Go/NoGo condition assessed the integrity of response-selection and 
executive control of attention (Posner, Sheese, Odludas, & Tang, 2006; Rubia et al., 
2001). Visual stimuli were presented one by one. For two out of ﬁve stimuli an in-
stant reaction is required, and for the others a reaction needs to be inhibited. Re-
action times and correctness of responses were recorded. Reaction times, like those 
examined in our studies are thought to reﬂect alerting and orienting functions of 
the brain’s attentional networks. Executive control of action is involved to a lesser 
degree, although at least slightly, in the Go/NoGo task. 
Working memory tests included the Letter-Number-Sequencing task from the 
WMS-III and a computerized version of the Paced Auditory Serial Addition Task 
(PASAT) from the FORAMENRehab software package (Gronwall, 1977; Koski nen 
& Sarajuuri, 2002; Wecshler, 1996). The Letter Number Sequencing task assess-
es verbal working memory storage with added processing demands. In the PASAT, 
the complex working memory functions that are required are continuous storage 
of previous number, rapid arithmetical processing, and executive control of in-
terference from previous items or from ongoing adding process. In our study, the 
presentation rate of a new number to be added to the previous one was set as one 
every 1.6 second. The Letter Number Sequencing and the PASAT both draw on the 
resources of the verbal/auditory component of working memory and also to some 
degree on other components like the central executive. The PASAT, however, is not 
considered a pure cognitive test since emotional reactivity to stress may also mod-
ulate performance in the PASAT (Mathias, Stanford, & Houston, 2004). 
Episodic memory tests included two verbally presented list-learning and sto-
ry recall tasks: the Memory for Persons Data and the Logical Memory (Kaitaro, 
Kos kinen, & Kaipio, 1995; Lezak, 1995; Wecshler, 1996). Both tests were presented 
in modiﬁed versions. In the Logical Memory, which is a subtest of WMS-III, on-
ly one story was presented and recalled immediately and again after 30 minutes. 
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For those participants tested repeatedly a different story was given than previous-
ly (Studies II – IV). In the Memory for Persons Data only three persons, each with 
5 items, were presented. First there were two learning trials with immediate recall. 
If the participant could recall all 15 items correctly in both trials, no more learn-
ing trials were administered. If this condition was not met, there were additional 
trials until the participant was able to recall all the items correctly in two consec-
utive trials. A maximum of four trials were administered. After ﬁve minutes, re-
call of the items was requested and possible errors were corrected for. Finally, after 
30 minutes, delayed recall of all the items was requested. This measure was used in 
Study I as described here, with long-term delayed recall of the items (4–8 months 
after learning) tested in Study II. Study IV included also a visual memory measure, 
the Benton Visual Retention Test. It measures immediate visual memory by asking 
the examinee to draw a copy of a design that is ﬁrst shown for a study period of 
10 seconds (Benton, 1963). The number of correctly drawn designs was used as a 
score. In Study II subjective memory functioning was assessed by the Finnish ver-
sion of the Memory Complaint Questionnaire (Antikainen et al., 2001; Crook, Fe-
her, & Larrabee, 1992).
Verbal intelligence estimation was based on WAIS-R Vocabulary score 
(Wechsler, 1993). 
On-road driving test was done by the same licensed driving instructor for each 
participant. The test included various car driving tasks done in driving evalua-
tions devised for neurological patients (Peräaho & Keskinen, 2005). This evalua-
tion was meant for driving a car for non-professional purposes (Kuikka & Mäkin-
en, 2004). The driving instructor completed two formal evaluation sheets. Driving 
errors were classiﬁed as nonhazardous vs. hazardous errors. An error was classiﬁed 
as hazardous if it exposed anyone on the road to a potential risk. The marking of 
the errors was done according to the manual developed by the Finnish Vehicle Ad-
ministration (Keskinen, Hatakka, & Laapotti, 1998). In addition, the driving in-
structor gave a performance score for each of 11 driving domains. Scoring for per-
formance was as follows: 5=clearly strong, 4=strong, 3=neither strong nor weak, 
2=weak and 1=clearly weak (Peräaho & Keskinen, 2005). Finally, an overall driving 
safety assessment was done using four levels (Ramet & Summala, 2004). The high-
est level of driving safety was ‘safe driver in all conditions’, meaning that she/he was 
considered to be a safe driver in all places and in any road conditions. The next best 
level was ‘safe driver in normal conditions’, meaning that she/he was considered as 
a safe driver in all places, though good road conditions were necessary for safe driv-
ing. According to Finnish driving regulations, drivers belonging to the classes ‘safe 
driver in all conditions’ or ‘in normal conditions’ are considered ﬁt to drive a car. 
The last two classiﬁcations ‘safe driver only in the best conditions’ and ‘unsafe driv-
er’ are not considered ﬁt to drive. 
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Driving-related cognitive tests included the Determination, Peripheral Percep-
tion, Signal Detection, Stroop Interference, and Tachistoscopic Trafﬁc Perception 
tests from the computer-aided Vienna Test System (Biehl, 1996; Neuwirth & Ben-
esch, 2003; Puhr & Wagner, 2004; Schuhfried, 2004; Schuhfried, Prieler, & Bauer, 
2004). The determination test measures ‘resilience of attention and reaction speed 
under conditions of sensory stress’. The examinee is instructed to identify color or 
sound stimuli and react to them by pressing a correspondent response button us-
ing a response panel. The number of correct reactions was used as a score. The Pe-
ripheral Perception test measures visual perception and processing of peripheral 
information. The examinee is instructed to focus on a simple visual tracking task 
presented on the computer screen. Simultaneously, she/he should react by pressing 
a pedal whenever a critical visual stimuli is presented at their left or right periphery. 
Tracking deviation, a measure of divided attention, was used as a score. The Signal 
test measures long-term selective attention by demanding differentiation of rele-
vant visual signals from irrelevant ones. Median RT and the number of correct or 
delayed reactions were used as score variables. The purpose of the Stroop test is to 
evaluate inhibition of overlearned responses as opposed to consciously controlled 
ones. Median RT in the interference condition was used as a score. Version S4 (light 
pen) was used. The purpose of the Trafﬁc Perception Test is to evaluate visual ob-
servation ability and skill in obtaining an overview, and also of visual orientation 
ability and speed of perception. The examinee is shown 20 pictures of trafﬁc scenes 
for one second each. Then she/he has to select from a list that contains ﬁve differ-
ent items those that she/he remembers having seen in the picture. The number of 
correctly answered lists for the ‘Overview’ was used a score. In evaluating cognitive 
results age-independent norms were used, whenever possible. Scores that were not 
above the 16th percentile were considered to indicate problems in driving ability 
according to the ‘passed/non-passed test method’ (Gaertner et al., 2006). 
3.3.2 Other measures
In each study the eligibility of all participants was checked by a clinical psychiatric 
interview SCID I and diagnostic criteria from DSM-IV were applied (First, Gibbon, 
Spitzer, Williams, & Benjamin, 1997). Study V included also a clinical neurologi-
cal status and a trafﬁc vision evaluation done by a neurologist. All studies included 
urine drug screening, which was carried out in the clinics. For normal controls, drug 
screening was done on a random basis (one third were screened at each test point). 
Screening was done by using the Nano5 test (from Ferle Produkter AB; Helsing-
borg, Sweden). Also, the participants were interviewed about their recent and life-
time substance abuse history and medication use. Whenever possible, the data were 
checked against medical reports. In Study III, data about childhood mental health or 
behavioral problems were gathered using the Childhood Behavioral Checklist (Tart-
er, McBride, Buonpane, & Schneider, 1977) as a basis for interview, with medical 
reports used whenever possible. Driving experience information and the patient’s 
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own view about driving safety in Study V was asked by a questionnaire devised for 
the study. In addition the patients evaluated the distressing effects of 22 driving sit-
uations by choosing one of four alternatives (not at all distressing, somewhat dis-
tressing, quite distressing, or very distressing); they also reported the frequency of 
22 driving errors by choosing one of four alternatives (never, occasionally, quite 
often, almost every time I drive) (Peräaho & Keskinen, 2005). Table 6 presents the 
variables used in each study.
3.3.3 Procedures
Since the timing of the test after administration of a psychoactive drug is an impor-
tant variable when cognitive performance is examined, cognitive testing was done 
to all participants according to the same time frame: three to six hours (Studies I 
– IV) or two to seven hours after the administration of opioid substitution drug 
(Study V). In order to estimate the current benzodiazepine doses of the groups, all 
benzodiazepines were converted to diazepam equivalent doses. There was, howev-
er, slight variation on the conversion tables used in the studies. In Studies I and II 
the Ashton table was used (Ashton, 2005). In Studies III and IV the Nelson’s and 
Chouinard’s table was used (Nelson & Chouinard, 1999). In Study V Bazire’s psy-
chotropic drug directory was used (Bazire, 2003). The changes in the conversion 
tables were motivated by the search for the clinically most relevant table. For the 
drugs used only as hypnotics, the dose was halved before conversion. 
3.4 Statistical analyses
In all analyses, statistical signiﬁcance was set at p < 0.05 (two-tailed).
3.4.1 Comparison of cognitive performance in OST patients in 
early treatment against normal controls (Study I)
Analysis of variance (ANOVA) was used to study the overall group effect in each 
cognitive measure of the study. This was followed, when appropriate, by pairwise 
group comparisons (patient groups against normal controls). We used multiple 
planned ANOVAs because comparisons were aimed at each variable separately. 
The Holm’s sequential Bonferroni procedure was used to control for Type I error 
across the pairwise comparisons (Holm, 1979). We examined the homogeneity of 
variances in each measure by means of Levene’s test. Whenever necessary, the da-
ta were ﬁrst transformed by reciprocal or logarithmic transformation to normalize 
the distributions. For both of the Go/NoGo conditions, the last two learning trials 
of the Memory for Persons Data, and in the delayed recall of the Memory for Per-
sons Data, the distributions could not be normalized. We analyzed these results by 
non-parametric Kruskal-Wallis ANOVA, which were then followed, when appro-
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Time
Outcomes
Attention Working memory Memory Driving-re-
lated cogni-
tive tests
Other variables of 
interest
T1 Alertness and Go/
NoGo tests from 
the TAP
(I and III) 
The Letter Number 
Sequencing from 
the WMS-III 
(I, II and III)
The PASAT
(I, II and III)
The Logical Mem-
ory from the 
WMS-III 
(I, II and III)
The Memory for 
Persons Data 
(I and II)
T2 Alertness and Go/
NoGo tests from 
the TAP
(III) 
The Letter Number 
Sequencing 
(II and III)
The PASAT (III and 
III)
The Logical 
Memory  
(II and III)
The Memory for 
Persons Data (II)
Subjective memory 
complaints (II)
T3 Alertness (III and 
IV)) and Go/No-
Go (III) tests from 
the TAP 
The Letter Number 
Sequencing 
(III and IV)
The PASAT
(III)
The Benton Visual 
Retention Test (IV) 
The Logical 
Memory
(III and IV)
Five sub-
tests from 
the Vienna 
Test 
System (V)
Driving safety 
assessment (V)
Driving performance 
assessment (V)
Time
Background variables and other measures
Demographic and 
comorbidity
 variables
SUD variables Drug treatment variables
T1 Age, education, 
sex, and VIQ  (I, II, 
III) DSM-IV diag-
nostic  (prevalence 
of axis I and II di-
agnoses; II)
Drug screen (I–III), Current SUD (de-
pendencies; I and II), The past month 
substance use (substances abused I 
and II),  Frequency of substance abuse 
in the past month (IIII and IV), Dura-
tion of any substance abuse (I and II), 
Onset age of any substance abuse (II– 
III), Onset age of opioid abuse (II – III) 
OST drug (type, duration I–V), BZD 
(type; I (prevalence, diazepam 
equivalent dose), Other psychoac-
tive drugs (type;  I and II), Other psy-
choactive drugs (number:  III and VI)
T2 Age, education, 
sex, and VIQ  (I, 
II, III), Early neu-
robehavioral prob-
lems (III) 
Drug screen (II–III), Duration of sub-
stance any abuse history (II), Duration 
of opioid abuse (II) Frequency of sub-
stance abuse in the past month (III 
and IV), Years of heavy alcohol abuse 
(III)
OST drug (type, duration I–V), BZD 
drugs (prevalence, diazepam equiv-
alent dose) Other psychoactive 
drugs by type (type I and II; number 
III and IV)
T3 Age, education, 
and sex (V), Age, 
driving informa-
tion, mild head in-
jurius, and sex (V)
Drug screen (III and IV), Onset age of 
any substance abuse (IV, and Opioid 
overdoses (V)
OST drug (type, duration I–V), BZD 
drugs (prevalence, type, diazepam 
equivalent dose), and Other psycho-
active drugs by type (type I and II; 
number III and IV)
TABLE 6. Measures and background variables used in the studies
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priate, by a pair-wise Mann-Whitney U test. We did not covary for the group dif-
ference in education, which favored the control group over the methadone group. 
This was based on the contention that the assumption of a similar linear relation 
between education and cognitive performance in both groups needed for an anal-
ysis of covariance (ANCOVA) was not met. All participants with opioid depend-
ence had started substance abuse in their early teen years. Once the substance abuse 
history begins it soon affects educational achievement through class non-attend-
ance etc. So, years of education does not reﬂect cognitive ability in this population 
similarly to the general population (Lynskey & Hall, 2000). However, in the second 
phase of the analysis, in order to evaluate the role of premorbid intellectual factors, 
we set verbal IQ as a covariate for other measures than RT measures. The associ-
ation between simple RT measures and intelligence is weak and may not be linear 
(Der & Deary, 2003). Demographic data was studied as pairwise group compari-
sons without ﬁrst requiring a signiﬁcant overall group effect.
3.4.2 Longitudinal change of memory performance during the 
first half year of OST in patients treated with benzodiazepines 
(Study II)
Overall group differences in memory performance at T1 and T2 were tested for 
statistical signiﬁcance using multiple planned analyses of covariance (ANCOVA) 
with years of education and verbal IQ estimate as covariates. Although there were 
no statistically signiﬁcant differences between the groups in the verbal IQ, it was 
used as a covariate since it is known to affect memory performance in tasks with 
verbal content (Alexander & Smales, 1997). ANCOVA was followed, when appro-
priate, by pairwise group comparisons using the normal comparison group as a 
reference group. Similarly to Study I the Holm’s sequential Bonferroni procedure 
was used to control for Type I error. In the Memory for Persons Data, the data were 
highly skewed at T1 and T2. Therefore, we analyzed these conditions by means 
of Kruskal-Wallis ANOVAs, which were followed, when appropriate, by pairwise 
Mann-Whitney U tests. In order to conﬁrm the validity of combining buprenor-
phine/naloxone and buprenorphine-only patients, the ANCOVAs and ANOVAs 
were also performed with buprenorphine/naloxone patients (n=12). The cross-
sectional Memory Complaint Questionnaire scores and the Memory Complaint 
Questionnaire differences between high vs. low score groups at T2 were analyzed 
by t-tests or Mann-Whitney U tests. Correlations between the Memory Complaint 
Questionnaire values and cognitive variables were analyzed by Pearson’s product 
moment correlation or Spearman’s rho correlations, depending on the normality 
of the variables. The statistical signiﬁcance of correlations was determined by using 
the Holm-Bonferroni procedure. Longitudinal changes were analyzed by repeated 
measures ANCOVA, using education and VIQ as covariates and normal controls 
as a reference group.
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3.4.3 Longitudinal change of cognitive performance during the 
first year of OST and its correlates (Study III)
Longitudinal changes in cognitive performance were examined by repeated-meas-
ures analysis of variance (ANOVA) using a general linear model approach. Group 
was used as a between-subjects factor and time as a within-subjects factor. Before 
the analyses, the normality assumptions of cognitive variables were examined by 
Shapiro-Wilk’s test and homogeneity of variance by Levene’s test. The data were 
also screened for outlying values. On the basis of these procedures, RT and the 
PASAT scores were subjected to log transformations before further analyses, and 
the Go/NoGo errors were examined by non-parametric Kruskal-Wallis ANOVA. 
Sphericity assumption was tested by Mauchly’s test, and when appropriate, anal-
yses of effects were interpreted using the Huynh-Feldt correction. The effects of 
demographic variables on cognitive performance were tested as covariates. Only 
signiﬁcant covariates were retained in the model. Statistically signiﬁcant between-
groups effects were followed by planned contrast using normal controls as a refer-
ence group. Signiﬁcant time-effects were examined using repeated contrast (T2 vs. 
T1 and T3 vs. T2). When a signiﬁcant group-by-time interaction effect was noted, 
it was examined further by combining previous contrasts (normal control vs. bu-
prenorphine group * T2 vs. T1, normal control vs. buprenorphine group * T3 vs. 
T2; and normal control vs. methadone group, respectively).
Cognitive tests selected for the analyses of correlations were the same as used 
when analyzing longitudinal changes, except that the PASAT was excluded from the 
analyses because of the practice effect on this measure. In order to reduce the num-
ber of cognitive variables, correlations between the variables analyzed—and when-
ever justiﬁed, domain-wise cognitive sum scores for T2 and T3 performances—
were formed. T2 performance was used as a reference point in T3 summed scores. 
A mean composite score called attention performance was calculated after convert-
ing the test scores into z-scores. The working memory measure, the Letter-Number 
Sequencing task, showed only low to moderate correlations with other measures 
and therefore it was not combined with other measures. The verbal memory meas-
ures used in the study, that is immediate and delayed recall of the Logical Memory, 
correlated strongly at both test points (.80 at T2 and .91 at T3). Therefore, a mean 
sum score called verbal memory was formed after z-score conversion. Then group 
differences in cognitive function were examined by a repeated-measures analysis of 
variance (ANOVA) using a general linear model approach. After this all signiﬁcant 
or the three highest correlates of each cognitive variable were further examined by 
checking for any intercorrelations between these variables and other variables of 
interest. Also, medication variables were checked for signiﬁcant intercorrelations. 
Then the three highest correlations for each cognitive domain were investigated by 
an analyses of semipartial correlations. 
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3.4.4 Drug treatment variables as predictors of cognitive perfor-
mance in OST patients (Study IV)
Group-wise comparisons of cognitive performance between buprenorphine and 
methadone patients were done by an analysis of variance (ANOVA). As our ver-
bal and visual memory tests lacked age-corrected norm values and there was a sig-
niﬁcant difference between the patient groups on age, an analysis of covariance 
(ANCOVA) using age as a covariate was done when testing these parameters. In 
all group-wise comparisons, the normality assumptions of the cognitive variables 
were ﬁrst examined by Shapiro-Wilk’s test and the homogeneity of variance by the 
Levene’s test. When appropriate, analyses of the main effects were interpreted us-
ing the Welch correction for heterogeneous variances. The data were also screened 
for outlying values. There was a strong positive correlation (.78) between the alert-
ness task conditions, and therefore these measures were combined by standardiz-
ing the values and pooling them. The assumption of a linear relationship between 
the dependent variable and predictors was checked by plotting the data (LOWESS 
curves) and by a lack-of-ﬁt test. In order to ascertain the linearity between the de-
pendent variable and predictors, many of the predictors were transformed into di-
chotomous ordinal variables. Buprenorphine doses up to 16 mg were considered 
as low dose and higher values as high. BZD doses were considered as low if low-
er than 20 mg and higher if 20 mg or above. The number of prescribed psychoac-
tive drugs, other than OST or BZD drug, was considered as low if up to one drug, 
and high if two or more other drugs. Duration of OST was considered as short if 
between six and twelve months, and long if above this. Substance abuse in the pre-
vious month was dichotomized as high vs. low frequency of abuse. Abstinence or 
substance abuse up to two days a week was considered low-frequency substance 
abuse, and values above this as high-frequency substance abuse. Age of onset for 
substance abuse was considered as early onset up to 14 years of age, and as late on-
set if aged 15 years or older. Education was considered as low if no higher educa-
tion than primary education had been completed, and as high if any secondary 
education had been completed. Homogeneity of error variance (homoscedastic-
ity) was conﬁrmed graphically by plotting the standardized residual against the 
predicted values. Independence of errors was checked using the Durbin-Watson 
test. Normality of residuals was checked by normality plots and using the Shapiro-
Wilk’s test. Because our main interest was to examine drug treatment variables as 
predictors of cognitive performance, we employed multiple sequential/hierarchi-
cal linear regression analysis. First, the full model was examined as follows. Demo-
graphic variables, substance abuse variables, and the number of tests (one vs. more 
than one), were ﬁrst entered into the model as control variables. Demographic var-
iables included sex, level of education, and age if the test values were not age-cor-
rected initially. Substance abuse variables included age of onset of substance abuse 
and frequency of substance abuse in the past month. Control variables were re-
53THL – Research 130 • 2014
3 Methods
tained in the subsequent reduced model only if they gave a statistically signiﬁcant 
contribution to the full model as a block or individually. The number of tests was 
also checked for the direction of association, with a positive association indicating 
a practice effect of repeated testing. Drug treatment variables included opioid drug 
type (buprenorphine vs. methadone), BZD treatment (yes vs. no), the number of 
psychoactive drugs (other than opioid or BZD drugs), and duration of OST (long 
vs. short). All drug treatment variables were entered sequentially into the reduced 
model. Unless otherwise stated, explained variance (R2) is reported as an adjusted 
value, and the regression coefﬁcient as a standardized value (beta). 
3.4.5 Driving fitness of OST patients (study V)
Group comparisons between patients with probable vs. improbable drug-related 
driving impairment were performed using the non-parametric Mann-Whitney U 
tests or Fisher’s exact test. Correlations between driving test scores and drug doses 
were analyzed by the non-parametric Spearman’s rho. 
In all studies statistical analyses were done by IBM SPSS statistical software 
(“IBM SPSS Statistics for Windows,” 2011). Versions 13.0 (Study I), 15.0 (Studies 
II and III), and 20.0 (Studies IV, V, and additional analyses) were used. Effect sizes, 
however, were calculated by an effect-size calculator provided by Durham Univer-
sity, UK (“Effect size calculator,” 2006). In the effect-size analyses we used pooled 
samples and corrected the values by means of Hedge’s correction for small sam-
ple bias. 
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4.1 Cognitive performance of OST patients in early 
treatment (Studies I and II)
The main demographic characteristics of the samples in Studies I and II are shown 
in Table 7. As presented in the table the patient groups had attained less education 
than the controls. 
TABLE 7. Group demographics in studies I and II
Study I Buprenorphine/ 
Naloxone 
(n = 17)
Methadone 
(n =16)
Normal Control
(n = 17)
Group compari-
son  p-values
M  ± SD M  ± SD M  ± SD
Age (years) 28.1 ± 6.3 30.8 ± 8.8 31.1 ± 11.2 ns
Sex (female/
male)
7/10 9/7 9/8 ns
Verbal intelli-
gence a
102.4 ± 8.4 98.4 ± 8.7    105.4 ± 9.8 METH < NC*
Education, 
(years)
11.1 ± 2.2 10.4 ± 2.0 13.0 ± 1.7 BN < NC**
METH < NC**
Days in OST  11.0 ± 8.1 14.3 ± 7.4 – ns
Study II Buprenorphine 
and BZD
Methadone and 
BZD
Normal Control
(n = 15)b (n =13) (n = 15)
M ± SD M ± SD M ± SD
Age (years) 27.7 ± 6.8 29.2 ± 6.8 28.7 ± 9.6 ns
Sex (female/
male)
4/11 7/6 8/7 ns
Verbal intelli-
gence a
99.4 ± 9.3 100.6 ± 11.4    104.1 ± 9.6 ns
Education (years) 10.5 ± 2.0 10.1 ± 1.2 12.6 ± 1.3 METH <  NC*** 
BN <  NC**   
Days in OST at T1 19 ± 12 21 ± 14 – ns
Days in OST at T2 224 ± 17 213 ± 25 – ns
Note. Modifed from publications I and II. BN = buprenorphine/naloxone; METH = methadone, 
NC = Normal control.
aEstimation based on WAIS-R Vocabulary score. 
bIncludes buprenorphine and buprenorphine/naloxone treated patients.
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Buprenorphine patients in 
comparison to normal controls 
Methadone patients in comparison 
to normal controls
Attention METH < NC*
Go/NoGo RT  d = 0.88 (I)
Working memory BN < NC** METH < NC** 
Letter Number Sequencing  Letter Number Sequencing 
d = 1.21 (I)  d = 1.02 (I)
BN + BZD < NC**
Letter Number Sequencing 
d = 1.01 (II)
BN < NC*** METH < NC** 
PASAT PASAT 
d = 1.60 (I) d = 1.27 (I)
BN + BZD < NC*** METH + BZD < NC*** 
PASAT PASAT 
d = 1.54 (II) d = 1.43 (II)
Episodic memory BN < NC* METH < NC *
Memory for Persons Data, first trial Memory for Persons Data, first trial
d = 1.19 (I) d = 1.22 (I)
BN + BZD < NC* METH + BZD < NC *
Memory for Persons Data, first trial (II) Memory for Persons Data, first trial (II)
METH < NC **
Logical Memory
d = 1.17(I)
BN < NC* METH < NC*
Memory for Persons Data, delayed (I) Memory for Persons Data, delayed (I)
Subjective memo-
ry complaintsa
NC < BN + BZD** NC < METH + BZD **
Memory Complaint Questionnaire (II) Memory Complaint Questionnaire (II)
Note. Modifed from publications I and II. BN = buprenorphine/naloxone; METH = methadone; 
NC = Normal control.
aSmaller indicates less complaints.
< = inferior than or less than; ***= statistically significant at level p < .0.001; **= statistically signifi-
cant at level p < .0.01; *= statistically significant at level p < .0.05; d = eﬀect size.
TABLE 8. Statistically signiﬁcant differences in cognitive measures and subjective memory 
complaints between patient groups and normal controls during early treatment
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Tables 8 and 9 summarize the statistically signiﬁcant group differences found 
in early treatment studies in each cognitive domain examined. As presented in Ta-
ble 8, methadone patients showed inferior performance in relation to normal con-
trols in the Go/NoGo RT. In working memory, episodic memory, and subjective 
memory complaints patients showed deﬁcits in nearly every measure. 
As presented in Table 9, methadone-treated patients were inferior in com-
parison to buprenorphine/naloxone ones in tonic alertness (simple RT). This dif-
ference remained signiﬁcant when the comparison was done in the subsample 
of patients having an opioid drug along with a BZD drug (n=13 in both opioid 
drug groups). In addition, patients treated with methadone (mean dose 54.2 mg ± 
SD=18.7) along with a BZD drug (mean diazepam equivalent dose 28.3 mg ± 18.6) 
were inferior to the respective buprenorphine/naloxone ones (mean dose 16.3 mg 
± 2.9 for buprenorphine and 25.6 mg ± 10.1 for BZD) in the delayed story recall 
(the Logical Memory). All participants in both groups were dependent on BZDs 
and had used them in the month before OST. In the demographic variables, there 
were no signiﬁcant differences between these subgroups.
TABLE 9. Statistically signiﬁcant comparisons between opioid drug groups during early 
treatment
Group comparison significance level
Measure, Eﬀect size, if possible (Study number)
Attention METH < BN **
TAP, tonic alertness  
d = 1.11 (I)
METH + BZD < BN + BZD*a
TAP, tonic alertness (I)
Working memory All comparisons ns
Memory METH + BZD < BN + BZD*a
Logical Memory
d = 0.94 (I)
Note. Modifed from publications I and II. BN = buprenorphine/naloxone; 
METH = methadone; NC = Normal control.
aSubsample of patients in study I.
< = inferior than or less than; ***= statistically significant at level p < .0.001; **= statis-
tically significant at level p < .0.01; *= statistically significant at level p < .0.05; d = ef-
fect size.
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Further post hoc analyses were done to study the role of OST doses on cog-
nitive performance in Study I. For these analyses, we split the patient groups in-
to low vs. high dose groups, depending on their median OST drug dosage. After 
this division the mean doses of methadone in the low dose (n=8) and high dose 
group (n=8) were 40.0 ± 5.3 mg and 66.9 ± 17.3 mg, respectively. Patients with a 
low methadone dose had faster RTs in all conditions than patients with high dose. 
Figure 4 depicts these differences. In the tonic alertness (simple RT) the difference 
reached statistical signiﬁcance (p=0.025, d=1.19). The mean simple RT time in the 
low methadone dose group was 240 ± 30 ms which practically equals the perfor-
mance of the normal control group (244 ± 30 ms). The low dose group had been 
fewer days on OST medication than the high dose group (9 ± 2 vs. 20 ± 6, respec-
tively, p < 0.001). No other signiﬁcant differences between the groups emerged 
in the demographic or medication variables. Among buprenorphine/naloxone pa-
tients, nine patients received the same dose of 16 mg, and very few cases fell in the 
tails of the dose distribution. As a result, dose analyses were not carried out.
0
100
200
300
400
500
600
Tonic Alertness 
(Simple RT)
Phasic Alertness 
(RT with signal)
Go/NoGo RT
Milliseconds
Low dose 
(mean 40.0 ± 5.3 mg)
High dose
(mean 66.9 ± 17.3 mg)
Note. Modified from publication I.
FIGURE 4. Comparison of high vs. low methadone dose groups in reaction times in early 
treatment (Study I).
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4.2 Longitudinal change (Studies II and III)
4.2.1 Longitudinal change of memory performance during the 
first half year of OST in patients treated with benzodiazepines (II)
The main demographic characteristics of the sample in Study II are presented in 
the lower part of the Table 7. Results concerning T1 (within two months from OST 
initiation) are presented in Table 8 (marked with II). Analyses of T2 results (af-
ter 6–9 months from OST initiation) are presented in Table 10. As shown by Ta-
bles 8 and 10, both patient groups were inferior in comparison to normal controls 
in both working memory tests and memory complaints. As the overall group ef-
fect was non-signiﬁcant in all episodic memory tests, pairwise comparisons were 
not performed in these measures. All time or group-by-time effects were non-sig-
niﬁcant.
After correction for multiple comparisons, the only signiﬁcant correlation 
between objective and subjective memory performance was the one between the 
Memory Complaint Questionnaire score at T1 and the long delay free recall of 
the Memory for Persons Data items at T2; that is, at least four months after initial 
learning, (-.58 , p =0.028). This relationship is depicted in Figure 5. 
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TABLE 10. Group comparisons of memory functions at T2
BN along 
with BZD 
(n = 15)
METH along 
with BZD  
(n = 13)
Normal
Control  
n = 15)
Statistical 
comparisons 
between normal 
control and 
patient groupsa,b
Eﬀect sizes 
as Cohen’s d 
whenever 
possible 
  M ± SD M ± SD M ± SD
Working memory
Letter Number 
Sequencing (raw score)
9.2 ± 2.3 8.6 ± 2.1 11.6 ± 2.9 BN + BDZ < NC*
M+ BZD < NC*
0.83
1.05
PASAT (raw score) 34.1 ± 8.4a 31.6 ± 8.6 46.0 ± 8. 7c BN + BZD < NC**
M + BZD < NC**
1.24
1.42
Immediate episodic memory
Logical Memory  imme-
diate recall (raw score)
14.1 ± 3.3 14.2 ± 3.1 16.3 ± 3.1 - -
Episodic memory consolidation
Logical Memory (free 
recall retention % 
after short-term delay 
of 30 min) 
93.8  ± 17.1 87.1 ±14.4 98.3 ± 14.1  -
Memory for Persons 
Data (free recall  reten-
tion % after long delay  
of 4–8 mo)  
29.8 ± 23.2 22.1 ± 18.1 32.4 ± 22.1 - -
Memory for Persons 
Data (recognition  % 
after long delay  of 4–8 
mo) 
82.1 ± 12.9 79.6 ± 10.6 81.3 ± 10.7 - -
Memory complaints
Memory Complaint 
Questionnaire (raw 
scored)
24.5 ± 6.7 25.6 ± 3.2 20.4 ± 1.5 NC < BN + BZD*
NC < M + BZD***
n/a
n/a
Note. Modified from study publication II. BN = buprenorphine or buprenorphine/naloxone; METH or 
METH or M = methadone.NC = Normal control;  n/a = not available
a  =   using  years of education  and VIQ adjusted scores, whenever possible;   
b = done only if overall ANOVA is significant and the corrected for multiple comparisons by Bonferro-
ni-Holm method.
c = Missing value of one participant was substituted by carry-over value from the first test; 
d = smaller indicates less complaints.
< = inferior than or less than; *** = statistically significant at level p < 0.001, ** = statistically signifi-
cant at level p < 0.01, * = statistically significant at level p < 0.05.
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FIGURE 5. Correlation between memory complaints (T1) and the Memory for Persons Da-
ta, delayed recall (T2).
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Note. Modified from publication II.
4.2.2 Longitudinal change of cognitive performance during the 
first year of OST and its correlates (III)
There were two parts in Study III. Part I presents the results of the follow-up study 
of fourteen buprenorphine-treated and 12 methadone-treated patients in compar-
ison to 14 normal controls. Tests were done within two months (T1), 6–9 months 
(T2) and 12–17 months (T3) from the beginning of OST. The controls were tested 
at similar intervals. Part II analyzed the correlates for cognitive performance at T2 
and T3 using a sample of 36 patients. Table 11 shows the main demographic char-
acteristics of the samples.
The pattern of means in Table 12 identiﬁes change over time in cognitive per-
formance in each group. There were statistically signiﬁcant overall group differenc-
es in all attention and memory measures. As is apparent from the Table, the meth-
adone-treated patient group constantly lagged behind the normal control group 
in the TAP RT tests that measured attention. Planned contrasts conﬁrmed that the 
normal controls outperformed the methadone group in these measures (p=0.002 
for the TAP tonic alertness/simple RT; p=0.002 for the TAP phasic alertness/RT 
with-auditory-warning-signal; and p=0.001 for the TAP Go/NoGo RT). There 
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TABLE 11. Group demographics in Study III
Group Group
 comparison 
p-values
Group Group or 
time point 
comparison 
p-values
BN part I METH part I NC BN part II METH part II 
(n = 14)a  (n = 12) (n = 14) (n = 18)a (n =18) 
M ± SD M ± SD M ± SD M ± SD M ± SD
Age (years)   30  ± 7  31 ± 8   29 ± 10 ns  30 ± 8  32  ± 8 ns
Sex (female 
/male)
 36 
/ 64%
50 
/ 50%
 50 
/ 50 %
ns   28 
/ 72%
  33 
/ 67%
ns
Intelli-
genceb
101 ± 11  98 ± 9 105 ± 8 ns 101 ± 8 100 ± 11 ns 
Education 
(years)
 10 ± 2 10 ± 1  13 ± 1 BN < NC ***
METH  < NC***
 10 ± 2  11 ± 1 ns
Days in OST at testc 
T1 21 ± 15 20 ± 14 − ns
T2 210 ± 20 200 ± 28 − ns 211 ±19 196 ± 27 ns
T3 414 ± 46 405 ± 31 − ns 411 ± 43 405 ± 29 ns
Note. Modified from study publication III. BN = buprenorphine patients, METH = methadone patients, and 
NC = normal controls.
a Includes buprenorphine/naloxone-treated patients.  
b Estimation based on the vocabulary and picture completion subtests of the Wechsler Adult Intelligence 
Scale – Revised (WAIS-R) (Wechsler, 1993). 
c Tested only between patient groups. 
< = inferior than, *** = statistically significant at level p < 0.001, ** = statistically significant at level 
p < 0.01, * = statistically significant at level p < 0.05.
were no signiﬁcant time or group-by-time interaction effects in these measures. 
Errors in the Go/NoGo task were rare in all groups, and no signiﬁcant between-
group differences were observed. In both working memory measures there was an 
overall group effect. In the PASAT the planned contrast revealed that both patient 
groups performed overall worse than the normal controls at the level of p=0.001. 
In the Letter-Number Sequencing the values were p=0.016, for normal controls vs. 
buprenorphine patients and p=0.008 for normal controls vs. methadone patients. 
However, since there was also a time effect (the PASAT), or a group-by-time inter-
action effect (the Letter-Number Sequencing) in these measures, further analyses 
are needed before making a ﬁnal interpretation. In the PASAT the improvement 
in overall performance between T1 and T2 turned out to be non-signiﬁcant, but 
the overall improvement betweenT2t and T3 was signiﬁcant (p=0.01). As appar-
ent from Figure 6, the source of the group-by-time interaction in the Letter-Num-
ber Sequencing was due to differences between the groups between T2 and T3. This 
was conﬁrmed by a planned contrast that showed improved performance in the 
buprenorphine patients between T2 and T3 relative to the normal control group, 
p=0.017. Effect size of the T2−T3 improvement in the buprenorphine group, as 
measured by Cohen’s d, was 0.77.
63THL – Research 130 • 2014
4 Results
TABLE 12.  Group comparisons of cognitive performances using repeated measures  
ANOVA in the part I sample
Buprenorphine 
(n = 14)
Methadone
(n = 12)
Normal control 
(n = 14)
Statistical 
comparison 
p-values M ± SD M ± SD M ± SD
TAP Tonic Alertness/ simple RT (ms)
T1 232 ± 25 261 ± 21 238 ± 22  Group,  p = 0.002
T2 236 ± 18 263.± 21 233 ± 21a Time, ns
T3 242  ± 25 267 ± 36 241 ± 25 Group x Time, ns
TAP Phasic Alertness/ RT  with warning signal (ms)
T1 227 ± 24 244 ± 20 226 ±21 Group,  p = 0.005
T2 229 ± 21 255 ±28 224 ± 21 a Time, ns
T3 229 ± 19 254 ±45 225 ± 22 Group x Time, ns
TAP Go-NoGo RT (ms)
T1 490 ± 50 548 ± 74 460 ± 41 Group,  p = 0.001 
T2 480 ± 42 548 ± 104 443 ± 72 a Time, ns
T3 493 ± 43 529 ± 63 462 ± 47 Group x Time, ns
TAP Go-NoGo errors
T1 1.1 ± 1.3 0.7 ± 0.6 0.5 ± 0.5 ns
T2 0.5 ± 0.7 1.0  ± 0.9 0.5 ± 0.8 a ns
T3 0.6 ± 0.8 0.5 ± 1.0 0.2 ± 0.4 ns
The Letter-Number Sequencing (raw score)
T1 8.4 ± 2.2 9.3  ± 2.4 11.8 ± 3.4 Group,  p = 0.009
T2 8.8  ± 2.2 8.5 ± 2.3 11.6  ± 3.0 Time, ns
T3 10.6 ± 2.2 8.8 ± 2.4 11.2 ± 3.2 Group x Time, p = 0.007 
The PASAT (raw score)
T1 32.4 ± 10.5 31.0 ± 8.5 46.3 ± 9.7 Group,  p = 0.001
T2 35.0 ± 6.8 33.4 ± 10.1 45.8 ± 9.0 a Time, p = 0.013
T3 35.8 ± 10.0 34.9 ± 11.0 49.8 ± 8.4 Group x Time, ns
Logical memory, immediate(raw score)
T1 12.8 ± 2.6 14.9 ± 4.5 15.9 ± 3.3 Group,  p = 0.016
T2 13.8 ± 3.1 14.8 ± 3.7 16.3 ± 3.2 Time, ns
T3 15.5 ± 4.1 14.3 ± 4.3 17.9 ± 2.9 Group x Time, ns
Logical memory, delayed (raw score)
T1 11.8 ± 3.0 13.1 ± 4.0 13.9 ± 4.0 Group,  p = 0.013
T2 12.0 ± 4.0 13.7 ± 4.0 15.6 ± 3.1 Time, ns
T3 12.4 ± 4.1 11.8 ± 4.7 15.9 ± 3.6 Group x Time, ns
Note. Modified from study publication III. Bold indicates a statistically significant eﬀect.
a One missing value was replaced by the carry-over value from the preceding testing point.
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In verbal memory, there was a signiﬁcant overall group effect both in immedi-
ate and delayed condition of the Logical Memory. Both patient groups performed 
worse than the normal controls in the immediate Logical Memory, p=0.029 for the 
buprenorphine group; and p=0.007 for the methadone group. In the delayed Log-
ical Memory the values were p=0.005, and p=0.028, respectively. 
FIGURE 6. Longitudinal change of group performances in the Letter Number Sequencing 
Task in the sample I of study III.
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65THL – Research 130 • 2014
4 Results
4.3 Drug treatment variables as predictors of 
cognitive performance in OST patients (study IV)
There were equal number of buprenorphine- and methadone treated patients in 
the sample (n=52 in both groups). Methadone patients were four years older on 
average than the buprenorphine ones (35 ± 8 and 31 ±7 years, respectively), and 
this difference was statistically signiﬁcant (p=0.007). Buprenorphine patients had 
been in treatment for a slightly, non-signiﬁcantly, shorter time than methadone 
patients (14 ± 7 vs. 17 ± 10 months, respectively; p=0.08). Otherwise the groups 
were very close to each other in terms of demographic variables.  The mean dose 
of buprenorphine was 20 ± 6 mg and 113 ± 49 mg of methadone in the respective 
patient groups. Other prescribed co-mediations and especially BZD prescriptions 
were common in both opioid drug groups (81 and 71% in buprenorphine patients 
vs. 83 and 73% in methadone patients, respectively). Sixty-ﬁve percent in the bu-
prenorphine group and 63% in the methadone group were prescribed some other 
psychoactive drug than opioid or BZD drugs. These could include anticonvulsants 
(used as mood stabilizers), antidepressants, neuroleptics (used with anxiolytic in-
dications), non-benzodiazepine hypnotics, and non-opioid pain killers. Thirty-
ﬁve percent of patients in the buprenorphine group and 42% in the methadone 
groups had high-frequency substance abuse in the past month.  In group compar-
isons of cognitive performance buprenorphine-treated patients showed statistical-
ly signiﬁcantly faster simple RTs than methadone-treated ones (the ‘without warn-
ing signal’ condition of the alertness test, 247 ± 21 and 260 ± 30, respectively; 
F(1,100)=5.00, p=0.028). No other signiﬁcant differences emerged. 
4.3.1 Predictors of attention performance
When control variables were ﬁrst entered into the full model they could predict on-
ly 1.3% of the performance variance (2.8% in the sample) of the combined alert-
ness measure. In contrast, drug treatment variables as a block could predict an ad-
ditional 6.3% (9.7% in the sample). The increment of drug treatment variables as a 
block signiﬁcantly improved the model (F(4, 93)=2.59, p=0.041), but the full mod-
el remained statistically non-signiﬁcant (p=0.12). None of the individual predic-
tors turned out to be signiﬁcant in the full model. When the reduced model includ-
ing only the drug treatment variables was tested, the OST drug group turned out 
to be the only signiﬁcant predictor in the model (beta=.20, t(97)=2.09, p=0.040). 
The reduced model was signiﬁcant (R2, adjusted)=.056, F(4, 97)=2.51, p=0.047). In 
order to examine the role of the opioid drug further, we then separately analyzed 
models for buprenorphine- and methadone-treated patients. As shown in Table 
13, in the buprenorphine group, being on BZD drug treatment was the only sig-
niﬁcant predictor in the model. In the methadone group, the high number of oth-
er psychoactive drugs was the best predictor in the model. Adding methadone dose 
to the model made it signiﬁcant. However, the negative association of methadone 
dose only approached signiﬁcance. 
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TABLE 13. Hierarchical regression results for combined RTs in the Alertness test by opioid 
drug group
Buprenorphine (n = 51)
Predictors in the reduced model Step1 Step 2 Step 3 Step 4
Beta a Beta  Beta Beta
Drug treatment variables 
BZD treatment (yes vs. no) .34* .36*  .37* .38*
Buprenorphine dose  (high vs. low)b -.16 -.17 -.19 
The number of psychoactive drugs, other     .05 .05
 than opioid or BZD (high vs. low)c
Duration of OST (long vs. short)d -.05
R2 (adjusted) and significance of the model (ANOVA) .096* .103*  .084# .069
Change (ANOVA)a ns ns ns
Methadone- (n = 51)
Predictors in the reduced model Step1 Step2 Step3f
Beta Beta  Beta 
Drug treatment variables 
The number of psychoactive drugs, other .27# .30* .31*
 than opioid or BZD (high vs. low)  
Methadone dose .26 # .26 #
BZD treatment (yes vs. no) -.02
R2 (adjusted)  and model (ANOVA) .051# .098* .073 #
Change (ANOVA) 0.066 # ns
Note. Modified from publication IV. P-value shown when p ≥ 0.10. Bold indicates a statistically 
significant eﬀect. 
a Signs of beta values are reversed so that positive values refer to slower RTs. 
b Considered as low up to 16 mg.
c Considered as low up to one drug.
d Considered as  short when between six and twelve months. 
*p < 0.05. #p < 0.10. 
4.3.2 Predictors of working memory performance
The full model including control variables predicted 8.2% of the variance (16.4% 
in the sample). The model as a whole was signiﬁcant (F(8, 93)=2.28, p=0.028). 
None of the control variables as a block or individually gave a signiﬁcant contribu-
tion to the model. Consequently the control variables predicted a very low propor-
tion of the variance (−2.5%). In contrast, the drug treatment variables as a block 
signiﬁcantly improved the full model (F(4, 93)=4.13, p=0.004), predicting 11.7% 
of the variance above the control variables. Therefore, the control variables were 
removed from the model. As shown in Table 14, treatment with a BZD drug was 
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negatively associated with working memory performance while being in OST for 
more than one year was positively associated with working memory performance. 
The BZD drug treatment effect was signiﬁcant but the duration of the treatment 
effect only approached signiﬁcance. Finally, the predictive power of the drug treat-
ment variables, including the BZD variables (type or dose), on working memory 
performance was tested using the group that included only patients with BZD in 
their drug regimen (n=75). However, this model had very low predictive power on 
working memory (− 0.6%) and was statistically non-signiﬁcant (p=0.48).
4.3.3 Predictors of episodic memory performance 
When repeated testing was entered as the ﬁrst variable of the full model, it was 
signiﬁcantly associated with verbal memory performance (beta=.36, t (93)=3.49, 
p=0.0007). Therefore, in order to eliminate the signiﬁcant effect of repeated testing 
from the model, a model including only patients tested once was formed (n=74). 
Because demographic variables had a minimal effect in the initial full model, this 
block was dropped from the next model. Thus, the model included substance 
abuse variables and drug treatment variables. Because age of onset of substance 
abuse (early vs. late) showed a non-signiﬁcant effect in the model, it was dropped 
from the ﬁnal model. As shown in Table 15, high-frequency substance abuse and 
a high number of other psychoactive drugs (other than opioid or BZD drug) were 
the only individual signiﬁcant predictors of verbal memory performance, both of 
which were associated negatively with verbal memory performance. 
TABLE 14. Hierarchical regression results for working memory (n=102)
Predictors in the reduced model Step 1 Step 2 Step 3 Step 4
Beta Beta Beta Beta 
Drug treatment variables  
BZD treatment (yes vs. no) -.34 *** -.30 ** -.28 * -.28*
Duration of OST (long vs. short)a .17 # .17 #  .16 #  
The number of psychoactive drugs, -.06 .07
  other than opioid or BZD (high vs. low)b
OST drug type (buprenorphine vs.  methadone) -.03
R2 (adjusted) and model (ANOVA) .104 *** .124*** .119** .100**
Change (ANOVA)  0.074# ns ns
Note. Modified from from publication IV. P-value shown when p ≥ 0.10. Bold indicates  
a statistically significant eﬀect. 
aConsidered as short when between six and twelve months.
bConsidered as low up to one drug.
***p < 0.00. **p < 0.01. *p < 0.05. #p < 0.10.
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TABLE 15. Hierarchical  regression results for verbal memory (n=74)
Predictors in the reduced model Step 1 Step 2 Step 3 Step 4 Step 5
Beta Beta Beta Beta Beta
Substance abuse variable
Frequency of the past month sub-
stance abuse   (high vs. low)a
.35** -.34 ** -.36 ** -.35 ** -.36 **
Drug treatment variables
The number of psychoactive  
drugs, other than opioid or  BZD 
(high  vs. low)b
-.32 ** -.35** -.35** -.35**
BZD treatment (yes vs. no) .10 .10 .10
OST drug type   
(buprenorphine vs.  methadone)
 -.03  -.03
Duration of OST (long vs.  short)c .01
R2 (adjusted) and model (ANOVA) .110** .203*** .199*** .189*** .177*
Change (ANOVA) 0.003** ns ns ns
Note. Modified from from publication IV. P-value shown when p ≥ 0.10. Bold indicates  
a statistically significant eﬀect. 
aConsidered as high when three or more days a week. Alcohol use was taken into account if it 
was at least mean weekly 16 portions (12 g) for females and 24 portions for males or binge 
drinking occurred on any day.  
bConsidered as low up to one drug.
cConsidered as short when between six and twelve months. 
***p <0.001. **p < 0. 01. *p < 0.05. #p < 0.10.
4.4 Additional analyses: opioid drug only patients 
in comparison to normal controls (combination of 
Study I and IV data)
In our samples patients with opioid drug only and without co-substance were rare. 
This made the analysis of pure opioid-drug associated cognitive performance very 
challenging. Comparing a subsample of OST patients from Study IV against nor-
mal controls from Study I, however, gave us an opportunity for examining this is-
sue. When we excluded all other patients than those treated with opioid drug-on-
ly, with low or no past-month substance abuse, and who had been in treatment for 
a minimum of one year, this left us with 14 OST patients (7 buprenorphine and 
7 methadone). Between-drug group (buprenorphine vs. methadone) analyses on 
demographic and cognitive variables showed no signiﬁcant differences between 
them. In these analyses, age-corrected values of cognitive scores were used whenev-
er possible. On the basis of this observation, which is in line with our previous ob-
servations and those of other research groups (Darke, McDonald, Kaye, & Torok, 
2012; Soyka et al., 2008) we combined the patient groups. Table 16 shows the de-
mographic characteristics of the new patient sample in comparison to our previ-
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ous control sample from Study I. As presented in the table the combined patients 
had a lower level of education than the normal controls. Also, the patient group 
tended to be elder, although the between-group difference was non-signiﬁcant.
As shown in Table 17 the normal control group outperformed opioid-drug-
only patients in one test in each of the cognitive domains. However, in all measures 
with Finnish general population norms available (the Letter Number Sequencing 
task, Logical Memory, and the Benton Visual Retention Test), the performances in 
the opioid drug-only group were also very close to the 50th percentile. For the TAP 
tests the norms are available only for the German population, and the mean GoNo-
Go RT time of OST patients remained between the 31st and 34th percentiles, giv-
ing a preliminary indication of deviation from the normality. Also notable here is 
the ﬁnding that subjective memory complaints showed a higher effect size than any 
of the objective cognitive tests.
TABLE 16. Group demographics in the additional analyses
OST patients with 
opioid drug-only
(n = 14)
Normal controls
(n = 17)
Group comparisonsa
Age (years; M ± SD)   37  ± 8  31 ± 11 ns
Sex (female/male)   50 / 50%  53 / 47% ns
Verbal intelligence 102 ± 10  105 ± 10  ns
(M ± SD)b
Education (patients with prima-
ry education only) 
79% 24% OST < NC 
p = .004
Opioid drug treatment 
characteristics
50% with buprenor-
phine, mean dose  
19 ± 6 mg
     
50% with methadone, 
mean dose  140 ± 37 
mg 
Duration of OST 
(months; M ± SD) 
23 ± 5
Number of cognitive testing (pa-
tients with two or three testing) 
14% 0% ns
Patients with  high-frequency sub-
stance abuse in the past monthc 
0% 6%  ns
Note. Unpublished data. OST = Opioid-substitution treated patients; NC = Normal control.
a Tested with t-test or Fisher’s Exact  Test. 
bEstimation based on the vocabulary subtest of the WAIS-R.
c Considered as high when three or more days a week. Alcohol use was taken into account if it was 
at least mean weekly 16 portions (12 g) for females and 24 portions for males or binge drinking 
occurred on any day.  
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TABLE 17. Comparison of opioid-drug-only patients with minimum of one year in OST and 
normal controls on cognitive performance and subjective memory complaints title
 OST patients 
with opioid 
drug only
(n = 14)
Normal con-
trols
(n = 17)
Statistical
compari-
sons between 
groups
Eﬀect size
(Cohen’s d)
Power 
of the 
analysis
Attention M ± SD M ± SD
TAP Tonic Alertness/ 
simple RT 
(age corrected ms)
248 ± 32 257 ± 31 ns – 0.13
TAP Phasic Alertness/ 
RT  with warning signal 
(age corrected ms)
243 ± 28 244 ± 31 ns – 0.52
TAP Go/NoGo RT 
(age corrected ms)
558 ± 95 487 ± 42 OST > NC
p = 0.01
0.98 0.76
TAP Go/NoG errors 0.2 ±0.4 0.5 ± 0.6 ns –
Working memory
Letter Number 
Sequencing 
(standard score)
9.9 ± 2.5 11.3 ± 2.9 ns – 0.28
PASAT (raw score) 36 ± 13 48 ± 9 OST < NC
p = 0.007
1.02 0.80
Memory
Logical memory, imme-
diate  recall (raw score)
14.3 ± 3.3 16.3 ± 3.3 ns – 0.33
Logical memory, de-
layed recall (raw score)
13.1 ± 3.2 14.5 ± 4.1 ns – 0.17
Benton Visual 
Retention Test
(correct figures)
7.9 ± 1.4 8.9 ± 1.1 OST > NC
p = 0.024
0.83 0.63
Subjective memory 
complaints /
The Memory Complaint 
Questionnaire 
(raw score)
26 ± 3 21 ± 2a OST < NC
p = 0.0006
1.70 0.996
Note. Unpublished data. OST = Opioid-substitution treated patients; NC = Normal control.
All other cognitive performance test values are age-corrected except the PASAT and Logical memory. 
a Tested by analysis of variance (ANOVA).
an = 13.
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4.5 Driving fitness of OST patients (Study V)
Study V was a case series including both buprenorphine- and methadone-treat-
ed patients. However, the sample was not analyzed on the basis of opioid drug. 
Instead, two groups were formed on the basis of probability of total drug-related 
driving impairment. Notably, as shown in Table 18, all patients considered to have a 
probable drug-related driving impairment had at least one BZD drug on their drug 
regimen while in the ‘improbable’ group none had a BZD drug. 
TABLE 18. Demographic and other background variables in two groups of Study V
Patients with 
improbable 
drug-related
 driving 
 impairment 
Patients with 
probable drug-
related driving  
impairment 
Statistical 
comparisons 
between groupsa
(n =10) (n =12)
Age (years; (M ± SD)  32 ± 8 38 ± 9 p = .08
Sex (Female/Male) 40 / 60% 17 / 83% p = .35
Opioid agonist drug 
Buprenorphine /Methadone 80 / 20 %  8  / 92 % p = .002 
Buprenorphine dose, if any (M ± SD) 18 ± 7 mg 24 mg –
Methadone dose, if any (M ± SD) 115 ± 21 mg 133 ± 30 mg –
 Time in OMT (years; M ± SD)  3 ± 1 3 ± 2 p = .75
Other drugs than opioid agonist  
Any drug 40% 100% p = .09
Antihistamine 0% 8% p = 1.00
BZD drug 0% 100% p = .0001 
BZD dose, if any  
(M ± SD)b
 –  24  ± 22 mg –
Mood stabilizerc 10% 17% p = 1.00
Neuroleptic 0% 25% p = .22
Non-BZD hypnotic 0% 25% p = .22
Second generation antidepressant 30% 8% p = .29
Tricyclic antidepressant 0% 8% p = 1.00
Years since obtaining a driver’s 
license 
10 ± 9 14 ± 10 p = .25
Driven kilometers within the last 
year (participants with more than 
5000 km)
50% 25% p = .38
Patients with professional driving 
experience 
17% 20% p  = 1.00
Minor head injury 40% 42% p  = 1.00
Note. Modified from publication V. Bold indicates a statistically significant eﬀect. 
aTested by Fisher’s Exact Test.  
bBZD equivalent doses (Bazire, 2003). 
cThese included anticonvulsants and lithium. 
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4.5.1 On-road driving
All patients (n=22) showed normal visual ﬁelds and were considered neurological-
ly ﬁt to drive. According to the driving instructor’s overall safety assessment 94% 
of the patients were ‘safe drivers in all conditions’ or ‘safe drivers in normal con-
ditions’ and thus considered ﬁt to drive a car for non-professional purposes (all 
except one patient). Fifty-ﬁve percent of them drove the route without any driv-
ing errors and 83% without any hazardous error. As shown in Table 19, signiﬁcant 
between-group differences favoring the ‘improbable’ group were seen in the total 
score for the on-road driving test and domains evaluated as ‘weak’ or ‘either weak 
or strong’. Also, it can be noted that 5 out of 6 patients treated with an opioid drug 
only drove the test route without committing any error in the route. On the con-
trary, all three patients that made any hazardous errors in the driving test belonged 
to the group with ‘probable drug-related driving impairment.
Patients with ‘probable drug-related driving impairment’ scored statistically 
signiﬁcantly lower in the on-road driving test (Table 19). As can be seen in Figure 
7 there was much more variance in the driving test score among the patients with 
‘probable drug-related driving impairment’. In order to explore the possible asso-
ciation of drug doses with driving performance we analyzed the correlations be-
tween these variables. Both buprenorphine and methadone dose negatively cor-
related with the driving test score (-.21, ns and -.68, p=.01, respectively). Figure 8 
depicts the relationship between methadone dose and driving test score, and the 
number of driving errors. The correlation between BZD equivalent dose and driv-
ing test score could be analyzed in the methadone patients. It was negative (-.40), 
but non-signiﬁcant.
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TABLE 19. Results from the driving-related tests by group
Patients with improba-
ble drug-related 
driving  impairment 
Patients with probable 
drug-related driving  
impairment 
Statistical compari-
sons between drug 
groupsa
(n =10) (n = 12)
 Driving test score 
(M ± SD, max = 55)
51 ± 3 46 ± 5 p = .021 
Safe drivers in all con-
ditions according to 
driving instructor’s 
assessment 
90% 83% p = 1.00
Participants driving 
the test route with no 
errors 
60% 55% p = 1.00
Participants showing 
no ‘weak’ or ‘either 
weak or strong’ driving 
domains 
100% 42% p = .005 
Participants pass-
ing all driving-related 
cognitive tests above 
‘passed’ levelb
80% 25% p = .030 
Note. Modified from publication V. 
aTested by Fisher’s Exact Test .
bn = 9. 
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– = group mean 
* = p < 0.05
FIGURE 7. On-road driving test scores by group.
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FIGURE 8. The relationship between methadone dose and driving test performance.
4.5.2 Performance in cognitive driving related tests
In driving-related cognitive tests, which are not mandatory in the Finnish driving 
assessment, half of the patients passed every test above the 16th percentile, a rec-
ommended ‘passed test’, criterion. As shown by Table 19 performing in all cognitive 
tests above the pass level was more common in the ‘improbable drug-related driv-
ing impairment’ group. Of note here is the observation of high variance of cogni-
tive performance in the group with ‘probable drug-related driving group’. For in-
stance in the median RT in the Stroop interference condition the values were 1.35 
± 0.55 s in the ‘probable’ group and 0.88 ± 0.11 s in the ‘improbable’ group.
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The studies in this thesis were designed to examine cognitive performance in OST 
patients treated with buprenorphine or methadone and to analyze the role of drug 
treatment variables as correlates of cognitive performance. 
5.1 Main findings in relation to the hypotheses
Attention was the only cognitive domain that was consistent with our ﬁrst hypoth-
eses of buprenorphine advantage over methadone. Methadone-treated patients’ 
RTs in the attention tests were slower than RTs of normal controls in most of our 
studies while buprenorphine patients showed no deﬁcits in the attention measures. 
As an exception, when we compared the pooled opioid drug-only patients (n=14 in 
the unpublished analyses) against normal controls, a signiﬁcant difference between 
the pooled opioid drug-only patients and normal controls emerged in the Go/
NoGo RT. In this test there were no signiﬁcant differences between opioid drugs 
groups. However, due to small sample size, the comparison between buprenor-
phine and methadone-only patients (n=7 in both group) remain underpowered, 
and needs to be repeated with more a powerful sample before a conclusion can be 
reached. In working memory both buprenorphine- and methadone-treated pa-
tients lagged behind normal controls fairly consistently, which does not support 
the advantage of buprenorphine over methadone in working memory. As an ex-
ception, however, the results of the longitudinal study (Study III) showed work-
ing memory improvement in the Letter Number Sequencing task between 6–9 and 
12–17 months into treatment, while no such improvement was seen in methadone 
patients. In episodic memory, both opioid drug groups showed impaired perfor-
mance in most of the studies. In the early-treatment comparison (Study I) an ex-
ception was seen, since methadone patients treated also with a BZD drug showed 
impaired delayed verbal memory performance in relation to buprenorphine/na-
loxone patients treated also with a BZD drug. 
Contrary to our hypothesis we could did not ﬁnd evidence of a memory con-
solidation impairment in OST patients treated also with a BZD drug (Study II). 
The only ﬁnding concerning memory consolidation was the substantial negative 
correlation between memory complaints at early treatment (T1) and free recall af-
ter a minimum of four months (T2). Thus, memory complaints in OST patients 
may indicate a memory problem that is not easily captured by objective tests. 
Our third hypothesis predicted greater cognitive improvement in buprenor-
phine-treated patients. In Study III there was a group-by-time interaction in the 
Letter-Number Sequencing task, revealing a greater cognitive improvement for bu-
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prenorphine patients in long-term treatment relative to methadone-treated pa-
tients. However, in our largest sample of long-term treated patients (Study IV) no 
difference in this measure was seen in buprenorphine- vs. methadone-treated pa-
tients. Thus, the evidence supporting the potential for greater cognitive improve-
ment with buprenorphine remains preliminary.
We hypothesized that there would be negative associations between various 
drug treatment variables and cognitive performance in OST patients. In the regres-
sion analysis study, about 10% of the variance in methadone-treated patients’ RT 
performance was related to the number of other psychoactive drugs (other than 
opioid or BZD) and the methadone dose. Thus, our result supports the idea that 
drug-treatment variables have a negative effect on attention performance in meth-
adone patients. A further indication of a negative association between methadone 
treatment and attention-related behavior appeared in our driving ﬁtness study, in 
which a signiﬁcant negative correlation was seen between methadone dose and 
driving test score. 
In the regression analysis study (IV), about 10% of the attention performance 
variance in buprenorphine-treated patients was associated with having BZD drug-
treatment along with buprenorphine. This supports our hypotheses that among 
buprenorphine patients, co-treatment with a BZD drug is negatively associated 
with attention performance. Since BZD dose had no effect on this relationship, 
the nature of this relationship (pharmacological or non-pharmacological) remains 
to be determined. In the same study, about 10% of working memory impairment 
in the combined opioid drug groups was associated with having a BZD drug and 
about 10% of episodic memory impairment with the number of psychoactive 
drugs (other than opioid or BZD). In sum, there are several indications showing 
negative drug associations with cognitive performance in multidrug treated OST 
patients, but the drug speciﬁcity of the associations remains to be determined. 
5.2 Attention findings in relation to other studies 
In methadone patients there were two indications of dose-related negative associ-
ation with attention performance. In early treatment, patients with higher metha-
done dose (mean 67 mg) showed slower RTs than those with lower doses of 40 mg 
(Figure 5). In the regression analysis study higher methadone dose predicted, as a 
statistical trend, longer RT in the combined alertness measure (Table 13). The ﬁnd-
ings of other research groups, however, do not indicate a negative methadone effect 
on RT measures. For instance, in the Curran et al. study, short-term treated (ﬁve 
days) methadone patients actually had faster RTs 3 h after the dose (mean 33 mg) 
than before the dose (Curran et al., 2001). In Baewert et al., opioid-dependent pa-
tients treated for a mean two years did driving-related RT tests 1.5 or 20 h after the 
methadone dose (mean 53 mg) (Baewert et al., 2007). No differences in RTs were 
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observed. Thus, there is no consistent evidence that methadone dose alone would 
be associated with RTs among OST patients. However, on the basis of our results 
a negative association between methadone and RTs in OST patients may be seen 
when methadone is used along with other psychoactive drugs. Notably, most pa-
tients in our methadone-patient samples were given a BZD drug and there is evi-
dence for pharmacodynamic interactions between these drugs (Lintzeris & Niels-
en, 2010). 
5.3 Working memory findings in relation to other 
studies 
Our second working memory measure, the Letter Number Sequencing task, resem-
bles the better known Digit Span because the storage demands are nearly similar 
in both tasks. Several studies have examined the Digit Span performance of meth-
adone or buprenorphine patients. The results of these studies show almost consist-
ently no difference between OST patients and normal controls (Darke et al., 2012; 
Gritz et al., 1975; Lombardo, Lombardo, & Goldstein, 1976; Mintzer & Stitzer, 
2002; Soyka et al., 2008; Z. X. Wang, Xiao, Zhang, Liang, & Zhang, 2008). Two 
studies showing impaired performance in the Digit Span both compared metha-
done patients against normal controls (Darke et al., 2000; W.-C. Lin et al., 2012). 
The Letter Number Sequencing task and the PASAT, however, are considered more 
sensitive tasks than the Digit Span for discovering a working memory deﬁcit in 
various populations. Both include the processing demand of the presented items, 
which is not included in the Digit Span task. This idea is supported by our results 
and by at least two other opioid-related studies. In the ﬁrst of these latter studies, 
short-term abstinent opioid-dependent patients showed intact Digit Span perfor-
mance, although the PASAT performance was impaired (Rapeli et al., 2006). In 
another study, short-term abstinent opioid-dependent patients were administered 
the Digit Span and the Letter Number Sequencing tasks (Verdejo-Garcia & Perez-
Garcia, 2007). Although the patients were impaired in both of the working memo-
ry measures, the Letter Number Sequencing task performance was more impaired 
than the Digit Span performance (Cohen’s d-values, 1.83 and 0.80 respectively). In 
addition, our results support the idea that the PASAT as a multimodal test would 
be more sensitive for showing cognitive deﬁcits in OST patients than the relatively 
pure working memory measure, the Letter Number sequencing task (Study III and 
additional analyses for opioid drug-only patients). 
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5.4 Episodic memory findings in relation to other 
studies 
In our studies the only episodic memory performance difference between opioid 
drug groups was the better performance seen in buprenorphine patients treated 
along with BZDs in comparison to methadone patients treated along with BZDs 
in early treatment (Study I). However, in later studies, no differences between the 
opioids drug groups were seen. The other studies with relatively large samples have 
likewise not found differences between opioid drug groups in episodic memory, 
namely the Darke et al. study (2012) with 125 OST patients (buprenorphine; n=31 
and methadone, n=94) and the Loeber et al. study (2012) with 54 patients (n=24 
and 30, respectively). A study with a smaller sample size of 37 patients (n=24 and 
13, respectively) is an exception, showing a buprenorphine advantage in verbal 
memory (Giacomuzzi, Thill, Riemer, Garber, & Ertl, 2008). However, as the ev-
idence for very small, if any, differences between opioid drug groups in episodic 
memory is stronger than the opposite, the ﬁndings of both drugs groups are dis-
cussed together. 
Many studies have shown memory deﬁcits in OST patients when compared 
against normal controls (Darke et al., 2012; Darke et al., 2000; Messinis et al., 2009; 
Soyka et al., 2008). For, instance in the Darke et al. study (2000) a verbal list-learn-
ing test administered to methadone patients showed the most pronounced cogni-
tive deﬁcits out of a great number of cognitive tests. However, there are also many 
studies which have found no signiﬁcant memory performance differences between 
OST patients and controls (P. E. Davis, Liddiard, & McMillan, 2002; Grevert et al., 
1977; W.-C. Lin et al., 2012; W. C. Lin et al., 2012; Mintzer & Stitzer, 2002). An im-
portant study was performed already in 1977 in which memory performance of 
methadone patients was longitudinally tested using a word-list learning task and a 
visual matrix memory task (Grevert et al., 1977). The patients were ﬁrst tested be-
fore the treatment and then twice within the ﬁrst three months of treatment. No 
baseline or subsequent differences between the methadone patients and a compar-
ison group were seen in objective or subjective memory function. Thus the results 
of Grevert et al. provide evidence for normal memory performance in OST pa-
tients. However, it can be noted that the patients performed the tests immediately 
before or after the administration of the methadone dose, that is, when their plas-
ma concentration is known to be at the lowest level. Therefore short-term nega-
tive effects of high methadone concentrations may have been missed. More recent-
ly, this issue has been controlled in two studies. In Curran et al., opioid-dependent 
patients treated with methadone for a minimum of 6 months were randomly allo-
cated to either normal dose, 33% increased dose, or placebo linctus; they were test-
ed both pre-drug and again 3 hours after the dose (Curran, Bolton, Wanigaratne, & 
Smyth, 1999). No signiﬁcant treatment effect was seen, and the authors concluded 
that single doses of higher methadone are devoid of verbal memory effects among 
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long-term methadone users. The issue, however, may not be fully resolved, because 
in a later study the same study group got a different result (Curran et al., 2001). 
After ﬁve days in methadone treatment, opioid-dependent patients who were giv-
en a withdrawal stabilization dose of the drug showed signiﬁcantly worse perfor-
mance in comparison to the placebo condition in a story recall test repeated 3 h af-
ter the dose. Furthermore, a recent study using a long-term treated sample of OST 
patients (minimum three months in treatment) found that after controlling for 
several demographic variables and recent polydrug use, OST patients still showed 
verbal memory deﬁcit in the Logical Memory test (Darke et al., 2012). The mag-
nitude of deﬁcit was substantial for immediate memory (d=0.72) and strong for 
delayed memory (d=0.93). Nevertheless, no opioid dose effect on verbal memory 
was observed.
In visual memory, buprenorphine and methadone patients showed similar 
performance (Study IV); and in the comparison against normal controls, opioid-
drug-only patients showed impaired performance in the Benton Visual Retention 
Test (unpublished additional analysis). The only other study that has used this test 
for both main OST drugs also found a visual memory deﬁcit when buprenorphine 
or methadone patients treated for a minimum of 12 months were compared sep-
arately against normal controls (Pirastu et al., 2006). As reviewed by Gruber et al. 
a visual memory deﬁcit using this test has been reported in early studies focusing 
on methadone patients only (Gruber, Silveri, & Yurgelun-Todd, 2007). Thus, our 
result adds to the evidence for visual memory deﬁcit among buprenorphine- or 
methadone-treated opioid-dependent patients. 
Our studies are one the ﬁrst studies to examine simultaneously several cor-
relates of episodic memory performance among OST patients. Whereas our study 
found a negative association between the past month substance abuse and ver-
bal memory, the only other study dealing with the same issue (Loeber et al. 2012) 
found an association between impaired verbal memory performance and male sex 
and duration of cocaine use. Thus, both studies just mentioned found an associa-
tion between memory deﬁcit and drug use, though rather different assocations. In-
terestingly a recent study of a different population, but with high frequency of drug 
use, namely HIV positive women, also found a signiﬁcant negative association with 
recent substance use and memory performance in a multivariate regression analy-
sis (Meyer et al., 2013). In sum, the evidence that buprenorphine or methadone as 
such would affect negatively on memory functioning is not convincing, since there 
are many confounding variables that need to be controlled for before strong con-
clusions can be made.  
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5.5 Driving fitness findings in relation other studies 
Our study of driving ﬁtness in OST patients ﬁts to the case series approach rath-
er than the experimental control approach. Thus, our study had no control group 
as a reference for normality. Instead, a driving safety assessment carried out by a 
licensed driving instructor was used as a reference for normality. The major out-
come was that 21 out of 22 participants were considered as safe drivers. Thus, our 
ﬁnding is in agreement with earlier studies using an on-road driving test (Fishbain, 
Cutler, Rosomoff, & Rosomoff, 2003; Strand, Fjeld, Arnestad, & Morland, 2013). 
In spite of this general ﬁnding of driving ﬁtness, important points of caution need 
to be mentioned. First, when we divide our case-series of patients into those with 
improbable vs. probable drug-related driving impairment, signiﬁcant differences 
emerged. Patients with ‘probable drug-related driving impairment’ scored statisti-
cally signiﬁcantly lower in the on-road driving test total score and in the number 
of ‘passed’ cognitive tests. Second, further analyses showed that higher methadone 
dose was signiﬁcantly associated with lower driving test scores as well as more er-
rors while driving. Notably, four out of 26 voluntary patients with a valid driving 
license coming into the driving test were found to be positive in the preceding drug 
screen. This raises concerns about the proportion of OST patients driving under 
the inﬂuence of drugs. 
5.6 Implications of the findings on the 
neuropsychology of opioid-dependence 
Our results give preliminary support to the idea of the compensatory plasticity of 
the human brain, with a high tendency for preserving cognitive functioning (Fig-
ure 3 and related review in the Introduction section). For instance, we could not ev-
idence any negative correlations with lifetime substance abuse measures and cogni-
tive performance (Study III). Instead, there was a negative association between the 
past month substance abuse and verbal memory in the largest sample (Study IV) 
and working memory at T2 and T3 in the longitudinal study (III). Thus, these ﬁnd-
ings are in line with the hypothesis of short-term neurotoxic effects of substance 
use but do not support the hypothesis of negative long-term effects. Yet, there is 
a lot of evidence indicating long-term negative brain changes in opioid-depend-
ent patients (section 1.1.3 in the Introduction). Furthermore, a study concerning 
chronic pain patients without opioid-dependence (n=10) indicated that after one 
month of mu agonist morphine use with adequate pain relieving doses (maximum 
of 120 mg/day), 13 brain regions showed signiﬁcant volumetric changes, and many 
of these correlated signiﬁcantly with morphine dosage (Younger et al., 2011). 
There are many routes to compensatory neural activity in continuous working 
memory tasks like the PASAT, but the most consistent brain areas linked to it are 
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the middle and medial frontal gyrus (BA 6,8, 9, and 10), the bilateral insular cortex 
(BA 13), and parts of the parietal cortex (BA 7 and 40) (Bryer, Medaglia, Rostami, 
& Hillary, 2013; Caseras et al., 2006; Fassbender et al., 2011a; Paskavitz et al., 2010; 
Squeglia et al., 2012). Medial frontal gyrus hyperactivity (BA 10) is supposed to be 
only relatively due to the lack of deactivation of the default-mode network in this 
area (Fassbender et al., 2011a). The need for the insular cortex activation in work-
ing memory may be especially pertinent to our ﬁndings. The insula is an area with 
very high mu opioid receptor density; and it plays a major role as a switch between 
task-irrelevant and task-relevant mental states (Baumgartner et al., 2006; Naqvi & 
Bechara, 2010; Tang, Rothbart, & Posner, 2012). Although OST has been shown 
to restore cortical activity in many brain areas, the insula is one of the areas in 
which activity remains abnormally low in relation to normal controls (Galynker et 
al., 2007). This hypoactivation could be related to working memory performance 
in OST patients. Also, our results may indicate that working memory deﬁcits in 
opioid-dependent patients are related to incomplete switching from task-irrele-
vant neural networks to task-relevant/speciﬁc brain networks while on task. Of 
relevance in this matter is the observation that several brain areas with probable 
compensatory activity are the same areas that show cortical atrophy among opi-
oid-dependent patients (section 1.1.3 in the introduction). Simultaneous cortical 
thinning and hyperactivation, however, are a possible combination in cognitive 
deﬁcits (Reuter-Lorenz & Cappell, 2008; Schneider-Garces et al., 2010). 
5.7 Implications of the findings on the opioid-
substitution treatment
As reviewed in the previous section the human brain may have a high capacity to 
compensate for neurotoxic costs from substance abuse or side-effects of polyphar-
macy. Thus, OST patients, in general, have better cognitive functioning than com-
monly believed. Therefore, psychoeducation about the positive side of our ﬁndings 
is needed. In fact, positivity in itself may improve cognitive function, create curi-
osity, and foster creative problem solving (Ashby, Isen, & Turken, 1999; Johnson, 
Waugh, & Fredrickson, 2010). On the other hand, cognitive deﬁcits among OST 
patients should not be underestimated. 
Our results indicate that episodic memory deﬁcits persist among multidrug-
treated patients (Study III), and working memory deﬁcits may be partly persistent 
among all OST patients (Study III and the additional analyses of opioid-drug on-
ly patients). These ﬁndings are of practical relevance, since the episodic memory 
test used, The Logical memory, correlates well with everyday memory function-
ing (Sunderland, Harris, & Baddeley, 1983), while optimal working memory func-
tion is vital for reading comprehension, learning, and reasoning (Baddeley, 2003). 
Furthermore, if working memory is compromised, drug cues are harder to resist 
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(Goldstein & Volkow, 2011). There are some preliminary ﬁndings that working 
memory training may improve cognitive control in drug addiction patients (Bickel 
2011) but transfer from laboratory to real-life remains to be shown. 
Our case-series ﬁndings of well-preserved driving ﬁtness in 21 out of 22 exam-
ined patients is in line with the idea that OST patients in stable treatment without 
co-substance abuse are ﬁt to drive. One may ask if the driving ﬁtness of OST patients 
could be approached using the same guidelines as exist for long-term pain patients 
with opioid agonist medications. The relevant European guidelines are as follows: “If 
a patient on long-term, stable opioid therapy is considering driving a car, the health 
care provider should make sure that the patient: should do this only if the opioid 
dose has been stable at least for 14 days; should never drive if he/she feels tired, sedat-
ed, fatigued, dizzy, sleepy; should always report to the physician when feeling tired, 
sedated, or fatigued and discuss with the doctor the possibility of reducing the opi-
oid dose; must never combine opioid medication with alcohol, sedatives, anxiolytics, 
or any other psychoactive medications (or illegal drugs of any kind). The physician, 
at all times, should inform the patient about the effects of opioids on driving ability 
and the regulations made by the authorities of their country”(Monteiro & De Gier, 
2011). However, another expert opinion from the same project recommends that if 
a patient is given methadone or buprenorphine for addictive disorders then driving 
during the treatment should require an approval from a driving license administra-
tion (Gómez-Talegón, Fierro, Del Río, & Alvarez, F.J., 2011). On the basis of our case-
series with OST patients, this requirement seems valid. 
5.8 Strengths, limitations, and other 
methodological considerations
A notable strength in our studies was the use of relatively liberal inclusion criteria 
for patients. Thus our study samples represent typical opioid-dependent patients 
in OST in Finland. In terms of the clinical relevance of a study, having a represent-
ative sample is often more important than having full control of all known con-
founding factors. Also, ethical and practical concerns limit the possibilities for ful-
ly controlled trials (= inpatient settings) in longitudinal studies. 
The strength of Study I was the inclusion of both buprenorphine and meth-
adone patients in the same study during early treatment. The strength in our lon-
gitudinal studies (II–III) was the use of a control group, because otherwise the 
practice effects that were seen in some measures would not have been reliably con-
trolled for. Study II was the ﬁrst outpatient study with a representative sample of 
OST patients treated along with benzodiazepines, which is a common combina-
tion in real-life patients. Study III was among the most comprehensive longitu-
dinal studies carried out to date, and it included analyses of correlates of perfor-
mance, which served as a preparation for the more detailed analyses of Study IV. 
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Moreover, Study IV was one of the most comprehensive studies examining drug 
treatment variables as predictors of cognitive performance in OST patients. Study 
V was one of the few studies with an actual driving test in normal trafﬁc carried 
out by OST patients. 
Some of the characteristics of our study can be considered both a strength and 
a limitation. In our studies, the substance abuse history of the patients is report-
ed in more detail than in many previous studies. The sample descriptions show 
that our results do not concern “pure” opioid-dependence. In fact, pure opioid-de-
pendence with heroin, which used to be quite common some decades ago, has be-
come much rarer in Finland as well as in many other countries. However, having a 
representative sample limits a comparison of our results with many of the earlier 
studies that used “pure” opioid-dependent patients.
In most of our group comparisons the sample sizes are lower than initially 
planned (the aim was for 25 participants/group). For this reason some of our anal-
yses are statistically underpowered and strong conclusions about group differenc-
es need to be avoided. Non-randomized sampling and small sample size may pro-
duce false positive ﬁndings (Ioannidis, 2005). Some important information about 
participants’ lifetime and current characteristics, such as learning disability histo-
ries, are missing from our analyses, and this may affect our results. Premorbid cog-
nitive functioning was estimated only on the basis of a vocabulary test. However, to 
my knowledge, in the only addiction study with the available data of comprehen-
sive childhood cognitive testing, the analyses showed premorbid vocabulary deﬁ-
cits in mixed-type drug-dependent patients (Block, Erwin, & Ghoneim, 2002). On 
the other hand, in the most comprehensive study of methadone patients’ cognitive 
performance, the same premorbid verbal IQ estimate that was used in our study, the 
WAIS-R vocabulary test, was the only test not showing a difference between patients 
and age-, gender-, and education-matched controls (Darke et al., 2000). In our study, 
matching for education was not done, since it is not a valid method for matching in 
our country, in which continuous vocational education after primary school is very 
common, and patients with opioid-dependence typically drop-out from vocation-
al education. Lifetime or current psychiatric and neuropsychiatric morbidity was 
screened for acute DSM-IV axis I. Thus, axis II morbidity with a potential to affect 
the results was not taken into account in the analyses. Nicotine dependence or hep-
atitis C status, both with a probable role in cognitive functioning in substance de-
pendence, was not controlled for in the analyses, which limits the speciﬁcity of our 
ﬁndings. Time of the tests after administration of the dose may have been too late 
to capture the cognitive effects of peak drug-concentrations (Lintzeris et al., 2006). 
Our analyses were focused on attention, working memory, and episodic mem-
ory. However, even within these cognitive domains we could cover only some of the 
essential components. Furthermore, only some of the cognitive control functions 
related to addictive behaviors can be revealed by “cold” cognitive tests. Thus, tests 
with affective neutral material may not reveal cognitive control deﬁcits which be-
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come evident only after a shift from “cold” memory systems to “hot” memory sys-
tems (Schwabe, Dickinson, & Wolf, 2011). “Hot” memory systems are found to be 
active for instance during withdrawal augmented antirewad/anhedonia or stress-
precipated discomfort (Bonson et al., 2002; Schwabe et al., 2011). Hot mental states 
are thought to able to activate rigid conditioned motivational memory circuits and 
thus act like a bottleneck for “cold” and ﬂexible higher order cognitive control cir-
cuits (Volkow et al., 2010)
Our study design was quasi-experimental, without randomization of the sam-
ples, and this needs be taken into account in comparisons between buprenorphine- 
vs. methadone-treated patients. In order to corroborate our ﬁndings these studies 
should be complemented with longitudinal studies that include cognitive pretreat-
ment assessment and, if possible, more accurate information about premorbid 
functioning (school records or similar).
5.9 Conclusions 
OST patients treated with buprenorphine or methadone tend to show cognitive 
deﬁcits in working memory and episodic memory. Methadone patients tend to 
show also attention deﬁcits. Buprenorphine patients tend to show less attention 
deﬁcits than methadone patients or possibly none of them. Although the magni-
tude of cognitive performance deﬁcits in stable OST patients cannot be fully deter-
mined in our study, the results give a preliminary indication that the deﬁcits are of 
smaller magnitude than often believed. Also, the results give preliminary support 
to the idea of improvement cognitive function during OST. The close to normal 
cognitive function in stable OST patients may indicate an efﬁcient compensation 
of neural burden related to opioid abuse history. On the other hand, the ﬁndings 
indicate negative associations between recent frequent substance use and poor ep-
isodic memory as well as between polypharmacy and poor working and episodic 
memory. OST patients in stable treatment are, in general, ﬁt to drive a car. Patients 
with high methadone dose treated along with a BZD drug may be more prone to 
driving errors than patients with buprenorphine medication only. 
The ﬁndings may be relevant for patients and prescribers when discussing the 
choice of OST or co-medication drugs. Also, our results may be informative when 
the patient and her/his treatment team discuss the time and intensity of psycho-
social rehabilitation, such as participation in employment programs, psychother-
apy or education. 
Finally, opioid substitution is in many cases a lifelong treatment, and this 
should be taken into account in future research. Does the hypothesized neural 
compensation taking place in OST patients, which counterbalances their previous 
and current neural burden on cognition, break down earlier among them than in 
normal aging?
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Abstract
Background: Both methadone- and buprenorphine-treated opioid-dependent patients frequently
show cognitive deficits in attention, working memory, and verbal memory. However, no study has
compared these patient groups with each other during early opioid substitution treatment (OST).
Therefore, we investigated attention, working memory, and verbal memory of opioid-dependent
patients within six weeks after the introduction of OST in a naturalistic setting and compared to
those of healthy controls.
Methods: The sample included 16 methadone-, 17 buprenorphine/naloxone-treated patients, and
17 healthy controls matched for sex and age. In both groups buprenorphine was the main opioid
of abuse during the recent month. Benzodiazepine codependence, recent use, and comedication
were also common in both patient groups. Analysis of variance was used to study the overall group
effect in each cognitive test. Pair-wise group comparisons were made, when appropriate
Results: Methadone-treated patients, as a group, had significantly slower simple reaction time (RT)
compared to buprenorphine/naloxone-treated patients. In Go/NoGo RT methadone patients were
significantly slower than controls. Both patient groups were significantly debilitated compared to
controls in working memory and verbal list learning. Only methadone patients were inferior to
controls in story recall. In simple RT and delayed story recall buprenorphine/naloxone patients with
current benzodiazepine medication (n = 13) were superior to methadone patients with current
benzodiazepine medication (n = 13). When methadone patients were divided into two groups
according to their mean dose, the patient group with a low dose (mean 40 mg, n = 8) showed
significantly faster simple RT than the high dose group (mean 67 mg, n = 8).
Conclusion: Deficits in attention may only be present in methadone-treated early phase OST
patients and may be dose-dependent. Working memory deficit is common in both patient groups.
Verbal memory deficit may be more pronounced in methadone-treated patients than in
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buprenorphine/naloxone-treated patients. In sum, to preserve cognitive function in early OST, the
use of buprenorphine/naloxone may be more preferable to methadone use of, at least if
buprenorphine has been recently abused and when benzodiazepine comedication is used.
Longitudinal studies are needed to investigate if the better performance of buprenorphine/
naloxone-treated patients is a relatively permanent effect or reflects "only" transient opioid
switching effect.
Background
In opioid substitution treatment, the opioid-dependent
patient receives long-acting mu opioid receptor agonists
in order to prevent withdrawal symptoms and to reduce
craving for street opioids. The full mu opioid agonist
methadone is the most commonly used drug in OST pro-
grams. If overdosed, which may happen in cases of abuse,
methadone may cause fatal respiratory depression. There-
fore, partial mu opioid receptor agonist and kappa recep-
tor antagonist buprenorphine, with a ceiling effect on
respiratory depression, has been increasingly used in OST
programs. Buprenorphine, however, is commonly abused
in several countries; and in combination with other psy-
choactive substances it may also be hazardous [1,2].
Therefore, a safer drug combining buprenorphine and
naloxone has been developed. The compound contains
buprenorphine and naloxone in 4:1 ratio, and if used sub-
lingually, it has practically equal pharmacokinetic proper-
ties as buprenorphine alone [3,4].
Already during the first few weeks of their OST patients
often show reduction of use of illegal opioids and related
problem behaviors [5,6]. Some patients, however, experi-
ence negative treatment effects including cognitive distur-
bances and relate them to their OST drug. This needs to
taken seriously as drug-dependent patients experiencing
troubles in concentrating and remembering have poor
treatment engagement and treatment prognosis [7,8].
Thus, it is relevant to study objective cognitive function of
early OST patients.
When given to healthy volunteers, both methadone and
buprenorphine have shown adverse effects on attention
and memory [9,10]. When these drugs are given to opi-
oid-dependent patients, their cognitive effects may be dif-
ferent because these patients have tolerance for opioids.
As an example of this, a single dose of methadone (5 or 10
mg) slowed down simple RT of healthy volunteers but
had no such an effect on methadone-treated opioid-
dependent patients in stabilized treatment (a stable meth-
adone dose regimen from 20 mg to 70 mg for at least one
month) [11]. In the same vein, a one third increase in
methadone did not affect memory or RT performance of
opioid-dependent patients who had been in treatment at
least for 6 months [12]. However, switching from opioid
of abuse to different opioid for OST purposes may cause
transient cognitive side-effects. In accordance with this
idea heroin abusing opioid-dependent patients studied
during the first week of methadone-aided withdrawal
treatment showed verbal memory deterioration after the
full methadone dose of 35 mg on average compared to
placebo or to halved dose [13].
Cognitive effects of buprenorphine in OST patients are
not well known. Some evidence exists for buprenorphine
having less adverse effect on driving-related attention than
methadone [3,4,14,15]. However, in a recent comparison,
made after 12 months of OST, both buprenorphine and
methadone-treated patients were inferior to controls in
visual memory [16].
In clinical settings, OST patients typically have used, and
may still use, other substances of abuse. Benzodiazepine
abuse is particularly common among individuals starting
OST [17]. At the same time other psychoactive drugs are
often prescribed to them. Yet, few studies have dealt with
this issue. For instance, the studies of Soyka et al., which
showed better performance among buprenorphine-than
among methadone-treated OST patients, mainly describe
patients with current polysubstance abuse and psychoac-
tive polytherapy [14,15].
In sum, both methadone and buprenorphine/naloxone as
such or in combination with other psychoactive medica-
tions may have negative effect on cognition in OST
patients. To our knowledge, no study has addressed this
issue in a naturalistic clinical sample of patients who are
starting their OST – a period when cognitive deficits might
be pronounced. Therefore, we evaluated attention, work-
ing memory, and verbal memory of methadone- or
buprenorphine/naloxone-treated patients starting OST
and compared these to those of controls.
Methods
Participants
The study participants with opioid dependence were vol-
unteers from a consecutive series of patients accepted for
standard OST in the addiction clinics of Helsinki area. The
introduction of combined buprenorphine/naloxone OST
in Helsinki in 2004 enabled a comparison of cognitive
abilities between the methadone-treated and the
buprenorphine/naloxone-treated patients. Healthy con-
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trol participants were recruited from adult education cent-
ers and by word of mouth.
The inclusion criteria for all participants were age between
18 – 50 years. The additional inclusion criteria for OST
patients were opioid dependence according to DSM-IV,
and the start of OST during the last six weeks. We excluded
participants with current uncontrolled polysubstance
abuse, acute alcohol abuse, or acute axis I psychiatric mor-
bidity according to Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) other than substance abuse
disorders. Also we excluded participants with severe brain
injury, chronic neurological disease, history of other than
substance-induced psychoses, epileptic seizures, human
immunodeficiency virus (HIV) infection, pregnancy, or
primary cognitive deficit. Each opioid-dependent partici-
pant eligible for our study was screened by urine sample
for substance abuse on the day of testing and at least once
in the preceding week. Healthy controls were selected for
substance abuse screening at random and we screened
one third of them. After excluding participants showing
positive drug screen on the day of testing we included 16
methadone-, 17 buprenorphine/naloxone-treated
patients, and 17 healthy controls.
The study protocol was accepted by the Ethics Committee
of Helsinki University Central Hospital. We obtained a
written informed consent according to the Declaration of
Helsinki from all participants, and paid them ? 60 if they
attended all the necessary visits.
Table 1 shows major demographic variables of each
group. When appropriate, we performed pair-wise group
comparisons with analysis of variance (ANOVA) or with
chi-square-test. The groups did not differ in age or sex dis-
tribution. The OST groups did not differ in history of sub-
stance abuse or duration of OST. As shown in Table 1 the
control group had more education than the patient
groups. The control group had superior verbal intelligence
(Verbal IQ) relative to the methadone patients but not to
the buprenorphine/naloxone patients. The main opioid
of abuse within the last month was buprenorphine
among all participants of the buprenorphine/naloxone
group and among most participants (75%) in the metha-
Table 1: Group demographics
Methadone
(n = 16)
Buprenorphine/Naloxone
(n = 17)
Control
(n = 17)
Group comparison
p-values
Age, years (M, SD) 30.8 (8.8) 28.1 (6.3) 31.1 (11.2) ns
Sex: females/males 9/7 7/10 9/8 ns
Verbal intelligence a (M, SD) 98.4 (8.7) 102.4 (8.4) 105.4 (9.8) C > M*
Education, years (M, SD) 10.4 (2.0) 11.1 (2.2) 13,0 (1.7) C > M**
C > BN**
Dependencies
Opioid 100% 100% - nsb
Alcohol 0% 6% nsb
Amphetamine 0% 11% nsb
Benzodiazepines 100% 89% nsb
Cannabis 6% 11% nsb
Main opioid of abuse used within last month (%)
Buprenorphine 75% 100% - nsb
Heroin 13% 0% nsb
Methadone 13% 0% nsb
Other substances of abuse used within last month (%)
Alcohol (heavy use)c 6% 17% 6% ns
Amphetamine 19% 29% 0% ns
Benzodiazepined 94% 94% 0% M & BN > C**
Cannabis 38% 24% 0% M > C*
Nicotine (daily use) 100% 100% 35% M & BN > C**
Duration of opioid substitution treatment in the day of testing, days 
(M, SD)
14.3 (7.4) 11.0 (8.1) - nsb
Duration of opioid abuse, years (M, SD) 12.1 (7.7) 10.0 (3.5) - nsb
Duration of any substance abuse, years (M, SD) 16.9 (8.7) 15.7 (5.0) - nsb
aEstimation based on WAIS-R Vocabulary score.
bTested only between methadone- and buprenorphine/naloxone-treated patients.
cAlcohol use was considered heavy if it was at least mean weekly 16 portions (12 g) for females and 24 weekly portions for males.
dIncludes benzodiazepines used on prescription.
M = methadone, BN = buprenorphine/naloxone
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 
0.05.
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done group. There were four cases (25%) of recent month
abuse of heroin or methadone in the methadone-treated
group. Also participants in the buprenorphine/naloxone
group reported, however, earlier periods of heroin or
methadone abuse. As expected, nearly all opioid-depend-
ent participants had used also other substances of abuse
within the last month. In general, these non-selected opi-
oid-dependent participants represent reasonably well cur-
rent opioid abusing populations in Finland where
buprenorphine has become the main street opioid [18].
There has been a similar trend for increase of buprenor-
phine abuse world-wide [2].
Procedure
Cognitive testing was done three to six hours after the
administration of opioid substitution drug, i.e. when drug
plasma concentration is known to be highest [19]. Under
supervision, the methadone patients were given a mean
dose of 53.4 mg (SD = 18.6) of methadone, range 30 –
105 mg, in liquid form on the test day morning. The
buprenorphine/naloxone patients, also under supervi-
sion, received a mean dose of 15.8 mg (SD = 3.2) of
buprenorphine and 3.9 mg (SD = 0.8) of naloxone (range
8 – 24 mg of buprenorphine and 2 – 6 mg of naloxone) as
a sublingual tablet. In this naturalistic study, all partici-
pants received their prescribed psychoactive medications
on the test morning according to their clinical dose regi-
men. After that, however, opioid withdrawal syndrome
relievers were given according to individual needs of the
patients. Medications taken by the patients in the 24 hour
period before the test are described in Table 2. Notably, all
participants in both groups were either dependent on
benzodiazepines, had abused them during last month, or
were given them as a part of their early OST medications.
Table 2: Comedications among OST patients within the last 24 h before testing
Medications used within 24 hours of test Methadone-treated patients
(n = 16)
Buprenorphine/Naloxone- 
treated patients
(n = 17)
Proportion of patients Dose, range Proportion of patients Dose, range
Antidepressives (any) 44 % 35'%
Essitalopram 6% 5 mg
Citalopram 6 % 20 mg
Doxepine 12% 75 – 100 mg
Fluoxetine 13% 20 – 30 mg
Mirtazapine 13% 15 mg
Paroxetine 6% 50 mg
Sertraline 6% 50 mg 12% 50 mg
Venlaflaxine 12% 75 mg
Anxiolytics, sedatives and hypnotics:
Benzodiazepines (any) 81 % 76%
Diazepam 38% 5–20 mg 29% 15 -40 mg
Oxazepam 44% 45 – 120 mg 47% 30 – 90 mg
Nitratzepam* 6% 20 mg
Tematzepam * 19% 20 mg 12% 20 mg
Non-benzodiazepine hypnotics (any) 25% 35%
Zolpidem * 6% 10 mg 6% 15 mg
Zopiclone * 19% 7.5 – 15 mg 24% 7.5 – 15 mg
Neuroleptics † (any) 25% 18%
Chlorpromazine 6% 50 mg
Flupenthixole 6% 0.5 mg
Levomepromazine 6% 150 mg 6% 100 mg
Quetiapine 13% 50–100 mg 6% 300 mg
Opioid withdrawal symptom or pain relievers (any) 69 % 53%
Hydroxyzine 38% 25–200 mg 24% 75 – 300 mg
Ibuprofeine 13% 600– 2400 mg 6% 400 mg
Lofexidine 6% 0.2mg 18% 0.2 – 0.6 mg
Metoclopramide 6% 10 mg
Naproxen 6% 500 mg 6% 500 mg
Propranol 6% 20 mg
Valproate 13% 500 – 1000 mg 24% 500 – 1000 mg
None medication 13% 12%
* Used as a hypnotic the night before testing.
† Used with anxiolytic indications
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In order to estimate the current benzodiazepine doses of
the groups, all benzodiazepines were converted to
diazepam equivalent doses according to the Ashton table
[20]. In the cases of nitrazepam and temazepam the
diazepam equivalent doses were halved in order to
account for their use as hypnotics prior the night before
testing. After this conversion no statistically significant
difference existed between the patient groups in their
mean estimated diazepam equivalent dose, 23.0 mg (SD
= 20.2) in the methadone group and 19.6 mg (SD = 14.2)
in the buprenorphine/naloxone group.
Cognitive tests
A battery of cognitive tests included tests of attention,
working memory, and verbal memory.
Attention was assessed by the Alertness and Go/NoGo-
tasks from the Test for Attentional Performance (TAP)
which include computer software and RT key-pad. [21]. In
the Alertness task, visual RT was assessed with and with-
out preceding auditory warning signal. The without signal
condition of the Alertness test is a simple RT task, and is
thought to reflect tonic or intrinsic alertness [22]. The
with signal condition is thought to reflect both tonic and
phasic alertness. The conditions were presented in the A-
B-B-A – order. The Go/NoGo condition assessed integrity
of response-selection and executive control of attention
[23,24]. Visual stimuli were presented one by one. For two
stimuli out of five an instant reaction is required, and for
the others a reaction needs to be inhibited. Reaction times
and correctness of responses were recorded. In all the TAP
tests median of RTs was used as a RT parameter.
Working memory was assessed by the Letter-Number-
Sequencing task (LNS) from the Wechsler Memory Scale-
third version (WMS-III) and by the computerized version
of the Paced Auditory Serial Addition Task (PASAT) from
the FORAMENRehab software package [25-27]. The LNS
assesses verbal working memory storage added with
processing demand. In the PASAT complex working mem-
ory functions required are continuous storage of previous
number, rapid arithmetical processing, and executive con-
trol of interference from previous items or from ongoing
adding process. In our study presentation rate of a new
number to be added to the previous one was set as one in
every 1.6 second.
Verbal memory was assessed by a list learning task and by
a story recall task: the Memory for Persons Data (MPD)
and The Logical Memory (LM), respectively [25,28,29].
Both tests were presented in modified versions. In the LM,
which is a subtest of the WMS-III, only one story was pre-
sented and recalled immediately and again after 30 min-
utes. In the MPD only three persons, each with 5 items,
were presented. First there were two learning trials with
immediate recall. If the participant could recall all 15
items correctly in both trials no more learning trials were
administered. If this condition was not met, there were
additional trials until the participant was able to recall all
the items correctly in two consecutive trials. A maximum
of four trials were administered. After five minutes recall
of the items was asked for and possible errors were cor-
rected for. Finally, after 30 minutes delayed recall of all
the items was asked for.
Statistical analysis
Analysis of variance (ANOVA) was used to study the over-
all group effect in each cognitive test. This was followed,
when appropriate, by pair-wise group comparisons. We
used multiple planned ANOVAs because comparisons
were aimed at each variable separately. In all analyses, sta-
tistical significance was set at 0.05 (two-tailed). For each
variable we corrected multiple pair-wise comparisons by
Holm's procedure. We examined homogeneity of vari-
ances in each measure by Levene's test. In the simple RT
and the MPD first trial performance, the data was first
transformed by reciprocal or logarithmic transformation
to normalize the distributions. For the both of the Go/
NoGo conditions, the MPD last two last learning trials,
and in the MPD delayed recall the distributions could not
be normalized. First, we analyzed these results by non-
parametric Kruskal-Wallis ANOVA, which then were fol-
lowed, when appropriate, by pair-wise Mann-Whitney U
test. We did not covary for the group difference in educa-
tion favoring the control group over methadone group.
This was based on the contention that the assumption of
similar linear relation between education and cognitive
performance in both groups needed for analysis of covar-
iance (ANCOVA) was not met. All participants with opi-
oid dependence had started substance abuse in their early
teen years. Once the substance abuse history begins it
soon affects educational achievement by class non-attend-
ance etc. So, years of education does not reflect cognitive
ability in this populations similarly to the general popula-
tion [30]. However, in the second phase of the analysis, in
order to evaluate the role of premorbid intellectual fac-
tors, we set verbal IQ as a covariate for other measures
than RT measures. The association between simple RT
measures and intelligence is weak and may not be linear
[31]. Demographic data was studied as pair-wise group
comparisons without first requiring significant overall
group effect. Statistical analyses were done by SPSS statis-
tical software, version 13.0, with an exception of the effect
size calculations. For this purpose an effect size calculator
provided by Durham University, UK was employed [32].
In these analyses we used pooled samples and corrected
the values by Hedge's correction for small sample bias.
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Results
In the attention domain there were significant overall
group effects in two tasks: in the simple and Go/NoGo
RTs (F2,47 = 4.77, p = 0.013; ?22 = 6.39, p = 0.041, respec-
tively). In working memory, significant group effects were
found in both tasks employed; the LNS and the PASAT
(F2,46 = 11.99, p = 0.0001, F2,46 = 7.81, p = 0.001). In verbal
memory the group effect was significant in the verbal list
learning as measured by the MPD first trial and the MPD
delayed recall, and also in the immediate story recall as
measured by the LM (F 2,47 = 7.29, p = 0.002, ?22 = 9.24, p
= 0.01, F 2,47 = 5.49, p = 0.007). Table 3 shows group per-
formances in each cognitive test, along with statistical
analyses of pair-wise ANOVAs or Mann-Whitney U tests.
As seen in Table 3 buprenorphine/naloxone patients were
superior to methadone patients in the simple RT. The
buprenorphine/naloxone patients showed no difference
in attention tests compared to the control group. Rather
surprisingly, buprenorphine/naloxone patients were
slightly, but not statistically significantly, faster than con-
trols in simple RT. In this task their performance variance
was also reduced compared to other groups, which was
confirmed by Levene's test of equality of variances (F2,47 =
4.13, p = 0.022). Both methadone patients and controls
showed improvement of performance when RT was per-
formed after warning signal whereas buprenorphine/
naloxone patients showed no such improvement. In the
Go/NoGo RT, controls were superior to methadone
patients. In working memory tests controls were superior
to both groups of OST patients. In verbal memory con-
trols were superior to both patient groups in the MPD first
learning trial. In the immediate LM controls were superior
to methadone patients.
In order to investigate if group differences were due to dif-
ferences in premorbid intelligence between the groups,
the Verbal IQ estimate was set as a covariate for all tasks
with verbal stimuli. All statistically significant group dif-
ferences remained significant after adjusting for the cov-
ariate. Statistically significant group by Verbal IQ
interactions were not found.
Post hoc analyses were done in order to investigate the
role of benzodiazepine comedication on cognitive per-
formance between the OST drug groups. In these analyses
patients without current benzodiazepine medication were
Table 3: Groups comparisons of cognitive measures using ANOVA
Domain Test Methadone 
(n = 16)
Buprenorphine/
Naloxone
(n = 17)
Control
(n = 17)
Statistical comparisons 
between groups 
showing better 
performance first
Effect size 
(Cohen's d)
Mean ± SD Mean ± SD Mean ± SD
Attention
TAP Tonic Alertness, simple reaction time 257.6 ± 32.1 228.0 ± 13.0 244.4 ± 30.0 BN < M ** 1.11
TAP Phasic Alertness, reaction time after 
warning signal
245.6 ± 30.4 227.4 ± 17.0 230.3 ± 31.7
TAP Go/NoGo, reaction time 528.3 ± 82.0 496.9 ± 65.3a 465.5 ± 39.5 C < M* 0.88
TAP Go/NoGo, errors 0.6 ± 0.7 1.2 ± 1.4a 0.5 ± 0.6
Working memory
WMS-III LNS 8.8 ± 2.6b 8.7 ± 1.7 11.8 ± 3.1 C > M**
C > BN**
1.02
1.21
PASAT 34.9 ± 10.6b 31.3 ± 10.8 47.8 ± 9.3 C > M**
C > BN***
1.27
1.60
Memory
MPD, first trial 10.1 ± 3.0 10.6 ± 2.4 13.0 ± 1.4 C > M**
C > BN*
1.22
1.19
MPD, sum of two last trials 14.6 ± 1.0 14.8 ± 0.4 14.9 ± 0.2
MPD, delayed recall 13.9 ± 1.0 14.2 ± 1.0 14.8 ± 0.4 C > M**
C > BN*
WMS-III logical memory, immediate recall 12.5 ± 2.9 14.3 ± 3.6 16.3 ± 3.4 C > M** 1.17
WMS-III logical memory, delayed recall 11.1 ± 4.3 13.4 ± 3.3 14.5 ± 4.1
TAP = Test for Attentional Performance;
PASAT = Paced Auditory Serial Addition Task;
WMS-III = Wechsler Memory Scale-third version;
MPD = Memory for Persons Data.
C = control, M = methadone, BN = buprenorphine/naloxone
*** = statistically significant at level p < 0.001.
** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
an = 16.
bn = 15.
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excluded leaving 13 patients in both groups. After exclu-
sion all participants in both groups were dependent on
benzodiazepines and had used them within the last
month before the OST. The mean dose in the methadone
group was 54.2 mg (SD = 18.7) of methadone and 28.3
mg (SD = 18.6) of diazepam equivalent. The mean dose
in the buprenorphine/naloxone group was group was
16.3 mg (SD = 2.9) of buprenorphine and 25.6 mg (SD =
10.1) of diazepam equivalent. For demographic variables
there no significant differences emerged between groups.
The group with buprenorphine/naloxone and benzodi-
azepine medication was superior to the methadone group
with benzodiazepine medication in simple RT (U = 38.00,
p = 0.017) and in delayed recall of the LM (F1,24 = 6.15, p
= 0.021, d = 0.94)). Figure 1 depicts group performances
in both conditions of the LM.
Finally, post hoc analyses were made to study the role of
OST doses on cognitive performance. For these analyses
we split the patients groups into low and high dose groups
depending on their median OST drug dosage. After this
division the mean doses of methadone in the low dose (n
= 8) and high dose group (n = 8) were 40.0 mg (SD = 5.3)
and 66.9 mg (SD = 17.3). Among buprenorphine/
naloxone patients nine patients received the same dose of
16 mg, and very few cases fell in the tails of the dose dis-
tribution. Therefore, dose analyses were restricted to
methadone patients. Patients with low a methadone dose
had faster RTs in all conditions than patients with high
dose. Figure 2 depicts these differences. In the simple RT
the difference reached statistical significance (p = 0.025, d
= 1.19). The mean simple RT time in the low methadone
dose group was 240.3 ms (SD = 29.9), which was very
close to the performance of the control group. No signifi-
cant differences between the groups were found in demo-
graphic variables except in days in the OST. The low dose
group had been fewer days on OST medication, mean 8.6
days, and high dose group, mean 20.0 days (SD = 1.9 vs.
6.3 respectively, p < 0.001). No significant differences
between the groups emerged in other psychoactive medi-
cations. In the low dose group 75% of the participants had
benzodiazepine and 25% had neuroleptic medication,
the corresponding figures being 88% and 25% in the high
dose group. In the low dose group 38% received hydrox-
yzine vs. 25% in the high dose group. Conversion of long
or intermediate acting benzodiazepines to a diazepam
equivalent dose neither showed significant difference
between the groups, mean dose for the low dose group
being 29.6 mg (SD = 28.7) and 18.1 in the high group (SD
= 10.9).
Discussion
In this first study comparing cognitive function of metha-
done- and buprenorphine/naloxone-treated patients dur-
ing early OST both patient groups were inferior to controls
in working memory and verbal memory. Methadone-
treated patients showed inferior performance also in
attention and more deficits in verbal memory. In the
attention task measuring alertness methadone-treated
patient were inferior to buprenorphine/naloxone-treated
patients. The effect sizes of group differences in compari-
son to controls in working memory and verbal memory
were close to the ones obtained in other studies of opioid-
dependent populations [33-35]. In attention tasks studies
with stabile OST patients the effect sizes have been varia-
ble depending on specific tasks used [36].
Working memory performance, which was inferior in
both patient groups, was measured by the PASAT and the
LNS tasks combining maintenance with organization of
material or with interference. Efficient performance of
these tasks depends on activation of widespread neural
networks including bilateral frontal and parietal cortices.
Especially pronounced activity is seen in right hemisphere
Comparison of high vs. low methadone dose groups in reac-ti n time  (RT)Figure 2
Comparison of high vs. low methadone dose groups in reac-
tion times (RT). * = p < 0.05
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[37,38]. Methadone-treatment of opioid-dependence
reduces cerebral blood flow (CBF) particularly in frontal
cortices and the patients often have left-greater-than-right
CBF asymmetry [39]. There are no similar studies con-
cerning buprenorphine treatment though buprenorphine
administration has been shown to reduce brain CBF in
substance abusing population [40]. In general, the CBF
reductions associated with opioid-dependence are proba-
bly linked to inadequate energy supply to the brain and
changes in releases of several neurotransmitters such as
catecholamines and acetylcholine [41,42]. Catecho-
lamines are important for integrity of working memory,
while acetylcholine is important also for learning and
memory consolidation. [43,44]. Thus, it does not aston-
ish that both OST groups showed inferior verbal list learn-
ing performance relative to controls. Methadone patients'
performance was reduced also in immediate story recall.
After excluding patients without benzodiazepine medica-
tion the difference between the methadone and buprenor-
phine group in delayed story recall appeared statistically
significant and showed a large effect size. Thus, it is possi-
ble that full mu opioid agonist methadone disrupts more
acetylcholine release and consequently impairs more ver-
bal memory than partial mu opioid agonist buprenor-
phine. Other factors that may be involved in memory
deficits of the OST patients are alterations of glutamater-
gic synapses after chronic opioid administration or inhibi-
tion of new cell formation in the hippocampus after
chronic mu opioid receptor activation [45,46].
Methadone patients were slower than buprenorphine/
naloxone patients in simple RT reflecting alertness and
slower than controls in the Go/NoGo RT task reflecting
response selection and executive control of attention. On
test day methadone patients received a mean dose of 23
mg diazepam equivalent medication and buprenorphine/
naloxone patients had been given 20 mg. It is known that
benzodiazepines such as diazepam or oxazepam, which
were commonly administered to the patients in this study
may have a slight negative effect on simple RT even
among long-term benzodiazepine users [47,48]. Thus,
benzodiazepine comedication may have affected the
results in RT tasks. It also possible that benzodiazepine
comedication would interact differently with methadone
than with buprenorphine/naloxone. This possibility is
supported by the results of a recent study by Lintzeris et al.
showing that mixing 10 or 20 mg of diazepam with a
mean 55 mg of methadone had significant detrimental
effect on simple RT and focused attention in methadone
patients [49]. Mixing the same amounts of diazepam with
mean 11 mg of buprenorphine had, however, minimal
effect on buprenorphine patients. In sum, we suggest that
methadone-treated patients with current benzodiazepine
medication tend to show inferior performance in atten-
tion tests relative to buprenorphine/naloxone-treated
patients with the same characteristics during early OST.
Consequently, it cannot be concluded that methadone, as
an OST monotherapy, would have different effect on atten-
tion performance than buprenorphine/naloxone mono-
therapy.
The good performance of buprenorphine/naloxone
patients in simple RT without warning signal along with
their reduced performance variance in this measure is a
surprising finding because buprenorphine has adverse
effect on RTs in healthy controls [9]. In some earlier stud-
ies methadone patients with stable doses also have out-
performed healthy controls in simple RT [11,50]. In one
study, a relatively low dose of methadone of, 33 mg or 16
mg, given during early inpatient opioid withdrawal treat-
ment actually speeded RTs of opioid-dependent patients in
comparison to placebo condition [12]. In our study meth-
adone patients on 40 mg outperformed methadone
patients on 67 mg dose. Together these observations raise
the possibility that a low dose of full mu opioid agonist
methadone or normal dose of partial mu opioid agonist
buprenorphine may have a minimal effect on simple RTs
of opioid-dependent patients in OST with high tolerance
for these opioids – and also for benzodiazepine comedi-
cation.
Limitations
Cognitive differences between the patient groups may
partly relate to differences in their OST drug-tolerance.
The majority of the patients in both groups had abused
buprenorphine during the recent month. In spite of cross-
tolerance to opioids, it is possible that switching from
buprenorphine to methadone results in transient cogni-
tive deficits in methadone patients. Thus, the possibility
of opioid switching effect in methadone-treated patients
during early OST cannot be ruled out. In order to investi-
gate this issue we are currently working on a follow-up
study with same patients.
Several psychoactive medications were used nearly simi-
larly in both groups to treat psychiatric comorbidity dur-
ing the OST initiation. These drugs, such as short acting
non-benzodiazepine zopiclone, neuroleptics, anticonvul-
sant valproate, or antihistamine hydroxyzine may have
slight adverse cognitive effects [51-54]. The interactions of
OST medications and all these medications warrant for
further studies.
All our participants were free from current substance
abuse as confirmed by drug screens. Instead, during the
recent month preceding the OST patients had used several
psychoactive substances. There were no major differences
between the uses of these substances within the patient
groups. Thus, these substances such as cannabis may
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explain the differences between the studied OST patient
groups only if they have long-term effects and they inter-
act differently with the OST drugs. Therefore, long-term
benzodiazepine use may explain part of the similarities
between the OST patient groups. Long-term benzodi-
azepine monotherapy has adverse affect on several cogni-
tive functions, which may last at least for six months [55].
Opioid-dependent patients may already differ from the
general population in premorbid cognitive functions. Yet,
when we controlled for premorbid verbal intelligence by
using Verbal IQ estimate as a covariate in ANCOVA proce-
dure, this did not affect the results. Actually, this proce-
dure may be too conservative. A recent study has shown
that current smoking (if more than 8 cigarettes per day)
affects Verbal IQ [56]. Nearly all of our patients were daily
smokers. Thus, verbal IQ differences in these patients may
not to be primarily premorbid.
Conclusion
Both methadone and buprenorphine/naloxone-treated
OST patients show deficits in working memory and verbal
list learning during the early phase of their treatment. Def-
icits in attention may be seen only in methadone-treated
patients and their impairments may be dose-dependent.
Verbal memory deficit may be more extensive in metha-
done- than in buprenorphine/naloxone-treated patients.
Thus, this study further shows that in clinical samples, in
which recent benzodiazepine use and benzodiazepine
comedication as well as other psychoactive medications
are common, methadone-treated patients have more cog-
nitive deficits than buprenorphine- or buprenorphine/
naloxone-treated patients. Buprenorphine/naloxone may
preserve cognitive function in early OST better than meth-
adone, at least when benzodiazepine comedication is
used. Longitudinal studies are warranted to investigate
whether this advantage is permanent or is restricted to
early OST
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Abstract
Background: Opioid-substitution treatment (OST) for opioid dependence (OD) has proven effective in
retaining patients in treatment and reducing illegal opiate abuse and crime. Consequently, the World
Health Organization (WHO) has listed the opioid agonists methadone and buprenorphine as essential
drugs for OD that should be available worldwide. In many areas of the world, OD is often associated with
concomitant benzodiazepine (BZD) dependence and abuse, which complicates treatment. However,
possible changes in the cognitive functioning of these patients are not well-known. The present study is
the first to examine longitudinal stability of memory function in OST patients with BZD use, thus providing
a new tool for health policy authorities in evaluating the usefulness of OST.
Methods: Within the first two months (T1) and between 6–9 months (T2) after OST admission, we
followed the working memory, immediate verbal memory, and memory consolidation of 13 methadone-
and 15 buprenorphine- or buprenorphine/naloxone-treated patients with BZD dependence or abuse
disorder. The results were compared to those of fifteen normal comparison participants. All participants
also completed a self-reported memory complaint questionnaire on both occasions.
Results: Both patient groups performed statistically significantly worse than normal comparison
participants in working memory at time points T1 and T2. In immediate verbal memory, as measured by
list learning at T1, patients scored lower than normal comparison participants. Both patient groups
reported significantly more subjective memory problems than normal comparison participants. Patients
with more memory complaints recalled fewer items at T2 from the verbal list they had learned at T1 than
those patients with fewer memory complaints. The significance of the main analyses remained nearly the
same when the statistical tests were performed without buprenorphine-only patients leaving 12 patients
to buprenorphine/naloxone group.
Conclusion: Working memory may be persistently affected in OST patients with BZD use. A high
number of memory complaints among OST patients with BZD use may indicate memory consolidation
impairment. These findings show that recovery of memory function in OD patients treated along with
BZDs takes time, and their memory complaints may have practical relevance.
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Introduction
Opioid-substitution treatment with the full mu opioid
receptor agonist methadone or the partial agonist
buprenorphine is the most effective treatment for OD
[1,2]. Follow-up studies of OST patients have shown con-
sistently high retention in OST, fewer crimes, reduction in
substance abuse, and improved health [3,4]. However, the
psychosocial recovery of OD patients during treatment is
still controversial. It has been stated that while opioid
abuse and other problem behavior reduces during the
OST, there is little research-based evidence for improve-
ment if patient-centered indicators of quality of life are
used [5]. While this critique underestimates the impor-
tance of reduction of the health hazards of OD, it also
shows the shortage studies using objective measures of
psychological functions. In order to meet this challenge,
studying memory function of OD patients is an important
element, because the patients often complain poor mem-
ory [6,7]. Therefore, in this longitudinal study memory
function of OST patients was evaluated by tests and sub-
jective memory questionnaire. Because in Finland most
OD patients are prescribed benzodiazepines or abuse
them from illegal sources [7,8], we examined memory
function of this clinically relevant majority.
Some studies have shown substantial memory deficits
among OD patients in methadone treatment even after
years of treatment [9,10]. Also, buprenorphine-treated
patients may show poor memory function [11,12]. How-
ever, only two studies have examined the longitudinal sta-
bility of memory function during OST. In the seminal
longitudinal study by Grevert et al., the memory perform-
ance of OST patients, of whom about one third tested pos-
itive for other drugs of abuse during the tests, was assessed
three times within the first three months of treatment
[13]. No baseline or subsequent differences between the
methadone patients and a comparison group were seen in
objective or subjective memory function. No significant
correlations were seen between drug screen status and
memory test results. However, as the patients performed
the tests immediately before or after the methadone dose,
that is, when their plasma concentration is known to be at
the lowest level, short-term negative effects of high meth-
adone concentrations may have been missed. In a more
recent study by Gruber et al., the tests were done a few
hours after the methadone dose [14]. The patients' mem-
ory performance was tested first within the first few weeks
of OST and again after two months of treatment.
Although 65% of the patients tested positive for any illicit
use at the first test and 76% at the second test, the results
showed a statistically significant improvement in verbal
list learning among patients.
In our previous study, we found that both methadone-
and buprenorphine/naloxone-treated patients in early
OST performed worse than normal comparison partici-
pants on a working memory task [15]. The verbal memory
deficit was more pronounced in methadone-treated
patients than in buprenorphine/naloxone-treated
patients. Although the results partially favored buprenor-
phine/naloxone-treated patients, BZD co-medication that
was common in both patient groups, may have affected
the results. There are no longitudinal studies comparing
the effects of OST drugs while patients use BZDs. How-
ever, there is some evidence for acute negative effects of
opioid agonists on working memory in drug-naïve
healthy volunteers and for chronic negative effects in pain
patients [16,17]. The negative effects of BZDs on working
memory and long-term memory are better – known, vary
from small to moderate, and may last several months after
cessation of use [18]. Of special interest is the study of
Lintzeris et al., which found that in comparison to a pla-
cebo condition, methadone dose alone, or buprenor-
phine dose in combination with BZD diazepam impairs
verbal recall in OST patients [19]. Given these findings
suggesting memory deficits in OST patients using BZDs,
we did a follow-up study of memory function in OD
patients treated with methadone or buprenorphine
(including buprenorphine/naloxone) along with BZDs.
In order to control for the effects of repeated testing, a
comparison group performed similar tests. Working
memory, immediate verbal memory, and memory con-
solidation were examined. The participants also com-
pleted the Memory Complaint Questionnaire, which
assesses subjective memory function [20].
We hypothesized that working memory function in both
OST patient groups treated along with BZDs would be
impaired relative to normal comparison participants in
the first testing (T1) and would not show improvement.
Second, we hypothesized that immediate verbal memory
would be impaired relative to normal comparison partic-
ipants at T1 and would not show improvement in OST
patients also using BZDs. Third, we hypothesized that
memory consolidation would be impaired in OST
patients. Finally, we hypothesized that among OST
patients subjective and objective memory function would
correlate negatively.
Methods
The study participants with OD were volunteers admitted
for standard OST in the addiction clinics of the Helsinki
area. Normal comparison participants were recruited
from adult education centers and by word of mouth. All
participants included in the study were between 18 – 50
years of age and native Finnish speakers. For OST patients,
additional inclusion criteria were OD diagnosis, BZD
dependence or abuse diagnosis, start of OST during the
last two months, and treatment of OD with methadone,
buprenorphine, or buprenorphine/naloxone. We
excluded participants with uncontrolled polysubstance
abuse, acute alcohol abuse, or acute axis I psychiatric mor-
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bidity other than substance abuse related. We also
excluded participants with severe brain injury, chronic
neurological disease, history of other than substance-
induced psychoses, epileptic seizures, human immunode-
ficiency virus (HIV) infection, pregnancy, or primary cog-
nitive deficit. For these purposes, psychiatric interviews by
clinical psychiatrist were conducted for all participants,
and diagnostic criteria from the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) were applied
[21,22].
Each OST participant eligible for our study was screened
by urine sample for substance abuse on the day of testing
and at least once in the preceding month. One third of
normal comparison participants were chosen at random
for screening for drug of abuse. Participants showing signs
of current intoxication, ongoing binge on any substance
of abuse, and those with any extra psychoactive drug dose
within 24 h were all excluded. According to these criteria
13 methadone- and 15 buprenorphine/naloxone- or
buprenorphine-treated patients and 15 normal compari-
son participants could be studied twice. This represents
59% of volunteer methadone patients at T1, 52% of
buprenorphine patients (including both products), and
79% of normal comparison participants. Eight volunteer
patients were excluded from the study based on their sub-
stance abuse before the test. Fourteen eligible patients and
four normal comparison participants dropped out of the
study between T1 and T2. At T1, 23% of the methadone
patients and 40% of the buprenorphine patients were
tested in inpatient settings. At T2, none of the methadone
patients and 13% of the buprenorphine patients were
tested in inpatient settings.
Ethics
The study was approved by the independent Hospital Dis-
trict of Helsinki and Uusimaa Ethical Committee (permis-
sion 90/2001). The study was conducted in accordance
with the 1964 Declaration of Helsinki. All patients were
required to be able to read and understand the patient
information sheet and sign the informed consent form.
All participants were free to discontinue participation in
the study whenever they wanted. The participants were
reimbursed with ? 40 if they attended all study visits.
Procedure
Cognitive testing was done three to six hours after admin-
istration of the opioid-substitution drug. During this time
the drug plasma concentration is at its peak [23]. At T1,
the methadone patients were given, under supervision on
the morning of the test day, a mean dose of 72.9 mg (SD
= 35.2) of liquid methadone, range 35 – 150 mg. At T2,
the respective values for methadone were 125.7 mg (SD =
35.8), range 70 – 180 mg. At T1, the buprenorphine
patients were given, under supervision on the morning of
the test day, a mean dose of 17.3 mg (SD = 3.6) of sublin-
gual buprenorphine, range 12 – 24 mg. At T2, the respec-
tive values were 22.7 mg (SD = 2.9), range 16 – 28 mg.
Rise of the dose was statistically significant in both groups
(Wilcoxon's Signed Ranks test, exact (2-sided) p = 0.001 in
both groups). In the buprenorphine group, 80% of the
patients were given buprenorphine/naloxone; thus, they
were also given sublingual naloxone in a ratio of 1:4
together with their buprenorphine dose. Several studies
have shown that among OD individuals sublingual
naloxone has minimal if any interference with the opioid
agonist effects of the buprenorphine [24-26]. Other pre-
scribed psychoactive medications were given to the
patients according to their clinical dose regimen. Table 1
describes the BZDs and their doses used within the 24-
hour period before the tests. In order to compare the BZD
doses of the groups, all BZDs were converted to diazepam
equivalent doses according to their known clinical
potency [27]. Temazepam and midazolam doses were
halved in order to account for their use as hypnotics on
the night before testing. After this conversion, no statisti-
cally significant difference existed between the patient
groups in their mean estimated diazepam equivalent dose
at T1 or T2. There was no significant change between the
T1 and T2 BZD doses within the groups. The diazepam
equivalent dose at T1 was on average 26.2 mg (SD = 18.5)
in the methadone group and at T2 26.5 (SD = 10.0); in the
buprenorphine group, the respective values were 27.7 (SD
= 24.1) and 21.0 (SD = 11.1). In other types of psychoac-
tive drugs there were no statistically significant changes
between the test points.
Memory tests
Working memory refers to the limited capacity short-
term store that temporarily maintains information, which
is lost without rehearsal [28]. It was assessed by the Letter-
Number-Sequencing task from the Wechsler Memory
Scale-third version (WMS-III) and by the computerized
version of the Paced Auditory Serial Addition Task
(PASAT) from the FORAMENRehab software package [29-
31].
Immediate verbal memory refers to immediate storage of
verbally presented items in those situations that exceed
the capacity of sensory-specific working memory stores.
Typical examples of immediate verbal memory measures
include recall of a list or story. Immediate verbal memory
is thought to rely on both working and long-term memory
stores. This concurrent activation of two memory stores
has recently been experimentally confirmed [32]. Imme-
diate verbal memory was assessed by two verbal memory
tasks, a list learning and a story recall task: the Memory for
Persons Data and The Logical Memory [29,33]. Both tasks
were presented in modified versions. The details of these
tasks are presented in our previous study [15].
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Table 1: Co-medications among patients used within the last 24 h before testing at T1 and T2
Methadone (n = 13) Buprenorphine or Buprenorphine/Naloxone (n = 15)
Proportion of patients Dose, range Proportion of patients Dose, range
Antidepressants (any), T1/T2 54%/46% 40%/53%
Citalopram T1 8% 40 mg - -
Citalopram T2 - - 13% 10 mg
Escitalopram T1 8% 5 mg - -
Escitalopram T2 8% 10 mg - -
Doxepine T1 - - 13% 75 – 100 mg
Doxepine T2 8% 50 mg 20% 25 – 100 mg
Fluoxetine T1 15% 20 – 30 mg - -
Fluoxetine T2 8% 40 mg - -
Milnacipran T1 - - - -
Milnacipran T2 - - 7% 50 mg
Mirtazapine T1 25% 15 – 30 mg - -
Mirtazapine T2 25% 30 mg 7% 30 mg
Paroxetine T1 8% 50 mg 7% 50 mg
Paroxetine T2 - - 13% 40 mg
Sertraline T1 - - 7% 50 mg
Sertraline T2 - - 7% 50 mg
Trimipramine T1 - - - -
Trimipramine T2 8% 150 mg - -
Venlafaxine T1 - - 13% 75 mg
Venlafaxine T2 - - 7% 75 mg
Anxiolytics, sedatives and 
hypnotics: Benzodiazepines (any), 
T1/T2
87%/100% 93%/100%
Alpratzolam T1 - - 13% 1 – 2 mg
Alpratzolam T2 - - 13% 1 – 2 mg
Clonazepam T1 - - 13% 2 – 5 mg
Clonazepam T2 - - - -
Diazepam T1 46% 10 – 55 mg 47% 10 – 40 mg
Diazepam T2 38% 15 – 30 mg 67% 5 – 30 mg
Oxazepam T1 31% 60 – 120 mg 33% 30 – 90 mg
Oxazepam T2 46% 15 – 60 mg 20% 55 – 60 mg
MidazolamT1a - - - -
MidazolamT2a - - 7% 30 mg
Temazepam T1a 31% 20 mg 13% 20 mg
Temazepam T2a 15% 20 – 40 mg 13% 20 – 40 mg
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Memory consolidation refers to the storage and consoli-
dation of memory traces. Early memory consolidation
lasts from minutes to hours and late memory consolida-
tion from weeks to years; these rely partly on separate neu-
ral processes [34,35]. Early memory consolidation was
assessed by the percentage of the Logical Memory and
Memory for Persons Data items successfully recalled by
free recall after a short delay (30 min). Late memory con-
solidation was assessed by free recall of the Memory for
Persons Data items at T2, which occurred after at least four
and on average six, months after initial learning. Partici-
pants were further asked to rate the certainty of their
answers after the long delay. This may give additional
information about the memory processes the participants
are employing [36]. If the participant gave the right
answer, it was asked if he/she was certain that he/she actu-
ally remembered the answer or if he/she only felt he/she
knew the answer but was not certain about it. In the case
of "felt" or no answer, three nearly identical alternatives
were given, one of them being correct. After the partici-
pant gave his/her choice, he/she was asked if he/she
remembered, felt, or just guessed the answer.
Non-benzodiazepine hypnotics 
(any), T1/T2
15%/8% 20%/7%
Zolpidem T1a - - - -
Zolpidem T2a 8% 10 mg 7% 10 mg
Zopiclone T1a 15% 7.5 mg 20% 7.5 – 15 mg
Zopiclone T2a 8% 7.5 mg 7% 7.5 mg
Neuroleptics (any), T1/T2b 20%/8% 7%/7%
Levomepromazine T1 - - - -
Levomepromazine T2 8% 50 mg - -
Quetiapine T1 20% 50 – 300 mg 7% 300 mg
Quetiapine T2 - - 7% 150 mg
Rispiderone T1 - - - -
Rispiderone T2 8% - - -
Substance abuse withdrawal 
symptom or (non-opioid) pain 
relievers (any), T1/T2
42%/25% 40%/13%
Disulfiram T2 - - - -
Disulfiram T2 8% 600 mg - -
Hydroxyzine T1 25% 25 – 200 mg 27% 75 – 200 mg
Hydroxyzine T2 8% 50 mg 7% 100 mg
Ibuprofen T1 8% 600 mg 7% 400 mg
Ibuprofen T2 - - 7% 600 mg
Lofexidine T1 8% 0,2 mg 20% 0.2 – 0.6 mg
Lofexidine T2 - - - -
Metoclopramide T1 8% 10 mg - -
Metoclopramide T2 - - - -
Naproxen T1 8% 500 mg - -
Naproxen T2 - - - -
Propranol T1 8% 20 mg - -
Propranol T2 - - - -
Valproate T1 8% 1000 mg 20% 500 – 1000 mg
Valproate T2 - - 7% 100 mg
a Used as a hypnotic on the night before testing.
b Used for anxiolysis.
Table 1: Co-medications among patients used within the last 24 h before testing at T1 and T2 (Continued)
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Subjective memory functioning was assessed by the Finn-
ish version of the Memory Complaint Questionnaire, the
MCQ [20]. In the MCQ, the participant is asked how his/
her memory now functions compared to when he/she was
younger. Several answers are given, using a Likert-type
scale, describing how well memory functions in everyday
tasks (remembering persons, things, news, shopping list
items, etc.). A high score indicates subjective memory
impairment.
Statistical Analysis
Overall group differences in memory performance at T1
and T2 were tested for statistical significance using multi-
ple planned analysis of covariance (ANCOVA) with years
of education and verbal IQ estimate as covariates.
Although there were no statistically significant differences
between the groups in the verbal IQ, it was used as a cov-
ariate because it is known to affect memory performance
in tasks with verbal content [37]. ANCOVA was followed,
when appropriate, by pairwise group comparisons using
normal comparison group as a reference group. The
Holm's sequential Bonferroni procedure was used to con-
trol for Type I error across the pairwise comparisons [38].
In all analyses, statistical significance was set at 0.05 (two-
tailed). In the Memory for Persons Data, the data were
highly skewed due to a ceiling effect in the initial learning
and recall at T1. At T2, the Memory for Persons Data for
delayed recall was skewed because of small variance.
Because of these violations of the assumptions of para-
metric testing, we analyzed these conditions by Kruskal-
Wallis ANOVAs, which were followed, when appropriate,
by pairwise Mann-Whitney U tests. In order to confirm
the validity of combining buprenorphine/naloxone and
buprenorphine-only patients, the ANCOVAs and ANO-
VAs were also performed with buprenorphine/naloxone
patients (n = 12). The cross-sectional MCQ scores and the
MCQ T2 differences between high vs. low score groups
were analyzed by t-tests or Mann-Whitney U tests. Corre-
lations between the MCQ values and cognitive variables
were analyzed by Pearson's product moment correlation
or Spearman's rho correlations depending on the normal-
ity of the variables. Correlations of at least .35 will be
reported. The statistical significance of correlations was
determined by using the Holm-Bonferroni procedure.
Longitudinal changes were analyzed by repeated meas-
ures ANCOVA using education and VIQ as a covariates
and the comparison group as a reference group. All statis-
tical analyses were performed using SPSS statistical soft-
ware, version 15.0, with the exception of the effect size
calculations. For this purpose, an effect size calculator
provided by Durham University, UK was employed
[39,40]; and the Cohen's d values were corrected by
Hedge's correction for small sample bias.
Results
Study demographics
Table 2 shows the comparisons of demographic variables
of each group. The group difference in verbal intelligence
(Verbal IQ) was statistically non-significant even though
the comparison group had more education than the
patient groups. There were no significant differences
between the OST groups in history of substance abuse,
duration of OST, or the prevalence of psychiatric co-mor-
bidity. Personality disorder diagnoses were common in
both patient groups. Buprenorphine was the main opioid
of abuse before the OST admission in both groups.
Among patients, no major change in the number of non-
opioid substances abused during the recent month before
the T1 or T2 testing was seen during the study period.
Group comparisons at T1
In Table 3, an overview of unadjusted memory test results
at both test points is presented together with statistical
comparisons for years of education and verbal IQ adjusted
values, whenever adjusting was possible. In working mem-
ory tests, the methadone patients were inferior to controls
in the PASAT, but in the Letter-Number Sequencing the
group difference remained non-significant. The buprenor-
phine patients were inferior to normal comparison partici-
pants on the both of the working memory tests. In
immediate verbal memory as measured by the first learning
trial of the Memory for Persons Data, both patient groups
performed significantly worse than normal comparison
group. In early memory consolidation as measured by
short-term retention of percentages of the Logical Memory
and the Memory for Persons Data items, no significant
group differences emerged. The statistical significance of
the analyses remained the same when the analyses outlined
in the Table 3 were done with buprenorphine/naloxone
patients (n = 12) instead of combining the buprenorphine-
only and buprenorphine/naloxone patients. Statistically
significant values of overall group effects were, in order, The
Letter-Number Sequencing, The PASAT, the first trial of the
Memory for Persons Data, and the MCQ (F (2, 35) = 3.63,
p = 0.009; F (2, 35) = 9.57, p < 0.001; ?2 (2, N = 40) = 7.99,
exact p = 0.018; ?2, (2, N = 40) = 11.83, exact p = 0.004).
After this, pairwise analyses between the buprenorphine/
naloxone and normal comparison groups were performed.
In the Letter-Number Sequencing the pairwise group com-
parison was statistically non-significant (t (26) = 2.67, p =
0.065). In the PASAT and in the first trial of the Memory
Persons Data, the buprenorphine/naloxone group showed
worse performance than the normal comparison group (t
(26) = 4.71, p = 0.00; Mann-Whitney U = 45.50, exact p =
0.028, respectively). In the MCQ, the buprenorphine/
naloxone patients reported more memory complaints than
the comparison participants (Mann-Whitney U = 26.00,
exact p = 0.004).
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Table 2: Group demographics
Methadone
(n = 13)
Buprenorphine or 
Buprenorphine/Naloxone
(n = 15)
Normal Comparison
(n = 15)
Group comparison
p-valuesa
Age, mean of years at T1 (SD) 29.2 (6.8) 27.7 (6.8) 28.7 (9.6) M vs. BN, p = 0.99
M vs. NC, p = 0.99
BN vs. NC, p = 0.99
Sex: females/males 7/6 4/11 8/7 M vs. BN, p = 0.14
M vs. NC, p = 0.98
BN vs. NC, p = 0.14
Verbal intelligence, Meanb (SD) 100.6 (11.4) 99.4 (9.3) 104.1 (9.6) M vs. BN, p = 0.99
M vs. NC, p = 0.74
BN vs. NC, p = 0.63
Education, mean of years (SD) 10.1 (1.2) 10.5 (2.0) 12.6 (1.3) M vs. BN, p = 0.54
M < NC***, p < 0.001
BN < NC**, p = 0.006
Opioid of abuse used within last 
month at T1
Buprenorphine 85% 100% - M vs. BN, p = 0.48c
Heroin 15% 0%
Other substances of abuse used within 
last month at T1 and T2
Alcohol (heavy use)d 15%/15% 13%/7% 7%/7% M vs. BN vs. NC (T1/T2),
p = 0.99c/0.99c
Amphetamine 8%/8% 13%/7% - M vs. BN vs. NC (T1/T2)
p = 0.99c/0.99c
Benzodiazepine, any Use 100%/100% 100%/100% 0%/0% M & BN > NC*** (T1/T2),
p < 0.001c/p < 0.001c
Benzodiazepine, extra doses 38%/38% 42%/33% - M vs. BN (T1/T2),
p = 0.62/p = 0.78c
Cannabis 31%/31% 40%/27% - M vs. BN (T1/T2),
p = 0.83c/0.84c
Nicotine (daily use) 100%/100% 100%/100% 33%/33% M & BN > NC*** (T1/T2),
p < 0.001c/p < 0.001c
Duration of OST in the day of testing 
at T1, Mean of days (SD)
21 (14) 19 (12) - M vs. BN, p = 0.69
Duration of OST on the day of testing 
at T2, Mean of days (SD)
213 (25) 224 (17) - M vs. BN, p = 0.15
Participants with other dependence or 
abuse diagnosis at T1
Alcohol 0% 0% 0% M vs. BN vs. NC, p = 0.99c
Amphetamine 0% 0% - M vs. BN, p = 0.99c
Benzodiazepine 100% 100% - M vs. BN, p = 0.99c
Cannabis 15% 20% - M vs. BN, p = 0.99
Nicotine 100% 100% 33% M vs. BN, p = 0.99c
M vs. NC, p = 0.13c
BN vs. NC, p = 0.12c
Participants with any DSM-IV axis I 
diagnosis at T1
15% 20% 0% M vs. BN, p = 0.99c
M vs. NC, p = 0.21c
BN vs. NC, p = 0.22c
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Group comparisons at T2
At T2, both patient groups were inferior to normal com-
parison group in working memory tests. In immediate
verbal memory assessed by the immediate recall of the
Logical Memory items, no significant group differences
were seen. In early memory consolidation assessed by the
Logical Memory short-term retention percentage, group
differences were not significant. In late memory consoli-
dation assessed by the Memory for Persons Data free recall
or recognition retention percentages after at least four
months' delay, there were no group differences. Again,
dropping buprenorphine-only patients from the
buprenorphine group did not change the statistical signif-
icance of the overall ANOVAs or ANCOVAs. Significance
values of overall group effects were, in order, the Letter-
Number Sequencing, The PASAT, and the MCQ (F(2, 35)
= 3.82, p = 0.032, (F(2, 35) = 7.52, p = 0.02, (?2, (2, N =
40) = 15.91, exact p < 0.001). Pairwise comparisons
between the buprenorphine/naloxone and normal com-
parison groups favored the comparison group in both
working memory tasks: the Letter-Number Sequencing
and The PASAT, respectively (t (26) = 2.21, p = 0.03; t (26)
= 3.33, p = 0.002). In the MCQ, the buprenorphine/
naloxone patients reported more memory complaints the
normal comparison participants (Mann-Whitney U =
29.50, exact p = 0.004).
Interestingly, total "black-outs" in long delay free recall
were rare. Only one methadone patient, two buprenor-
phine patients, and one comparison participant could not
recall any items from the Memory for Persons Data in this
condition. From Figure 1, which shows lines for cumula-
tive percentages, it can be seen that about 50% of the nor-
mal comparison participants and buprenorphine patients
could recall at least 4 items out of 15 correctly, while the
corresponding score was 2 items among the methadone
patients. When asked about the certainty of their answers,
the patients were non-significantly more certain than the
normal comparison participants that they actually
remembered, not just felt, the correct answers they gave.
On average, methadone-treated patients said that they
surely remembered a mean of 64.1% of their correct free
recall answers (SD = 38.8). In the buprenorphine group
the corresponding figure was 67.2% (SD = 24.1) and in
the normal comparison group 45.5% (SD = 31.3). In the
same vein, there were no significant group differences in
certainty of recognized correct answers (data not shown).
Both patient groups again reported significantly more
memory complaints in the MCQ.
Correlations between subjective and objective memory 
functions among the patients
The highest correlation between subjective MCQ score
and the objective memory tests completed by the OST
patients at T1 was – .38 for the Logical Memory retention
percent after short delay (30 min). However, after correc-
tion for multiple comparisons, this moderate correlation
was statistically non-significant. The correlation between
the MCQ score at T1 and the long delay free recall of the
Memory for Persons Data items at T2, that is, at least four
months after initial learning, was – .58 and statistically
significant, p = 0.028. This relationship is depicted in Fig-
ure 1. At T2, two moderate correlations between subjec-
tive MCQ score at T2 and objective memory performance
of the patients were seen: – .40 for long delay free recall of
the Memory for Persons Data items and – .39 for the
PASAT. However, after correction for multiple compari-
sons these were no longer statistically significant. In order
to explore how the OST patients with high MCQ scores at
the stabilized phase (T2) are different from those with low
MCQ scores, the patient group was divided into high vs.
low memory complaints groups using the T2 MCQ
median score as the cut-off. Patients with scores of 26 or
more at T2 made up the high memory complaints group
Participants with any personality 
disorder diagnosis (DSM-IV axis II) at 
T1
54% 59% 0% M vs. BN, p = 0.99c
M > NC**, p = 0.003c
BN > NC**, p = 0.002c
Duration of opioid abuse at T1, Mean 
of years (SD)
11.4 (5.5) 9.0 (2.9) - M vs. BN, p = 0.26
Duration of any substance abuse at 
T1, Mean of years (SD)
15.0 (5.1) 13.4 (5.2) - M vs. BN, p = 0.37
a Based on pairwise group comparisons with analysis of variance (ANOVA) or chi-squared test.
b Estimation based on the WAIS-R Vocabulary score.
c Fisher's Exact Test (2-tailed).
d Alcohol use was considered heavy if it was at least a mean of 16 portions weekly for females and 24 portions weekly for males. One portion was 
defined as 12 g of alcohol.
BN = buprenorphine or buprenorphine/naloxone, M = methadone, NC = Normal comparison.
*** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
Table 2: Group demographics (Continued)
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Table 3: Group comparisons of memory functions at T1 and T2
Domain or Test Methadone
(n = 13)
Buprenorphine or 
Buprenorphine/
Naloxone
(n = 15)
Normal 
Comparison
(n = 15)
Group effect Statistical com-
parisons 
between normal 
comparison and 
patient groups 
using years of 
education and 
VIQ adjusted 
scores, when-
ever possibleb
Effect sizes, 
whenever 
possible
M (SD) M (SD) M (SD)
Working memory, 
raw scores
WMS-III Letter-Number 
Sequencing at T1
9.6 (2.3) 8.4 (2.3) 11.7 (3.2) F (2, 38) = 4.57
p = 0.017*
t(27) = 1..84, p = 
0.074, M vs. NC = 
ns
d = 0.68
t(29) = 3.02, p = 
0.008, NC > BN **
d = 1.01
WMS-III Letter-Number 
Sequencing at T2
8.6 (2.1) 9.2 (2.3) 11.6 (2.9) F (2, 38) = 4.19, 
p = 0.023*
t(27) = 2.76, p = 
0.018, NC > M*
d = 1.05
t (29) = 2.39, p = 
0.022, NC > BN *
d = 0.83
PASAT at T1 31.4 (9.2) 31.8 (10.7)a 46.7 (9.4) F (2, 38) = 9.84
p = 0.001***
t(27) = 4.19, p < 
0.001, NC > M ***
d = 1.43
PASAT at T2 31.6 (8.6) 34.1 (8.4) 46.0 (8.7)a F (2, 38) = 7.15 
p = 0.002**
t(29) = 3.70, p < 
0.001, NC > BN***
d = 1.54
t(27) = 3.47, p = 
0.002, NC > M**
d = 1.42
t(29) = 3.32, p = 
0.002, NC > BN**
d = 1.24
Immediate verbal 
memory, raw scores
Memory for Persons 
Data, first trial at T1
10.7 (2.6) 10.8 (2.5) 13.0 (1.5) ?2(2, N = 43) = 
8.91
p = 0.012*
U = 43.0, p = 0.011, 
NC > M*
-
U = 51.5, p = 0.020, 
NC > BN*
Memory for Persons 
Data, sum of last two 
trials (T1)
14.9 (0.2) 14.6 (0.7) 14.9 (0.2) ?2 (2, N = 43) = 
2.75
p = 0.25
- -
WMS-III Logical 
Memory, immediate free 
recall (T1)
12.9 (2.4) 15.1 (4.3) 16.3 (3.6) F (2, 38) = 1.90, 
p = 0.16
- -
WMS-III Logical 
Memory, immediate free 
recall (T2)
14.2 (3.1) 14.1 (3.3) 16.3 (3.1) F (2, 38) = 1.25,
p = 0.30
- -
Memory 
consolidation, 
percentages
WMS-III Logical 
Memory, free recall after 
short-delay (30 min) 
(T1)
91.4 (15.3) 91.7 (14.0) 87.5 (13.1) F (2, 38) = 0.64,
p = 0.94
- -
124 THL – Research 130 • 2014
Cognitive function in opioid substitution treated patients Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
Page 10 of 15
(page number not for citation purposes)
(n = 14) and those with scores up to 25 the low memory
complaints group (n = 14). There were no statistically sig-
nificant differences between the high and low memory
complaint groups in demographics, substance abuse his-
tory, or treatment or medication variables. For cognitive
variables, there were no significant differences between
the groups except on the measure of Memory for Persons
Data free recall, on which the respective means for the
high and low groups were 16.7% (SD = 16.7) and 35.7%
(SD = 21.0); (t (27) = 2.66, p = 0.013). As can be seen from
Figure 2, most of the patients classified as high memory
complainers at T2 already had high MCQ scores at T1.
Seventy-one percent of the high memory complainers at
T2 complained of memory problems at T1 matching or
exceeding the MCQ high memory complaints cut-off
score of 26.
Longitudinal changes
In the first working memory task, the Letter-Number
Sequencing, methadone-treated patients' performance
seemed to deteriorate from T1 to T2 as shown by a
decrease in their raw scores. On the other hand, they
seemed to improve in immediate verbal memory per-
formance. Opposite trends were seen in the buprenor-
phine group. However, no significant group by time
interactions emerged.
Discussion
The main finding of this longitudinal study is the persist-
ence of the working memory deficit in OD patients treated
with methadone or buprenorphine along with BZDs. At
T1, the buprenorphine patients were inferior to normal
comparison participants in both working memory tests;
and the methadone patients performed worse than nor-
mal comparison participants at the second working mem-
ory task, the PASAT. At T2, both patient groups were
impaired relative to a normal comparison group on both
working memory tests. The working memory tests used in
this study have both been used also earlier in opioid-
related neuropsychological studies. In an earlier study by
Verdejo-Garcia et al., minimum 15 days abstinent heroin
abusers outperformed methadone-treated OST patients
WMS-III Logical 
Memory, free recall after 
short (30 min) delay 
(T2)
87.1 (14.4) 93 .8 (17.1) 98.3 (14.1) F (2, 38) = 1.28,
p = 0.29
- -
Memory for Persons 
Data, free recall after 
short delay (30 min) 
(T1)
92.8 (7.9) 98.2 (6.1) 98.7 (3.1) ?2(2, N = 43) = 
4.48
p = 0.11
- -
Memory for Persons 
Data, free recall after 
long delay
(4 – 8 mo) (T2)
22.1 (18.1) 29.8 (23.2) 32.4 (22.1) ?2(2, N = 43) = 
1.54
p = 0.46
- -
Memory for Persons 
Data, recognition after 
long delay (4 – 8 mo) 
(T2)
79.6 (10.6) 82.1 (12.9) 81.3 (10.7) F (2, 38) = 0.60
p = 0.55
- -
Memory complaints, 
raw score
The Memory Complaint 
Questionnaire (T1)
26.6 (5.7) 26.0 (5.4) 20.4 (2.5) ?2(2, N = 43) = 
11.25
U = 39.0,
p = 0.012, NC < 
M*
-
p = 0.004** U = 40.0, p = 0.008, 
NC < BN **
-
The Memory Complaint 
Questionnaire (T2)
25.6 (3.2) 24.5 (6.7) 20.4 (1.5) ?2 (2, N = 43) = 
14.04
U = 16.5, p < 0.001, 
NC < M***
p = 0.001*** U = 49.0, p = 0.015, 
NC < BN *
Note: PASAT = Paced Auditory Serial Addition Task;
WMS-III = Wechsler Memory Scale-third version.
BN = buprenorphine or buprenorphine/naloxone, M = methadone, NC = Normal comparison.
a = Missing value of one participant was substituted by carry-over value from the first test.
*** = statistically significant at level p < 0.001, ** = statistically significant at level p < 0.01, * = statistically significant at level p < 0.05, ns = non-
significant.
Table 3: Group comparisons of memory functions at T1 and T2 (Continued)
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on our first working memory measure, the Letter-Number
Sequencing [41]. In a study by Mintzer and Stitzer, meth-
adone-treated OST patients performed worse than a well-
matched normal comparison group on a two-back work-
ing memory task closely resembling the PASAT [42]. The
evidence for opioid agonist effects is not, however, unam-
biguous because in both of these studies, the OST patients
had a previous history of using other substances of abuse,
including BZDs. On the other hand, in a study by Sjögren
et al., pain patients treated with pain drugs other than opi-
oids outperformed non-addicted opioid-treated pain
patients on the PASAT [17]. In the same vein, a recent
study showed that the opioid agonist morphine nega-
tively affects working memory performance in healthy
volunteers [16]. Although pure OST drug effects on work-
ing memory seem possible, the effects of OST drugs, alone
or in combination with BZDs, on working memory can
only be reliably examined if OST patients with and with-
out a history of BZD use can be compared.
Our hypothesis of impaired performance in immediate
verbal memory was partially confirmed as both patient
groups were impaired at T1 in the first trial of a list learn-
ing task, the Memory for Persons Data. This finding is in
line with earlier studies showing similar deficits among
methadone patients [9,43]. However, the stability of this
deficit in verbal list learning remains to be studied
because the Memory for Persons Data learning task was
not repeated at T2. Of note here is the study of Gruber et
al. concerning an earlier treatment phase than was inves-
tigated in our study [14]. In their study methadone-
treated patients' verbal list learning performance,
improved between the first testing performed after a mean
of two weeks of OST and the second after two months of
treatment. However, a control group was lacking in their
study. Although alternate test forms were used, practice
effect in repeated verbal memory testing cannot be ruled
out [44]. Thus, the evidence for early improvement of
memory function is not strong.
Buprenorphine patients with concurrent BZD medication
showed inferior list learning during early OST (T1). This
finding is in line with a recent study by Soyka et al. in
which buprenorphine patients without other dependen-
cies were also inferior to normal comparison participants
in verbal learning [45]. In a recent study by Loeber et al.
no significant correlation was found between buprenor-
phine dose and verbal list learning performance [46]. On
the other hand, Lintzeris et al. have reported that
buprenorphine in combination with the BZD diazepam
impairs delayed verbal memory more than buprenor-
phine given alone [19]. In sum, further studies of the pos-
sible "pure" buprenorphine effects or the additive
negative effects of buprenorphine and BZDs on immedi-
ate verbal memory are needed.
Memory consolidation was examined by short- and long-
term retention percentages. No significant group differ-
ences between patient groups and normal comparison
group were observed in any condition. This is surprising
because mu opioid receptor agonists and BZDs are known
to negatively affect memory consolidation [47-50], How-
ever, our study is the first to study memory consolidation
up to late memory consolidation that starts few hours
after event occurrence [34,35]. Further studies are needed
Correlation percentage of the Memory for Persons Data, delay d recall (T2) scores by groupFigure 1
Correlation percentage of the Memory for Persons 
Data, delayed recall (T2) scores by group.
Cumulative percentage of the Memory for Persons Data, delayed recall (T2) scores by groupFigure 2
Cumulative percentage of the Memory for Persons 
Data, delayed recall (T2) scores by group.
126 THL – Research 130 • 2014
Cognitive function in opioid substitution treated patients Substance Abuse Treatment, Prevention, and Policy 2009, 4:6 http://www.substanceabusepolicy.com/content/4/1/6
Page 12 of 15
(page number not for citation purposes)
to examine if the observation of no memory consolida-
tion impairment among OD patients is due to develop-
ment of tolerance to negative effects of these drugs. There
is some evidence for tolerance to methadone's long-term
effects on episodic memory [51]. Tolerance for episodic
memory impairing effects of BZDs, in general, are small
[52], but among young individuals development of toler-
ance has been reported [53]. The second possible explana-
tion for no memory consolidation impairment is that
negative effects of opioids given along with BZDs may be
hard to detect without a change in drug status. This means
a change from a relatively highly drugged state to a low or
non-drugged state or reverse. It has been reported that
state change from BZD drug to placebo condition may
negatively affect on memory retrieval in comparison to
continuous BZD condition [54].
Analyses of long-term memory consolidation showed that
among OST patients those with high memory complaints
at T2 performed worse than those with low memory com-
plaints in late memory consolidation assessed by free
recall of the Memory for Persons Data items after a mean
delay of six months. Of note here is the observation that
there were no significant differences between high and
low memory complainers on any background or other
cognitive variables.
Self-rated memory problems were elevated among OD
patients treated along with BZDs at both test points. Thus
the patients feel that in regards to memory function their
quality of life does not improve during the OST. Although
OD patients often have both subjective and objective
memory problems, few studies have addressed the rela-
tionship between subjective and objective memory func-
tion among patients with substance abuse problems
[13,55,56]. In these studies patients' memory complaints
have had small, if any, associations with their objective
memory performance. In our study, though, moderate
relationships were seen between subjective memory com-
plaints and objective memory test performance, especially
in late memory consolidation. Unfortunately, late mem-
ory consolidation deficit is not easily captured by stand-
ard neuropsychological assessment.
Methodological innovations to assess long-term memory
consolidation in clinical settings are needed.
Treatment and policy implications
Working memory function is considered a gateway for
problem solving in new situations, which requires fluid
intelligence and executive function. Thus, when working
memory capacity is low, practical reasoning tends to result
in instant firm decisions that are based on readily availa-
ble salient observations [57,58]. Among OST patients this
may mean that individuals with low working memory
capacity readily associate their negative sentiments with
the common belief that their OST medication is "insuffi-
cient". They may feel overwhelmed if asked to consider
the counterexamples that co-occurrence of medication
and negative sentiments may be coincidental or that neg-
ative drug effects may be short-lived in comparison to the
positive effects that will show up later.
An OST patient who is using BZD medication and who
has working memory impairment may show excellent
memory in one instance and very poor memory in
another. The variability of a patient's performance level in
rehabilitation settings or at work or school may cause con-
fusion in the clinic and the community. To minimize this,
adequate examinations should be performed, and infor-
mation should be provided to the patient and his/her
treatment team more frequently than is currently the case.
The results indicate that memory deficits in OST patients
with current or recent BZD use are rather stable at least
during the first six months of their treatment. It is possible
that this is associated with OST drugs and BZDs given
legally to the OD patients. However, this does not mean
that OST would be harmful for the recovery of OD
patients. OD patients entering OST are, in general, so
stuck in the addiction, that a abstinence oriented treat-
ment program with no opioid or BZD agonists is a realis-
tic alternative only in rare cases [1,4]. Both treatment
alternatives are needed, but OST should be seen as the
mainstream option.
Limitations
Comparing a clinical sample of OST patients who use
BZDs and other psychoactive medications against normal
comparison participants imposes several limitations.
Some of the patients (see Table 2), but none of the com-
parison participants were abusing illicit drugs. This is clear
confounding factor that is difficult to eliminate when
evaluating performances in memory tests. The same
applies to other psychoactive medications that were
legally given to some of the patients but none of the com-
parison participants. Thus, our results cannot be general-
ized to OD patients without psychoactive medications
who have achieved long-term abstinence from any illicit
use of drugs. Psychiatric comorbidity that included Axis I
and Axis II disorders was common among patients and
absent among comparison participants. A recent study by
Prosser et al [59] examined correlates of cognitive func-
tion in a relatively large sample of opioid dependent
patients (n = 56). It was found that personality pathology
accounted for a greater portion of the variance in cognitive
performance than any of the variables of drug use history.
However, the only memory variable included in their
analyses was immediate visual memory.
The mean opioid agonist doses given to our patients
changed between test points, while the mean BZD doses
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and illegal substance abuse remained rather stable. The
methadone dose increased from a mean of 73 mg at T1 to
126 mg at T2. The buprenorphine dose increased from a
mean of 17 mg at T1 to 23 mg at T2. Thus, dose change
and time factors are both affecting the results, and with
our study design, separating these effects is not possible.
The buprenorphine group included both buprenorphine-
only and buprenorphine/naloxone patients. This was par-
tially a practical issue because the majority of buprenor-
phine patients in Finland have been transferred to
buprenorphine-naloxone combination medication. There
is no evidence that sublingual naloxone exhibits opioid
antagonist activity or would interfere with the opioid ago-
nist effects of buprenorphine [26,60]. However, because
there are no studies directly comparing buprenorphine-
only and buprenorphine/naloxone patients, combining
these patients can be considered a limitation of our study.
The list learning task (the Memory for Persons Data) was
not repeated at T2, which poses a limitation for the anal-
yses of immediate verbal memory. Psychoactive drugs,
such as short-acting non-BZDs, neuroleptics, or opioid
withdrawal relievers, were given to both patient groups in
order to alleviate opioid withdrawal symptoms or to treat
psychiatric comorbidity. The possible interactions of OST
medications with these medications warrant further stud-
ies with larger sample sizes. Recent-month drug screens
were considered important because it is known that long-
term use of benzodiazepines or cannabis may have a neg-
ative impact on cognitive function even weeks after cessa-
tion of use [18,61]. However, our data cannot determine
the precise doses used during the recent month, nor does
the data cover full time span of the follow-up. Thus, the
results do not reflect "pure" drug effects of OST drugs and
BZDs. On the other hand, no major differences between
the substance abuse profiles of methadone and buprenor-
phine patients were seen. OD patients may differ from the
general population already in their premorbid cognitive
functioning [62]. Screening for premorbid conduct or
attention deficit disorder could possibly reveal interac-
tions with current cognitive functions among OST
patients [63,64]. However, retrospective assessment of
these has low reliability in the absence of longitudinal
records [65]; therefore, these assessments were not done
in our study. Finally, our sample size was relatively small,
and therefore type 2 errors cannot be excluded.
Conclusion
OD patients treated with methadone or buprenorphine
along with BZDs showed substantial deficits in working
memory both during beginning of the treatment, and
after six months of treatment. Given the previously stated
limitations of this study, we conclude that OD patients
taking opioid agonist drugs and BZDs score worse than
normal comparison persons in tests of memory during
first six months of their OST. Thus, it is possible that the
working memory deficit observed among these patients
might be relatively permanent. An immediate verbal
memory deficit may also be seen among them. Surpris-
ingly, there were no significant memory consolidation dif-
ferences between the patient groups and normal
comparison group. On the other hand, OST patients
reported subjective memory problems that were associ-
ated with poor late memory consolidation. This has obvi-
ous functional relevance for the patients. Therefore, we
propose that the relationship between subjective and
objective memory function should be taken into account
in longitudinal studies of substance abuse treatment and
clinical practice.
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Abstract
Background: In many but not in all neuropsychological studies buprenorphine-treated opioid-dependent patients
have shown fewer cognitive deficits than patients treated with methadone. In order to examine if hypothesized
cognitive advantage of buprenorphine in relation to methadone is seen in clinical patients we did a
neuropsychological follow-up study in unselected sample of buprenorphine- vs. methadone-treated patients.
Methods: In part I of the study fourteen buprenorphine-treated and 12 methadone-treated patients were tested
by cognitive tests within two months (T1), 6-9 months (T2), and 12 - 17 months (T3) from the start of opioid
substitution treatment. Fourteen healthy controls were examined at similar intervals. Benzodiazepine and other
psychoactive comedications were common among the patients. Test results were analyzed with repeated
measures analysis of variance and planned contrasts. In part II of the study the patient sample was extended to
include 36 patients at T2 and T3. Correlations between cognitive functioning and medication, substance abuse, or
demographic variables were then analyzed.
Results: In part I methadone patients were inferior to healthy controls tests in all tests measuring attention,
working memory, or verbal memory. Buprenorphine patients were inferior to healthy controls in the first working
memory task, the Paced Auditory Serial Addition Task and verbal memory. In the second working memory task, the
Letter-Number Sequencing, their performance improved between T2 and T3. In part II only group membership
(buprenorphine vs. methadone) correlated significantly with attention performance and improvement in the Letter-
Number Sequencing. High frequency of substance abuse in the past month was associated with poor performance
in the Letter-Number Sequencing.
Conclusions: The results underline the differences between non-randomized and randomized studies comparing
cognitive performance in opioid substitution treated patients (fewer deficits in buprenorphine patients vs. no
difference between buprenorphine and methadone patients, respectively). Possible reasons for this are discussed.
Background
Opioid agonists buprenorphine and methadone prevent
opioid withdrawal symptoms and reduce craving for
opioids [1,2]. Both drugs are used in opioid substitution
treatment (OST), also known as opioid maintenance
treatment. OST has proven effective in reducing illicit
drug use, somatic diseases, mortality, and social or
mental health problems in opioid-dependent patients
[3,4]. Cognitive effects of OST drugs have been exam-
ined in clinical and experimental studies, but the results
have been mixed. Studies comparing OST patients
against healthy controls have, in general, shown cogni-
tive impairment among patients [5-8]. Yet, it has not
been proven that the impairment would be specifically
related to opioid substitution drugs [5,9,10]. In non-ran-
domized studies, however, buprenorphine-treated
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opioid-dependent patients have performed better than
methadone patients in several cognitive tests [7,11-13].
It is important to know if the possible cognitive differ-
ences between unselected buprenorphine vs. methadone
patients are stabile during the treatment and what are
the correlates of cognitive performance. Therefore, we
compared cognitive performance of buprenorphine and
methadone patients against healthy controls thrice (T1 -
T3) during the first year in the OST by (part I of the
study). In part II we analyzed correlates of cognitive per-
formance in patients after six (T2) and twelve (T3)
months in treatment by using extended patient pool.
The present study is an extension to our previous stu-
dies [7,14].
Part I: Stability
Opioid and dopamine systems in the brain have impor-
tant interactions, and current opioid drug use may nega-
tively affect cognitive functioning, especially working
memory [15-17]. However, Pirastu et al. have presented
evidence that buprenorphine as being a partial mu
opioid agonist and kappa opioid receptor antagonist
may improve cognitive performance after long-term
opioid abuse. According to them methadone as being a
full mu opioid agonist may lack properties for support-
ing normal cognitive function [18]. Also, there is evi-
dence that adverse interactive effects benzodiazepines
(BZD) and opioid substitution drugs on cognitive per-
formance are greater for methadone than buprenorphine
[19,20]. Therefore, we hypothesized that patients treated
with buprenorphine combined in most cases with BZD
and other comedications would show greater cognitive
improvement in long-term treatment in comparison to
methadone-treated ones.
Part II: correlates
In the part II of the study the patient sample was
extended to include additional patients examined at all
test points, but whose data were excluded at T1. After
this, data from 36 patients could be analyzed at T2 and
T3. We hypothesized that there would be negative cor-
relations between medication variables (opioid agonist
dose, BZD dose, and the number of psychoactive drugs)
and cognitive performance in opioid-dependent patients
treated either with buprenorphine or methadone. In
addition, we hypothesized that those with the highest
opioid dose would have higher BZD doses, because
BZDs have been associated with craving for higher
opioid dose [21]. The negative effects of methadone and
buprenorphine on cognition are dose-dependent in
healthy volunteers, although little is known about the
development of tolerance [22,23]. It is known that BZDs
have negative effects on memory performance in opioid
substitution treated patients, and these effects are
stronger for methadone than for buprenorphine [24].
Little is known about possible effects of polypharmacy
on cognition in opioid-agonist treated patients. How-
ever, in other patient populations, those patients treated
with several drugs perform worse in cognitive tests than
patients treated with single drug [25-27].
Negative correlations were also hypothesized between
cognitive performance and frequency of substance abuse
in the past month, benzodiazepine dosage, the number
of other psychoactive drugs, early onset of substance
abuse, early-onset mental health or behavioral problems,
opioid-related overdoses, and duration of lifetime alco-
hol abuse. In our sample recent alcohol and/or cannabis
abuse were common, and these negatively affect cogni-
tive function [28-31]. Early onset substance abuse and
childhood mental health or behavioral problems have
been associated with poor adult cognitive functioning
among individuals with substance abuse problems
[32-35]. High number of opioid-related overdoses, life-
time alcohol abuse, and low level of education have all
been associated with poor cognitive performance among
opioid-dependent patients [5,36,37]. Verbal intelligence
(IQ) and years of education were hypothesized to corre-
late positively with memory performance.
Methods
All participants included in the study were between 18 -
50 years of age and participated voluntarily. Inclusion
criteria for patients were opioid dependence and BZD
dependence or abuse according to Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV), treatment
of opioid dependence with methadone, buprenorphine,
or buprenorphine/naloxone. We excluded participants
with uncontrolled polysubstance abuse, acute alcohol
abuse, or acute axis I psychiatric morbidity according to
DSM-IV other than substance abuse disorders. Full
description of our inclusion and exclusion criteria is
given in our previous report [7].
In order to screen for substance abuse an urine sam-
ple was collected from each patient on each day of test-
ing and at least once in the preceding week. Each
healthy control participant was screened for substance
abuse once during the study period. In addition, we
interviewed all participants about their past month and
lifetime substance use by using the European Addiction
Severity Index as a basis for further inquiry [38]. If any
indication of intoxication was observed, we excluded
them. Breath alcohol testing was used when considered
necessary. Participants who had used within 24 h alco-
hol more than four/five drinks (females/males, respec-
tively) or significant as-needed benzodiazepine dose (5
mg or more as diazepam equivalent dose) were excluded
as well. The study protocol was accepted by the Ethics
Committee of Helsinki University Central Hospital. We
Rapeli e al. BMC Cli ical Pharmacology 2011, 11:13
http://www.biomedcentral.com/1472-6904/11/13
Page 2 of 15
135THL – Research 130 • 2014
4 Results
obtained a written informed consent according to the
Declaration of Helsinki from all participants, and paid
them € 60 if they attended all study visits.
Part I participants
Participants who were eligible for T1-T3 follow-up (sam-
ple I) represent 42% (14/35) of the all buprenorphine
patients tested at T1, 55% (12/22) of the methadone
patients and 78% (14/18) of the healthy controls, respec-
tively. To test whether the follow-up completers of either
group were significantly different from the non-completers
of that group, we compared these groups by independent
samples t-tests, chi-square tests, or Mann-Whitney U-tests
(p-value = 0.05). No statistically significant differences
emerged in demographic, medication or cognitive vari-
ables. Because there were few follow-up non-completers
(n = 4) among the potential healthy controls, these com-
parisons were not made in healthy controls.
When the groups were compared on demographic
variables with analysis of variance (ANOVA) or chi-
square-test (Table 1) there were no statistically signifi-
cant differences in age, sex, or estimated premorbid
intelligence. Healthy controls had completed more years
in education than either one of the patient groups.
Because BZD use on prescription was very common,
their doses were converted to diazepam equivalent doses
according to the conversion tables given by Nelson and
Chouinard [39]. Temazepam doses were halved in order
to account for their use as hypnotics on the night before
testing. Substance abuse in the past month was esti-
mated as frequency of use. Because accurate number of
the days of abuse was hard to obtain we dichotomized
the frequency of the past month substance abuse into
two categories. The first category was labeled as low to
moderate use, and it included abstinence or substance
abuse up to two days a week. The second category was
labeled as high frequency group and included all the
participants with substance use of three days a week or
more. This classification was based on the findings
showing that mean three days of substance use a week
is one of the threshold values for getting into serious
substance abuse problems [40,41]. In the buprenorphine
group, 79% of the patients were given buprenorphine/
naloxone at all test points. Thus, they were also given
sublingual naloxone in the ratio 1:4 combined with their
buprenorphine dose. When the tablet is taken sublin-
gually the absorption of naloxone is low and eliminates
within first hours [42]. It has been concluded that
naloxone has minimal, if any effect, on the bioavailabil-
ity or pharmacokinetics of buprenorphine [43,44]. Also,
buprenorphine and buprenorphine/naloxone have simi-
lar physiological effects [43]. On the basis of these find-
ings, we combined patients using either one of the
buprenorphine compounds. Table 2 shows medication
characteristics of the sample I within the last 24 h
before testing. Both patient groups used more psychoac-
tive medications than healthy controls.
Part II participants
Sample II (n = 36) included 51% of all the buprenor-
phine-treated and 59% of methadone-treated patients
who entered the follow-up at T1. The methadone group
included also five patients who were tested without
opioid medication at T1, but who then started metha-
done treatment within few days after the testing. Thus,
all patients were tested after minimum 6 (T2) and 12
months (T3) of OST. They had been tested at start of
their treatment, but were excluded from the part I sam-
ple. Substance abuse history variables included in the
analyses were onset ages of any substance and opioid
abuse, years of heavy alcohol use, and the number of
self-reported opioid-related overdoses. Whenever possi-
ble, the data was checked using medical reports. It
turned out that no reliable information about the num-
ber of opioid-related overdoses could be obtained.
Therefore this variable was excluded from the analyses.
Current substance abuse variables were frequency of
substance abuse in the past month (low vs. high) and
drug screen result (positive vs. negative). Medication
drug use variables that were examined included opioid
substitution drug (buprenorphine vs. methadone), ben-
zodiazepine dose (diazepam equivalent), and the number
of other psychoactive drugs other than opioid substitu-
tion drug. Demographic variables included in the ana-
lyses were age, sex, years of education, early
neurobehavioral problems, and verbal IQ. Data about
childhood mental health or behavioral problems was
gathered using the Childhood Behavioral Checklist as a
basis for interview, and medical reports were used,
whenever possible [45]. Those participants who had had
treatment or referral to special services due to mental
health or behavioral problems before the onset of sub-
stance abuse were rated as early-onset neurobehavioral
problem group (31%). If significant change was seen in
cognitive performance then change (T3 - T2) in that
that variable, as well in medication, and substance use
changes were analyzed. Medication and substance abuse
change variables were made more reliable by dichoto-
mizing the data. Change in opioid drug dose between
T2 and T3 was dichotomized as steady or reduced dose
group (58%) or higher dose group (42%). Change in
BZD dose between T2 and T2 was grouped respectively.
The majority of the patients belonged to steady or
reduced BZD dose group (83%), and the rest (17%) had
higher BZD dose at T3. All those who reduced their fre-
quency of substance abuse as indicated by the shift from
the high frequency group to low to moderate frequency
group were put into group of reduced substance abuse.
Rapeli et al. BMC Clinical Pharmacology 2011, 11:13
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This group included also the patients who belonged to
the low to moderate frequency group at both time
points, totaling 58% of the patients. The rest were put
into group of non-reduced substance abuse (42%).
Change in the number of psychoactive drugs was
dichotomized similarly. All those with less psychoactive
drugs at T3 in comparison to T2 or no other psychoac-
tive prescribed drugs than opioid drug at both time
points were put in the group of reduced use of psy-
choactive drugs (42%). The rest were put into group of
non-reduced use of psychoactive drugs (58%). Table 3
presents the demographic characteristics of the sample
II. In the buprenorphine group, 78% of the patients
were given buprenorphine/naloxone at all test points.
Table 4 shows other medication characteristics of the
sample II within the last 24 h before testing.
Procedure
Cognitive tests were administered between three to six
hours after opioid substitution drug had been given.
Table 1 Group demographics in sample I
Buprenorphine
(n = 14)
Methadone
(n = 12)
Healthy
control
(n = 14)
Group comparison p-
values
Age (M ± SD) 30 ± 7 31 ± 8 29 ± 10 ns
Sex (female/male) 36%/64% 50%/50% 50%/50% ns
Intelligencea (M ± SD) 101 ± 11 98 ± 9 105 ± 8 ns
Education, years 10 ± 2 10 ± 1 13 ± 1 BN & M < HC ***
Main opioid of abuse used within last month at T1 (%)
Buprenorphine 93% 83%? - nsb
Heroin 7% 17% - nsb
Days in opioid substitution treatment at test (M ± SD)
T1 21 ± 15 20 ± 14 - nsb
T2 210 ± 20 200 ± 28 - nsb
T3 414 ± 46 405 ± 31 - nsb
Examined in inpatient settings %
T1 21% 25% - nsb
T2 7% 0% - nsb
T3 7% 8% - nsb
Participants with high frequency of use of any substance of abuse c
%
T1 86% 67% 14% BN > HC ***; M > HC *
T2 29% 42% 7% ns ; ns
T3 36% 33% 7% ns ; ns
T2 < T1** T3 < T1*
T3 < T1*
Participants with the past month extra doses of any opioid d, %
T1 86% 92% - nsb
T2 29% 33% - nsb
T3 36% 33% - nsb
T2 < T1** T2 < T1**
T3 < T1* T3 < T1**
Participants with the past month nicotine use (daily)
T1 100% 100% 36% BN & M > HC ***
T2 100% 100% 36% BN & M > HC ***
T3 100% 93% 29% BN > HC **; M > HC ***
Note. BN = buprenorphine patients, HC = healthy control group, and M = methadone patients.
a Estimation based on the vocabulary and picture completion subtests of the Wechsler Adult Intelligence Scale - Revised (WAIS-R) [67].
b Tested only between patient groups.
c High frequency = three or more days a week. Alcohol use was taken into account if it was at least mean weekly 16 portions (12 g) for females and 24 portions
for males or binge drinking occurred on any day.
d Extra doses of any non-prescribed opioid use during the recent month seen in drugs screens or admitted by the patients.
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
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Attention was assessed by two tests from the Test for
Attentional Performance (TAP) [46]. In the Alertness
test, the participant was instructed to respond to visual
stimuli by pressing a response key as quickly as possible.
The stimuli were presented without or with auditory
warning signal. The condition without warning signal is
a simple reaction time task reflecting tonic alertness.
The condition with auditory warning signal reflects both
tonic and phasic alertness. In the Go/NoGo test, the
participant was instructed to respond only to two out of
five alternative stimuli. Thus, selective attention and
executive control of action was assessed.
Working memory was assessed by two tests. In the
Letter-Number Sequencing task from the Wechsler
Memory Scale - III the participant was instructed to
repeat letters and numbers in specific order [47]. In the
Paced Auditory Serial Addition Task ( PASAT) the par-
ticipant was instructed to add two consecutive numbers
from an auditory series of digit [48]. A new digit was
presented after every 1.6 seconds. Both tests are thought
to tap complex working memory because simultaneous
storage and manipulation of the material is needed.
Verbal memory was assessed by the Logical Memory
from the Wechsler Memory Scale - III. However, only
Table 2 Medications given to participants within the last 24 h before testing in sample I
Buprenorphine
(n = 14)
Methadone
(n = 12)
Healthy
control
(n = 14)
Group or time point comparison p-
values
Opioid agonist drug, dose
Buprenorphine (M ± SD;
(range) )
T1 16 ± 3 mg
(12 - 24 mg)
- - -
T2 20 ± 5 mg
(14 - 28 mg)
- - T2 > T1**
T3
Methadone (M ± SD;(range) )
21 ± 6 mg
(6 - 28 mg)
- - T3 > T1**
T1 - 71 ± 39 mg
(30 - 135
mg)
- -
T2 - 127 ± 36
mg
(80 - 180
mg)
- T2 > T1 ***
T3 - 135 ± 34
mg
(75 - 180
mg)
- T3 > T1 ***
Participants treated with BZD medication ’
T1 79% 100% 0% BN & M > HC ***
BZD dose at T1 (M ± SD) 20 ± 17 mg 21 ± 11 mg - ns a
T2 71% 100% 0% BN & M > HC ***
BZD dose at T2 (M ± SD) 16 ± 11 mg 22 ± 11 mg - ns a
T3 64% 100% 0% BN & M > HC ***
BZD dose at T3 (M ± SD) 13 ± 12 mg 22 ± 9. mg - BN < M *
Number of other medications with possible cognitive
effects b
(M ± SD (range))
T1 1.9 ± 1.1
(0 - 4)
3.0 ± 1.3
(0 - 5)
0.2 ± 0.4
(0 - 1)
BN & M > HC ***; M > BN *
T2 1.9 ± 1.2
(0 - 3)
2.3 ± 0.8
(1 - 4)
0.2 ± 0.4
(0 -1)
BN & M > HC ***
T3 1.8 ± 1.3
(0 -4)
2.2 ± 1.0
(1 -4)
0.2 ± 0.4
(0 -1)
BN & M > HC ***
a Tested only between patient groups.
b These included antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and substance abuse withdrawal symptom or
(non-opioid) pain relievers. There were no significant differences between time points within the groups in medication variables.
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
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one story was presented. A full description of the tasks
is given in our previous report [7].
Statistical analyses: stability of function
Longitudinal changes in cognitive function were exam-
ined by repeated-measures analysis of variance
(ANOVA) using general linear model approach. Group
was used as between-subjects factor and time as within-
subjects factor. Before the analyses normality assump-
tions of cognitive variables were examined by Shapiro-
Wilk’s test and homogeneity of variance by Levene’s
test. The data were also screened for outlying values.
On the basis of these procedures, reaction time and the
PASAT scores were subjected to log transformations
before further analyses, and the Go/NoGo errors were
examined by non-parametric Kruskal-Wallis ANOVA.
Sphericity assumption was tested by Mauchly’s test, and
when appropriate, analyses of effects were interpreted
using Huynh-Feldt correction. The effects of demo-
graphic variables on cognitive performance were tested
as covariates. Only significant covariates were retained
in the model. Statistically significant between groups
effects were followed by planned contrast using healthy
controls as a reference group. Significant time effects we
Table 3 Group demographics in sample II
Buprenorphine or
Buprenorphine/
Naloxone
(n = 18)
Methadone
(n = 18)
Group or time point comparison p-
values
Age, years at T1
(M ± SD)
30 ± 8 32 ± 8 ns
Sex: females/males, % 28/72% 33/67% ns
Verbal IQ a
(M ± SD)
101 ± 8 100 ± 11 ns
Education, years
(M ± SD)
10 ± 2 11 ± 1 ns
Participants with early neurobehavioral problems % 33% 28% ns
Examined in inpatient settings %
T2 6% 6% ns
T3 11% 11% ns
Participants with high frequency use of any substance of
abuse % b
T2 44% 39% ns
T3 44% 44% ns
Participants with recent month extra doses of any opioid %
c
T2 36% 36% ns
T3 36% 43% ns
Nicotine, participants using daily, %
T2 100% 100% ns
T3 100% 100% ns
Days in opioid substitution treatment at test (M ± SD)
T2 211 ± 19 196 ± 27 ns
T3 411 ± 43 405 ± 29 ns
Age of onset, any substance abuse (M ± SD) 16 ± 4 15 ± 3 ns
Age of onset, opioid abuse
(M ± SD)
19 ± 5 19 ± 4 ns
Participants with lifetime alcohol abuse 72% 83% ns
Years of any substance abuse at T1 (M ± SD) 15 ± 7 17 ± 7 ns
Years of alcohol abuse at T1
(M ± SD)
3 ± 4 3 ± 3 nsb
Years of opioid abuse at T1, years (M ± SD) 10 ± 7 12 ± 7 ns
a Estimation based on the WAIS-R Vocabulary score.
b High frequency = three or more days a week Alcohol use was considered heavy if it was at least mean weekly 16 portions for females and 24 portions for
males. One portion was defined as 12 g of alcohol.
c Non-prescribed doses of opioids during the recent month seen in drugs screens or admitted by the patient.
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examined using repeated contrast (T2 vs. T1 and T3 vs.
T2). When a significant group by time interaction effect
was noted, it was examined further by combining pre-
vious contrasts (healthy control vs. buprenorphine
group * T2 vs. T1, healthy control vs. buprenorphine
group * T3 vs. T2; and healthy control vs. methadone
group, respectively). All statistical analyses were done by
SPSS statistical software, version 15.0, with an exception
of the effect size calculations. These were done by an
effect size calculator provided by Durham University,
UK [49]. For the effect size estimation we pooled the
samples and corrected the values by Hedge’s correction
for small sample bias.
Statistical analyses: correlates of cognitive functioning
Cognitive tests selected for the analyses were the same
as in the part I, except that the PASAT was excluded
from the second set of analyses. Improvement in the
PASAT is shown to be related to practice effect [50].
This makes it problematic to analyze the correlates of
this measure in repeated testing. In order to reduce the
number of cognitive variables correlations between the
variables analyzed, and whenever justified, domain-wise
cognitive sum scores for T2 and T3 performances were
formed. T2 performance was used as a reference point
in T3 summed scores. Analysis of correlation is sensitive
for the effects of outliers. Therefore, visual inspections
of scatter plots were used to check the linearity of the
relationship between variables and the role of possible
outliers. Then correlations between cognitive variables
we analyzed by the Pearson product moment method.
As expected there were high positive correlations
between all reaction time measures at both test points
(range .52 - .86); whereas correlations between reaction
time measures and other cognitive measures ranged
from zero to moderate (-.38 as highest). Therefore, a
mean composite score called attention performance was
calculated after converting the test scores into z-scores.
The working memory measure, the Letter-Number
Sequencing task, showed only low to moderate correla-
tions with other measures (.38 as highest) and therefore
it was not combined with other measures. The verbal
memory measures, immediate and delayed recall of the
Logical Memory, correlated strongly at both test points
(.80 at T2 and .91 at T3). Therefore, a mean sum score
called verbal memory was formed after z-score conver-
sion. Then group differences in cognitive function were
examined by repeated-measures analysis of variance
Table 4 Medications given to participants within the last 24 h before testing in sample II
Buprenorphine or
Buprenorphine/
Naloxone
(n = 18)
Methadone
(n = 18)
Group or time point comparison p-
values
Opioid drug, dose
(M ± SD (range) )
T2 22 ± 5 mg
( 10 - 28 mg)
- T2 vs. T3, ns
T3 21 ± 6 mg
( 6 - 30 mg)
-
T2 - 119. ± 33 mg
(80 - 180 mg)
T2 vs. T3, ns
T3 - 129 ± 33 mg
(75 - 180 mg)
Participants using BZD medication
T2/T3 78%/67% 89%/94% ns/ns
BZD dose at T2 (M ± SD (range)) 20 ± 16 mg
(0 - 60 mg)
21 ± 16 mg
(0 - 70 mg)
T2 vs. T3, ns
ns
BZD dose at T3 (M ± SD (range)) 16 ± 14 mg
(0 - 40 mg)
20 ± 10 mg
(0 - 40 mg)
ns
T2 vs. T3, ns
Number of other medications with possible cognitive
effects a
T2/T3 (M ± SD ; (range)) 1.8 ± 1.1 (0 - 3) 2.2 ± 0.7 (1
-4)
ns
1.9 ± 1.4 (0 - 4) 2.0 ± 1.0 (1 -
4)
ns
T2 vs. T3, ns
These included antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and substance abuse withdrawal symptom or
(non-opioid) pain relievers.
C = controls, M = methadone, BN = buprenorphine or buprenorphine/naloxone
> = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.
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(ANOVA) using general linear model approach. Group
was used as between-subjects factor and time as within-
subjects factor. After this all significant or three highest
correlates of each cognitive variable were further exam-
ined by checking for intercorrelations between these
variables and other variables of interest. Also, medica-
tion variables were checked for significant intercorrela-
tions. The sample size did not allow for multiple
regression analysis. Instead three highest correlations for
each cognitive domain were investigated with analyses
of semipartial correlations. Correlations between .10 -
.19 were considered to show low association and .20 -
29 mild association. Only some of these are reported.
Correlations between, .30 - .49 were considered to show
moderate association, .50 - 69 substantial and those .70
or above a strong association [51].
Results
Stability of cognitive functioning in sample I
The pattern of means in Table 5 identifies change over
time in cognitive performance in each group. There
were statistically significant overall group differences in
all attention and memory measures. As apparent from
the Table 5, the methadone-treated patient group con-
stantly lagged behind the healthy control group in the
TAP reaction time tests measuring alertness and selec-
tive attention. Planned contrasts confirmed that the
healthy controls outperformed the methadone group in
these measures (p = 0.002 for the TAP tonic alertness/
simple reaction time; p = 0.002 for the TAP phasic
alertness/reaction time with-auditory-warning-signal;
and p = 0.001 for the TAP Go/NoGo reaction time/
selective attention). There were neither significant time
nor group by time interaction effects in these measures.
Errors in the Go/NoGo task were rare in all groups, and
no significant between groups differences were observed.
In both working memory measures there was an overall
group effect. In the PASAT the planned contrast
revealed that both patient groups performed overall
worse than the healthy controls at the level of p =
0.001. In the Letter-Number Sequencing the values were
p = 0.016, for healthy controls vs. buprenorphine
patients and p = 0.008 for healthy controls vs. metha-
done patients. However, because there was also time
effect (the PASAT), or a group by time interaction effect
(the Letter-Number Sequencing) in these measures,
further analyses are needed before the final interpreta-
tion. In the PASAT the improvement in overall perfor-
mance between T1 and T2 turned out to be non-
significant, but the overall improvement between T2
and T3 was significant, p = 0.01. As apparent from Fig-
ure 1, the source of group by time interaction in the
Letter-Number Sequencing was due to differences
between the groups between T2 and T3. This was con-
firmed by a planned contrast which showed improved
performance in the buprenorphine patients between T2
and T3 relative to healthy control group, p = 0.017.
Effect size of the T2 - T3 improvement in the buprenor-
phine group, as measured by Cohen’s d, was 0.77. In
verbal memory, there was a significant overall group
effect both in immediate and delayed condition of the
Logical Memory. Both patient groups performed worse
than the healthy controls in the immediate Logical
Memory, p = 0.029 for the buprenorphine group; and p
= 0.007 for the methadone group. In the delayed Logical
Memory the values were p = 0.005, and p = 0.028,
respectively.
Cognitive functioning in sample II
The cognitive group comparisons in the part II (T2 -
T3) sample brought results that were in line with the
part I sample analyses. Buprenorphine patients outper-
formed methadone patients in the combined attention
performance (p = 0.004), and no significant time or
group by time effect were seen. In working memory as
measured by the Letter-Number Sequencing there was a
main effect of time (p = 0.01) and a significant group by
time interaction, (p = 0.04) indicating again that
improvement in this measure was due to enhanced per-
formance in the buprenorphine patients between T2
and T3. In the combined verbal memory measure there
were no significant differences between groups, time
effect, or group by time interaction.
Correlations between medication variables and non-
cognitive variables in sample II
At T2, buprenorphine dose correlated substantially with
BZD dose (.62, p = 0.006) and moderately with the
number of psychoactive drugs (.40, ns). In the metha-
done group, respective values were (.47, ns; and .58, p =
0.013). At T3, buprenorphine dose correlated at moder-
ate level with BZD dose (.33, ns) and at very low level
with the number of psychoactive drugs (.10, ns). In the
methadone group respective values were mild (.25, ns;
and .20, ns). In general, buprenorphine or methadone
doses did not show significant correlations with sub-
stance abuse or demographic variables. As an exception
buprenorphine dose correlated negatively with years of
alcohol abuse, at T2 the value was -.56 (p = 0.016) and
at T3 -.64 (p = 0.004). In the methadone group, no sig-
nificant correlations emerged. Other significant correla-
tions between medication variables and other non-
cognitive variables of interest are presented in Table 6.
It can be noted that high BZD dose was associated with
high frequency of substance abuse in the past month
and younger age at both time points.
Rapeli et al. BMC Clinical Pharmacology 2011, 11:13
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Correlates of cognitive performances in sample II
As shown in Table 7, the only significant correlate for
attention performance at both test points was the opioid
substitution drug group. High frequency of substance
abuse correlated negatively with the Letter-Number
Sequencing performance at both time points. Figures 2
and 3 depict this association. It can be noted from these
Figures that the association between working memory
performance and frequency of substance abuse in the
past month is similar in both groups. The T2 negative
correlation remained significant after controlling for two
next highest correlates. The T3 correlation dropped to
non-significant level after controlling for two next high-
est correlates (-.18). At T3, high benzodiazepine dose
correlated negatively with the Letter-Number
Sequencing performance. After controlling for the two
other highest correlates, this association was no longer
significant (-.22). In further analysis no evidence in sup-
port of high association between BZD dose and the Let-
ter-Number Sequencing performance was seen, because
T2 correlation between these variables was at zero level
(.02). Belonging to the buprenorphine group was the
only variable that correlated significantly (.34) with
change of the Letter-Number Sequencing performance.
After controlling for two other highest correlates, this
association was no longer significant.
The number of psychoactive drugs correlated positively
with verbal memory performances at both testing points.
At T3, the positive association with the number of psy-
choactive drugs reached significant level after two other
Table 5 Group comparisons of cognitive performances using repeated measures ANOVA in sample I
TAP Tonic Alertness/simple reaction time (ms)
T1 232 ± 25 261 ± 21 238 ± 22 Group, p = 0.002
T2 236 ± 18 263 ± 21 233 ± 21a Time, ns
T3 242 ± 25 267 ± 36 241 ± 25 Group × Time, ns
TAP Phasic Alertness/ reaction time with warning signal (ms)
T1 227 ± 24 244 ± 20 226 ± 21 Group, p = 0.005
T2 229 ± 21 255 ± 28 224 ± 21 a Time, ns
T3 229 ± 19 254 ± 45 225 ± 22 Group × Time, ns
TAP Go-NoGo reaction time (ms)
T1 490 ± 50 548 ± 74 460 ± 41 Group, p = 0.001
T2 480 ± 42 548 ± 104 443 ± 72 a Group, p = 0.002
T3 493 ± 43 529 ± 63 462 ± 47 Age, p = 0.022
Time, ns
Group × Time, ns
TAP Go-NoGo errors
T1 1.1 ± 1.3 0.7 ± 0.6 0.5 ± 0.5 ns
T2 0.5 ± 0.7 1.0 ± 0.9 0.5 ± 0.8 a ns
T3 0.6 ± 0.8 0.5 ± 1.0 0.2 ± 0.4 ns
The Letter-Number Sequencing
T1 8.4 ± 2.2 9.3 ± 2.4 11.8 ± 3.4 Group, p = 0.009
T2 8.8 ± 2.2 8.5 ± 2.3 11.6 ± 3.0 Time, ns
T3 10.6 ± 2.2 8.8 ± 2.4 11.2 ± 3.2 Group × Time, p = 0.007
The PASAT
T1 32.4 ± 10.5 31.0 ± 8.5 46.3 ± 9.7 Group, p = 0.001
T2 35.0 ± 6.8 33.4 ± 10.1 45.8 ± 9.0 a Time, p = 0.013
T3 35.8 ± 10.0 34.9 ± 11.0 49.8 ± 8.4 Group × Time, ns
Logical memory, immediate
T1 12.8 ± 2.6 14.9 ± 4.5 15.9 ± 3.3 Group, p = 0.016
T2 13.8 ± 3.1 14.8 ± 3.7 16.3 ± 3.2 Time, ns
T3 15.5 ± 4.1 14.3 ± 4.3 17.9 ± 2.9 Group × Time, ns
Logical memory, delayed
T1 11.8 ± 3.0 13.1 ± 4.0 13.9 ± 4.0 Group, p = 0.013
T2 12.0 ± 4.0 13.7 ± 4.0 15.6 ± 3.1 Time, ns
T3 12.4 ± 4.1 11.8 ± 4.7 15.9 ± 3.6 Group × Time, ns
Bold indicates statistically significant effects.
a One missing value was replaced by the carry-over value from the preceding testing point.
Rapeli et al. BMC Clinical Pharmacology 2011, 11:13
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correlates were taken into account. At T2, there was a
negative association with the highly frequent past month
substance abuse and verbal memory performance. After
controlling for two other highest this correlation dropped
to non-significant level (.28). Furthermore, at T3 the cor-
relation between highly frequent substance abuse in the
past month and verbal memory was very low and to the
opposite direction (-.08).
Correlations between opioid substitution drug dose
and cognitive performances opioid drug doses could be
examined only group-wise (n = 18 in both groups).
None of the correlations reached statistical significance.
Because there was a significant group by time interac-
tion in the Letter-Number Sequencing indicating speci-
fic improvement in this task in the buprenorphine
group, correlates for the improvement in the buprenor-
phine group were examined. No significant correlates
for the change score emerged.
Discussion
This study was designed to evaluate stability and correlates
of cognitive functioning in unselected buprenorphine- vs.
methadone treated opioid-dependent patients during the
first year in OST. The main findings are the following.
Buprenorphine-treated opioid-dependent patients do not
show deficits in attention, improve in one of the working
memory tests, the Letter-Number Sequencing, but they
show stable deficits in the other working memory test, the
PASAT, and verbal memory. Methadone-treated opioid-
dependent patients show stabile cognitive deficits in atten-
tion, working memory, and verbal memory. When corre-
lates of cognitive performances are analyzed 6 and 12 after
the start of the OST drug type (buprenorphine vs. metha-
done) is moderately associated with attention perfor-
mance. Highly frequent substance abuse in the past
month is negatively associated with performance in the
Letter-Number Sequencing. The number of other psy-
choactive drugs and verbal IQ both show mild positive
correlation with verbal memory.
Stability of buprenorphine patients’ cognitive function
during the first year in treatment
Our observation of no reaction time deficits in bupre-
norphine-treated opioid-dependent patients in relation
to healthy controls is in accordance with the idea that
some of the negative effects of buprenorphine on cogni-
tion disappear after the development of tolerance. Most
patients had abused buprenorphine before the treatment
(Table 1). Further studies are needed to examine if
buprenorphine patients’ normal performance in atten-
tion tests is related to the development of tolerance
only, or if a population selection process is affecting per-
formance in patient samples.
Our finding of partial recovery of working memory
function in buprenorphine-treated patients during the
OST is in line with the idea of Spiga et al. [52]. The idea
is supported by observations by Pirastu et al. showing
that buprenorphine patients outperform methadone
patients in spatial working memory [18]. They suggest
that buprenorphine could preserve working memory
function better than methadone because of its antagon-
ism on kappa opioid receptor, which then affects prefron-
tal dopamine tone known to be important for working
memory. This reasoning, however, does not explain why
the improvement in working memory in our study took
place between 6 and 12 months in the treatment.
?
?
?
?
?
??
??
??
??
??
??
?? ?? ??
?
??
??
??
??
??
??
???
??
??
??
??
??
??
??
??
?
??
??
??
??
??
??
??
???????????????
?????????????
?????????
Figure 1 Group performances in the Letter-Number
Sequencing Task during the study period in sample I.
Table 6 Significant correlations between medication variables and other non-cognitive variables in sample II
Medication variables Substance abuse variables Demographic variables
Benzodiazepine dose (T2) Frequency of substance abuse in the past month
.36 ( p = 0.033)
Age
-.34 (p = 0.040)
Benzodiazepine dose (T3) Frequency of substance abuse in the past month
.50 (p = 0.002)
Age
-.33 (p = 0.048)
Number of other psychoactive drugs (T2)
Number of other psychoactive drugs (T3) Years of opioid abuse
-.37 (p = 0.028)
Rapeli et al. BMC Clin cal Pharmacology 2011, 11:13
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Table 7 Highest correlations between cognitive and non-cognitive variables in sample II
Domain or test Medication
variables
Substance abuse
variables
Demographic
variables
Significant correlations after
controlling for two other
correlates
Attention (T2) Opioid substitution
drug
.48 (p = 0.003)
Number of other
psychoactive drugs
(T2)
.24
Opioid abuse onset age
.25
Opioid substitution drug
.46, (p = 0.004)
Attention (T3) Opioid substitution
drug
.37 (p = .024)
Opioid abuse onset age
.28
Age
.26
Opioid substitution drug
.37, (p = 0.021)
The Letter-Number Sequencing
Task (T2)
Number of other
psychoactive drugs
.25
Frequency of substance
abuse in the past month
-49 (p= .002)
Verbal IQ
.29
Frequency of substance abuse in
the past month
-44 (p = .005)
The Letter-Number Sequencing
Task (T3)
Benzodiazepine dose
.-38
Frequency of substance
abuse in the past month
.-34 (p = .044)
Years of opioid abuse .28
Change score in the Letter-
Number Sequencing Task (T3 -
T2)
Opioid substitution
drug
.34 (p = .039)
Change in the opioid
agonist dose
-.33
Change in the number
of psychoactive drugs
-.24
Verbal memory (T2) Number of other
psychoactive drugs
(T2)
.25
Frequency of substance
abuse in the past month
-. 34 (p = .044)
Verbal IQ
.28
Verbal memory (T3) Number of other
psychoactive drugs
(T3)
.31
Verbal IQ
.32
Years of education
.27
Number of other psychoactive drugs
.34 (p = .035)
Bold indicates statistically significant correlation.
Figure 2 Correlation between the frequency of the past month
substance abuse and the performance in the Letter-Number
Sequencing at T2 in sample II.
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Figure 3 Correlation between the frequency of the past month
substance abuse and the performance in the Letter-Number
Sequencing at T3 in sample II.
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In the other working memory measure, the PASAT,
both patient groups are inferior to healthy controls
while all groups show improvement during the study
period. Improvement that is seen in all groups is a nor-
mal finding when the PASAT is administered, and most
likely reflects practice effect [50]. The result of no speci-
fic improvement in the buprenorphine patients in this
measure may be related to the finding that also several
other cognitive processes than working memory are
needed for good performance in the PASAT [53].
In verbal memory buprenorphine-treated patients per-
form worse than healthy controls during the whole fol-
low-up. Buprenorphine dose given to our patients was
relative high (range mean 16 mg (T1) - 21 mg (T3)).
High dose of buprenorphine (32 mg) have been asso-
ciated with verbal memory impairment [54]. In addition,
in recent study by Messinis et al. buprenorphine-treated
opioid-dependent patients with a fairly low mean dose
of buprenorphine (7 mg) performed worse than healthy
controls in verbal memory. Abstinent opioid-dependent
patients treated with mu opioid antagonist naltrexone
showed no significant difference relative to healthy con-
trols. In sum, buprenorphine may negatively affect ver-
bal memory, although evidence is still insufficient.
Stability of methadone patients’ cognitive function during
the first year in treatment
In this study, methadone patients show cognitive deficits
in all domains studied: attention, working memory and
verbal memory. Not all studies, however, have shown
attention deficits among them. Gordon found that
methadone-treated opioid-dependent patients outper-
formed controls in simple visual and visual multiple
choice reaction times [55]. Curran et al. found that 3 h
after methadone dose opioid-dependent patients in
methadone-aided opioid withdrawal actually had faster
simple reaction times than before the dose [56]. On the
other hand, in the Lintzeris et al study high dose of
methadone (150% of normal dose) was associated with
slower reaction times in OST patients [20]. Thus, the
issue whether methadone dose prolongs reaction times
in opioid-dependent patients is not fully resolved.
We found a stabile working memory deficit in both
complex working memory measures, the Letter-Number
Sequencing and the PASAT, in methadone patients. In
early study Gritz et al. found no deficit in methadone
patients in “simple” working memory test, the Digit
Span from the Wechsler scales, in which the items
needs to repeated without organizing them [57]. How-
ever, in a more recent study Darke et al. found medium
effect size difference between methadone patients and
healthy controls in the same test [5]. Interestingly, in
abstinent opioid-dependent patients “simple” working
memory seems to be spared while complex working
memory performance is impaired [58,59]. Thus, it
would be informative to compare methadone patients
against abstinent opioid-dependent patients using both
simple and complex working memory measures.
Methadone patients were inferior to healthy controls
in verbal memory. Also, in the Darke et al. study
opioid-dependent patients treated with methadone for a
minimum 5 months were impaired relative to healthy
controls in verbal memory [5]. However, in the Curran
et al. study opioid-dependent patients treated with
methadone for a minimum 6 months were given their
normal dose, 33% increased dose, or placebo linctus;
and then tested 3-4 after the dose. No significant treat-
ment effect was seen, and the authors conclude that sin-
gle doses of methadone are devoid of verbal memory
effects among long-term methadone users. Thus, nega-
tive effect of methadone on verbal memory is not well-
confirmed.
Correlates of cognitive functioning in opioid substitution
treated patients
The most consistent finding of analyses of correlates of
cognitive functioning after 6 (T2) or 12 months (T3) in
treatment is that belonging to the methadone group
negatively associates with attention performance. How-
ever, as stated earlier in randomized or well-controlled
studies methadone patients, in general, have performed
at equal level than buprenorphine ones in tests measur-
ing attention. Thus, it is possible that patient selection
or other medication or substance abuse factor is affect-
ing the results in non-randomized studies, in which
methadone patients perform worse than buprenorphine
patients.
We hypothesized that the number of prescribed psy-
choactive drugs given to the patients would show nega-
tive correlations with performance in cognitive tests.
Our results, however, show three mild to moderate posi-
tive correlations between the number of psychoactive
drugs and verbal memory. Thus, the results do not con-
firm the hypothesis that the number of psychoactive
drugs as such would correlate negatively with cognitive
performance in OST patients. We hypothesized that
those with the high opioid substitution drug dose would
have higher BZD doses. The results were in line with
this hypothesis. Benzodiazepine use was very common
in both patient groups, and experimental studies have
shown that benzodiazepines, when given in combination
with opioid substitution drug may affect negatively
attention or verbal memory functioning [24]. Therefore,
we hypothesized that a negative correlation between the
BZD dose and cognitive measures would be seen.
Although one moderate negative correlation between
working memory measures and BZD dose is seen in our
clinical sample, this does not remain significant when
Rapeli et al. BMC Clinical Pharmacology 2011, 11:13
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two other correlates are taken into account. In sum,
substantial differences between test points and many
significant intercorrelations show that relationships
between medication variables and cognitive performance
are not easily discovered in clinical sample studies.
High frequency of substance abuse in the past month
was negatively associated with the working memory
measure with executive function component, the Letter-
Number Sequencing, at both test points. This finding is
line with studies reporting negative association between
working memory and recent substance abuse, possibly
affecting fluid intelligence in general [31,58,60]. In addi-
tion, frequency of substance abuse in the past month
correlates positively with BZD dose at both test points
(.36 - .50), and BZD dose correlated negatively with the
T2 Letter-Number Sequencing performance. Further-
more, the opioid substitution drug doses show moderate
or substantial correlations with the BZD doses. There is
temptation to suggest an association between the past
month frequent substance abuse, high opioid agonist
dose, high BZD dose, and impaired working memory
performance. Yet, our data do not allow controlling for
all these intercorrelations.
The hypothesis of negative effect of lifetime substance
abuse on cognitive performance was examined using
substance abuse onset ages and durations of abuse as
correlates for cognitive performance. Some negative cor-
relations emerged, but these were moderate at best.
Demographic variables have been shown to be impor-
tant correlates for cognitive performance in opioid-
dependent patients [10,36,37]. In our study, the only
consistent finding is the positive correlation between
Verbal IQ measured by the vocabulary test and verbal
memory. This relationship is not surprising because
vocabulary and verbal memory correlate moderately in
normal and clinical populations [61,62].
Limitations
The main limitation of part I of this study is the fact
that, while the opioid-dependent patient groups were
comparable to each other in variables of interest, our
healthy comparison group had hardly any medication or
substance abuse. Although these differences relate to the
‘dark side’ of addiction [63] they limit the specificity of
our results. Some of the cognitive deficits seen in
patients may be premorbid or related to early-onset sub-
stance abuse [64,65]. In order to examine these ques-
tions analyses of correlations were done in extended
population in part II of our study.
Because of high drop-out rate in our study we could
not use statistical methods to test causal relationships
in part II. On the other hand, comparison of correla-
tions from two testing points gives possibility to evalu-
ate their reliability and consistency. In case of
prescription opioid drug, drug screen do not show
extra doses. Thus, it is possible that opioid doses are
not fully accurate. While much is known about the
pharmacological comparisons between different BZDs,
the values of BZD equivalent doses are approximations
instead of precise values [39]. Alcohol use estimates
may not be fully accurate. These estimates were based
on information given by the participants. Breath alco-
hol analyzer or other objective test was used only
when considered necessary. Finally, our results do not
imply that functional capacity of an opioid-dependent
patient could be determined on the basis of his/her
drug group. Instead, validation of cognitive test battery
to a functional task, for instance driving a car, as well
as exploration of non-cognitive factors is needed [66].
Only then individual assessment of the functional
capacity can be made.
Conclusions
In conclusion, our results show again that in non-rando-
mized clinical studies buprenorphine patients tend to
perform better than methadone patients. The results do
not support the idea that there would be substantial
negative associations with medication variables and cog-
nitive performance among patients in OST. A longitudi-
nal study of opioid substitution treated patients who
switch from buprenorphine to methadone or vice versa
would be ideal in detecting cognitive effects of these
drugs and the roles of other clinical variables.
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Do drug treatment variables predict
cognitive performance in multidrug-treated
opioid-dependent patients? A regression
analysis study
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Abstract
Background: Cognitive deficits and multiple psychoactive drug regimens are both common in patients treated for
opioid-dependence. Therefore, we examined whether the cognitive performance of patients in opioid-substitution
treatment (OST) is associated with their drug treatment variables.
Methods: Opioid-dependent patients (N = 104) who were treated either with buprenorphine or methadone
(n = 52 in both groups) were given attention, working memory, verbal, and visual memory tests after they
had been a minimum of six months in treatment. Group-wise results were analysed by analysis of variance.
Predictors of cognitive performance were examined by hierarchical regression analysis.
Results: Buprenorphine-treated patients performed statistically significantly better in a simple reaction time test
than methadone-treated ones. No other significant differences between groups in cognitive performance were
found. In each OST drug group, approximately 10% of the attention performance could be predicted by drug
treatment variables. Use of benzodiazepine medication predicted about 10% of performance variance in working
memory. Treatment with more than one other psychoactive drug (than opioid or BZD) and frequent substance
abuse during the past month predicted about 20% of verbal memory performance.
Conclusions: Although this study does not prove a causal relationship between multiple prescription drug use
and poor cognitive functioning, the results are relevant for psychosocial recovery, vocational rehabilitation, and
psychological treatment of OST patients. Especially for patients with BZD treatment, other treatment options
should be actively sought.
Keywords: Opioid-dependence, Opioid agonist therapy, Pharmacotherapy, Psychotropic drugs, Neurocognitive
performance, Neuropsychological testing
Background
Opioid abuse affects about 0.4% of the world’s popula-
tion in the age range of 15–64 years [1]. Many of them
are dependent on opioids and fail to complete opioid
withdrawal. Standard treatment for these individuals is
opioid substitution treatment (OST), also known as opi-
oid maintenance treatment. However, opioid-dependence
is often complicated with psychiatric comorbidity. In
epidemiological studies, the joint lifetime prevalence of
opioid dependence and non-substance-use psychiatric
disorders has ranged from almost 50% up to 90%, while
the current prevalence of mood, anxiety, or personality
disorders is also high [2-4]. Consequently, polypharmacy
with psychoactive medication is a common practice in
OST [5-9]. While several studies have examined the
cognitive performance differences between buprenorphine-
vs. methadone-treated opioid-dependent patients [10-14],
few studies have examined the possible role of other psy-
choactive medications on the cognitive functioning of
* Correspondence: pekka.rapeli@hus.fi
1Unit for Drug Dependence. Department of Psychiatry, Helsinki University
Central Hospital, Helsinki, Finland
2Department of Mental Health and Substance Abuse Services, National
Institute for Health and Welfare (THL), Helsinki, Finland
Full list of author information is available at the end of the article
© 2012 Rapeli et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Rapeli et al. Substance Abuse Treatment, Prevention, and Policy 2012, 7:45
http://www.substanceabusepolicy.com/content/7/1/45
152 THL – Research 130 • 2014
Cognitive function in opioid substitution treated patients 
these patients. Thus, the results of current studies may
not be fully appropriate for multidrug-treated patients.
However, studies concentrating on this patient group
would be important because opioid-dependent patients
who are treated with multiple drugs tend to have lower
quality of life than those who only use an opioid agonist
drug [15]. A recent study concerning cannabis-
dependent individuals found that even relatively subtle
cognitive deficits that were seen in test performance can
be verified by those who know the affected individual well
[16]. Furthermore, at least for BZDs, even prescription
drug use has been shown to be associated with serious
health and safety risks [17,18]. Thus, if a drug treatment
variable is negatively associated with cognitive perform-
ance in OST patients this may have practical relevance.
Earlier we have reported that opioid-dependent
patients treated with buprenorphine/naloxone along
with BZDs do not show attention deficit as measured by
reaction time tasks, but their working memory and ver-
bal memory performance is worse than that of healthy
controls, at least for the first six months in treatment
[19]. Patients treated with methadone along with BZDs
show deficits in attention, working memory, and verbal
memory. In our later study, OST drug group member-
ship (buprenorphine vs. methadone) correlated signifi-
cantly with attention performance and improvement in
the Letter-Number Sequencing. Recent high-frequency
substance abuse was associated with poor performance
in working memory. Although the effects of the other
two highest correlates were controlled for, many other
variables could not be taken into account.
Our major aim in the current study was to examine
the predictive power of drug treatment variables on spe-
cific cognitive performance measures in a naturalistic
sample of multidrug-treated opioid-dependent patients.
There is some evidence that short-term use of high dose
methadone and BZD diazepam affects negatively on sim-
ple reaction times in opioid-dependent patients, but in
buprenorphine patients only high diazepam dose affects
negatively on reaction times [20,21]. Therefore, we
hypothesized that in buprenorphine patients, BZD treat-
ment (use vs. non-use or dose) but not buprenorphine
treatment variables (dose) would be negatively associated
with attention performance; while in methadone patients
both methadone and BZD treatment variables would
affect negatively on attention performance as measured
by reaction times. There is preliminary evidence that
buprenorphine may preserve working memory perform-
ance better than methadone [22,23]. Thus, we hypothe-
sized that having buprenorphine as the OST drug would
predict good working memory performance among
opioid-dependent patients. It has been shown that long-
term use of BZD drugs is associated with a wide range
of cognitive deficits [24]. Sedative and anticholinergic
effects have been reported for various psychiatric drugs
[25,26]. Consequently, patients treated with several psy-
choactive drugs typically perform worse in cognitive
tests than patients treated with a single drug [27,28]. We
therefore hypothesized that being on a BZD drug or on
a high number of prescribed psychoactive drugs (other
than opioid or BZD) would predict poor cognitive per-
formance in all measures among opioid-dependent
patients treated with buprenorphine or methadone.
Methods
The study participants were volunteer opioid-dependent
patients admitted for OST in the addiction clinics of the
greater Helsinki or Tampere area. Further inclusion
criteria were the following: aged 18–50 years, native
Finnish speaker, opioid-dependence diagnosis, and mini-
mum six months in OST with methadone, buprenor-
phine, or buprenorphine/naloxone. Exclusion criteria
were the following: uncontrolled polysubstance abuse,
acute alcohol abuse, or acute axis I psychiatric disorder
(e.g. acute phase of major depression, suicidality, hypo-
mania, mania, or psychosis), initiation of new psycho-
active drugs within the past week, severe brain injury,
chronic neurological disease, history of other than
substance-induced psychoses, epileptic seizures, human
immunodeficiency virus (HIV) infection, pregnancy, or
primary cognitive deficit (estimated IQ less than 85). To
ensure study eligibility, the clinical psychiatric interview
SCID I was conducted for each participant, and diagnos-
tic criteria from the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) were applied [29]. Estima-
tion of IQ was done by the neuropsychologist and it was
based on the vocabulary subtest of the Wechsler Adult
Intelligence Scale – Revised (WAIS-R) [30].
Each participant was screened for substance abuse by
urine sample on the day of testing and at least once in
the preceding month using the Nano5 test (from Ferle
Produkter AB; Helsingborg, Sweden). Participants show-
ing signs of current intoxication or binging on any sub-
stance of abuse and those having extra psychoactive
drug doses within the last 24 h were all excluded. Also,
those showing a positive drug screen for non-prescribed
opioids or BZDs were excluded. The study included 104
OST patients, with 29% of them coming from the longi-
tudinal sample used in the previous studies [5,13]. The
rest were new long-term treated opioid-dependent
patients. As shown in Table 1, buprenorphine-treated
patients were statistically significantly younger than
methadone ones, otherwise there were no significant
demographic differences between buprenorphine- vs.
methadone-treated patients.
The study was approved by both the independent
Ethical Committee of the Hospital District of Helsinki
and Uusimaa (permission 90/2001) and the A-Clinic
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Foundation. The study was conducted in accordance
with the 1964 Declaration of Helsinki. All participants
were able to read and understand the patient informa-
tion sheet, and signed the informed consent form. The
participants were free to discontinue participation in the
study whenever they wanted. They were paid €20 if they
attended all study visits.
Procedure
The patients were tested with cognitive measures be-
tween three to six hours after the administration of the
opioid substitution drug. In the buprenorphine group,
54% of the patients were given buprenorphine/naloxone.
Thus, they received a dose of naloxone in the ratio of
1:4 combined with their buprenorphine dose. When the
tablet is given sublingually the absorption of naloxone is
low and eliminates within the first hours [31]. It has
been shown that naloxone has minimal, if any effect, on
the bioavailability or pharmacokinetics of buprenorphine
[32,33]. Therefore, we combined patients using either
one of the buprenorphine compounds. Benzodiazepine
doses of oxazepam were converted to a diazepam
equivalent dose in the ratio of 3:1 [34]. Table 2 describes
the psychoactive medications used by the participants in
the 24-hour period before the testing. Medication doses
were compared by using the Mann–Whitney U test.
Medication frequencies were compared using the chi-
square test.
Statistical analyses
Group-wise comparisons of cognitive performance
between buprenorphine and methadone patients were
done by an analysis of variance (ANOVA). As our verbal
and visual memory tests lacked age-corrected norm
values and there was a significant difference between the
patient groups on age, an analysis of covariance
(ANCOVA) was used when testing these parameters. In
all group-wise comparisons, the normality assumptions
of the cognitive variables were first examined by
Shapiro-Wilk’s test and the homogeneity of variance by
the Levene’s test. When appropriate, analyses of the
main effects were interpreted using the Welch correc-
tion for heterogeneous variances. The data were also
screened for outlying values. There was strong positive
Table 1 Group demographics
Buprenorphine
(n = 52)
Methadone
(n = 52)
Group
comparisonsa
Age (M ± SD) 31 ± 7 35 ± 8 BN < M, p = .007**
Sex, female/male 18/34 20/32 p =.84
35%/65% 38%/62%
Verbal intelligenceb (M± SD) 100 ± 10 101 ± 10 p =.44
Education, patients with primary education/any secondary education 35/17 34/18 p =1.00
67%/33% 65%/35%
Substance abuse onset age, years (M ± SD) 16 ± 3 15 ± 2 p = .17
Patients with early onset of substance abusec 15 23 p =.31
29% 44%
Duration of OST, months (M± SD) 14 ± 7 17 ± 10 p = .08
Patients with more than 12 month in OST 30 33 p = .69
57% 63%
Number of cognitive testing
patients with one testing 34 (65%) 40 (77%) p =.28
patients with two or three testing 18 (35%) 12 (23%)
Patients with high-frequency substance abuse in the previous monthd 18 22 p =.55
35% 42%
Patients with positive drug screen at test 13 13 p = 1.00
25% 25%
Patients with the past month daily nicotine use 52 51% p =.50
100% 98%
Note. BN = buprenorphine patients, M = methadone patients.
aTested with t-test or Fisher’s Exact Test.
bEstimation based on the vocabulary subtest of the Wechsler Adult Intelligence Scale – Revised (WAIS-R) [30].
cConsidered as early up to 14 years of age.
dConsidered as high when three or more days a week. Alcohol use was taken into account if it was at least mean weekly 16 portions (12 g) for females and
24 portions for males or binge drinking occurred on any day.
**p < 0.01.
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correlation (.78) between the alertness task conditions;
hence in order to reduce the number of dependent
variables in the regression analysis, these measures
were combined by standardizing the values and pool-
ing them.
The assumption of a linear relationship between the
dependent variable and predictors was checked by plot-
ting the data (LOWESS curves) and by a lack of fit
test. In order to ascertain the linearity between
the dependent variable and predictors, many of the
predictors were transformed into dichotomous ordinal
variables. Buprenorphine doses up to 16 mg were con-
sidered as low dose and higher values as high. This
was done because the dose-dependence of buprenor-
phine pharmacodynamics is not linear [33]. BZD doses
were considered as low if lower than 20 mg and higher
if 20 mg or above. The number of prescribed psycho-
active drugs, other than OST or BZD drug, was consid-
ered as low up to one drug, and high if two or more
other drugs. Duration of OST was considered as short
if between six and twelve months, and long if above
this. Substance abuse in the previous month was
dichotomized as high vs. low frequency of abuse.
Abstinence or substance abuse up to two days a week
was considered as low-frequency substance abuse, and
values above this as high-frequency substance abuse.
This was based on findings showing that a mean three
days of substance abuse a week is associated with a
worsening of psychosocial and cognitive problems
[35-37]. Substance abuse age of onset was considered
as early onset up to 14 years of age, and as late onset
age if 15 years of age or higher. This was based on
findings showing that substance abuse onset before 15
years is especially hazardous to psychosocial and cogni-
tive development [38]. Education was considered as
low if no other than primary education had been com-
pleted, and as high if any secondary education had
been completed. Homogeneity of error variance (homo-
scedasticity) was confirmed graphically by plotting the
standardized residual against the predicted values. Inde-
pendence of errors was checked using the Durbin-
Watson test. Normality of residuals was checked by
normality plots and using the Shapiro-Wilk’s test. Because
our main interest was to examine drug treatment variables
Table 2 Medications given to patients within the last 24 h before testing in sample I
Buprenorphine
(n = 52)
Methadone
(n = 52)
Group comparison
p-values
Opioid agonist drug (M ± SD) 20 ± 6 mg − −
Buprenorphine (M ± SD) − 113 ± 49 mg
Patients using any psychoactive medication, other than opioid 42 (81%) 43 (83%) p = 1.00
Patients using any BDZ drug 37 (71%) 38 (73%) p = 1.00
diazepam 29 (56%) 24 (46%) p = .43
oxazepam 8 (15%) 14 (27%) p = .15
Benzodiazepine, diazepam equivalent dose (M ± SD) 22 ± 10 mg 21 ± 10 mg p = 0.77
The number psychoactive drugs, other than opioid or BZDa
(M ± SD) 1.2 ± 1.2 1.2 ± 1.2 p = .81
0, no. patients (%) 18 (35%) 19 (36%) p = 1.00
1 no. patients (%) 19 (37%) 13 (25%) p = .29
2 no. patients (%) 9 (17%) 13 (25%) p = .47
3 no. patients (%) 2 (4%) 5 (10%) p = .44
4 or more no. patients (%) 4 (7%) 2 (4%) p = .68
Patients using psychoactive drug, other than opioid or BZD
Any drugb 34 (65%) 33 (63%) p = 1.00
Anticonvulsants 6 (12%) 5 (10%) p = 1.00
Antidepressants 22 (42%) 13 (25%) p = .096
Antihistamines 6 (12%) 10 (19%) p = .42
Neuroleptics 7 (13%) 9 (17%) p = .79
Non-Benzodiazepine hypnotics 16 (31%) 19 (37%) p = .68
Non-opioid pain killers 4 (8%) 6 (12%) p = .74
aTested with t-test or Fisher’s Exact Test.
bThese included anticonvulsants (used as mood stabilizers), antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and
non-opioid pain killers.
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as predictors of cognitive performance, we employed
multiple sequential/hierarchical linear regression analysis.
First, the full model was examined as follows. Demo-
graphic variables, substance abuse variables, and the
number of tests (one vs. more than one), were first
entered into the model as control variables. Demo-
graphic variables included sex, level of education, and
age if the test values were not age-corrected initially.
Substance abuse variables included age of onset of sub-
stance abuse and frequency of substance abuse in the
past month. Control variables were retained in the subse-
quent reduced model only if they gave a statistically sig-
nificant (p < 0.05) contribution to the full model as a
block or individually. The number of tests was also
checked for the direction of association, with a positive
association indicating a practice effect of repeated test-
ing. Drug treatment variables included opioid drug
type (buprenorphine vs. methadone), BZD treatment
(yes vs. no), the number of psychoactive drugs (other
than opioid or BZD drugs), and duration of OST. All
drug treatment variables were entered sequentially into
the reduced model. Unless otherwise stated, explained
variance (R2) is reported as an adjusted value, and the
regression coefficient as a standardized value (beta).
All statistical analyses were done by SPSS statistical
software, version 20.0, with the exception of effect
size calculations, which were done by an effect size cal-
culator devised by Durham University, UK [39]. Effect
size estimations were corrected by Hedge’s correction for
sample size bias.
Cognitive tests
Attention was assessed by two tasks from the Test for
Attentional Performance (TAP) [40]. In the Alertness
task, the participant is instructed to respond to visual
stimuli by pressing a response key as quickly as possible.
The stimuli are presented without and with an auditory
warning signal. The ‘without’ condition is a simple
reaction time task reflecting tonic alertness. The ‘with-
auditory-warning-signal’ condition reflects both tonic
and phasic alertness. Age corrected values were used in
analyzing reaction time results.
Working memory was assessed by the Letter-Number
Sequencing task from the Wechsler Memory Scale-III.
In this test the participant is instructed to repeat letters
and numbers in specific order [41]. Age corrected values
were used.
Verbal memory was assessed by the Logical Memory
from the Wechsler Memory Scale-III [41]. However,
only immediate recall was tested and one story used. For
those participants tested repeatedly a different story was
given than previously. Visual memory was assessed by
the Benton Visual Retention Test [42].
Results
Group comparisons
Buprenorphine-treated patients showed statistically sig-
nificantly faster simple reaction times in comparison to
methadone-treated ones (the ‘without warning signal’
condition of the alertness test; (F(1, 100) = 7.54,
p = 0.028). No other significant differences emerged.
(All test results shown as an Additional file 1).
Predictors of attention performance
When control variables were first entered into the full
model they could predict only 1.3% of the performance
variance (2.8% in the sample) of the combined alertness
measure. In contrast, drug treatment variables as a block
could predict an additional 6.3% (9.7% in the sample).
The increment of drug treatment variables as a block
significantly improved the model (F(4, 93) = 2.59,
p = 0.041), but the full model remained statistically non-
significant (p = 0.12). None of the individual predictors
turned out to be significant in the full model. When the
reduced model including only the drug treatment variables
was tested, the OST drug group turned out to be the only
significant predictor in the model (beta = .20, t(97) = 2.09,
p = 0.040). The reduced model was significant (R2
(adjusted) = .056, F(4, 97) = 2.51, p = 0.047).
In order to examine the hypothesis that reaction times
are predicted by different drug treatment variables in
buprenorphine- vs. methadone-treated patients, the
reduced model including drug treatment variables was
used. As shown in Table 3, in the buprenorphine group,
being on BZD drug treatment was the only significant
predictor in the model. In the methadone group, the
high number of other psychoactive drugs was the best
and only significant predictor in the model. Adding
methadone dose to the model made it significant, al-
though the negative association of methadone dose was
not independently significant.
Predictors of working memory performance
The full model including control variables predicted
8.2% of the variance (16.4% in the sample). The model
as a whole was significant (F(8, 93) = 2.28, p = 0.028).
None of the control variables as a block or individually
gave a significant contribution to the model. Conse-
quently the control variables predicted a very low pro-
portion of the variance (−2.5%). In contrast, the drug
treatment variables as a block significantly improved the
full model (F(4, 93) = 4.13, p = 0.004) predicting 11.7%
of the variance above the control variables. Therefore,
the control variables were removed from the model. As
shown in Table 4, treatment with a BZD drug was nega-
tively associated with working memory performance
while being more than one year in OST was positively
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associated with working memory performance. The BZD
drug treatment effect was significant but the duration
of the treatment effect only approached significance.
Finally, the predictive power of the drug treatment vari-
ables including the BZD variables (type or dose) on
working memory performance was tested using the
group including only patients with BZD in their drug
regimen (n = 75). However, this model had very low pre-
dictive power on working memory (− 0.6%) and was sta-
tistically non-significant (p = 0.48).
Predictors of memory performance
When repeated testing was entered as the first variable
of the full model, it was significantly associated with
verbal memory performance (beta = .36, t (93) = 3.49,
p = 0.0007). Therefore, in order to eliminate the sig-
nificant effect of repeated testing from the model, a
model including only patients tested once was formed
(n = 74). Because demographic variables had minimal
effect in the initial full model (data not shown), this
block was dropped from the next model. Thus, the
model included substance abuse variables and drug
treatment variables. Because age of onset of substance
abuse (early vs. late) showed a non-significant effect
in the model, it was dropped from the final model.
As shown in Table 5, high-frequency substance abuse
and a high number of other psychoactive drugs (other
than opioid or BZD drug) were the only individual
Table 3 Hierarchical regression results for combined reaction times in the Alertness test by opioid drug group
Buprenorphine-treated patients (n = 51)
Predictors in the reduced model Step1 Beta (t-test)a,b Step2 Beta (t-test) Step3 Beta (t-test) Step4 Beta (t-test)
Drug treatment variables
BZD treatment (yes vs. no) .34 .36 .37 .38
t(49) = 2.51 t(48) = 2.64 t(47) = 2.60 t(46) = 2.60
p = 0.015* p = 0.011* p = 0.012* p = 0.013*
Buprenorphine dose (high vs. low)c -.16 -.17 -.19
The number of psychoactive drugs, other than
opioid or BZD (high vs. low)d
.05 .05
Duration of OST (long vs. short)e -.05
R2 (adjusted) .096 .103 .084 .069
Model (ANOVA)a F(1,49)= 6.29 F(2,48)= 3.88 F(3,47) = 2.58 p = 0.12
p = 0.015* p = 0.027* p = 0.065#
Change (ANOVA)a p = 0.24 p = 0.76 p = 0.71
Methadone-treated patients (n = 51)
Predictors in the reduced model Step1 Beta (t-test)a,b Step2 Beta (t-test) Step3f Beta (t-test)
Drug treatment variables
The number of psychoactive drugs, other than
opioid or BZD (high vs. low)
.27 # .30 * .31 *
t(49) = 1.92 t(48) = 2.21 t(47) = 2.09
p = 0.060# p = 0.032* p = 0.042*
Methadone dose BZD treatment (yes vs. no) .26 # .26 #
t(48) = 1.88 t(47) = 1.86
p = 0.066# p = 0.069#
-.02
R2 (adjusted) .051 .098 .073
Model (ANOVA)a F(1,49) = 3.71 F(2,48) = 3.72 F(3,47) = 2.43
p = 0.060# p = 0.032* p = 0.077 #
Change (ANOVA)a 0.066 # 0.90
aOnly p-value shown when p ≥ 0.10.
bSigns of beta values are reversed so that positive values refer to slowing of reaction times.
cConsidered as low up to 16 mg.
dConsidered as low up to one drug.
eConsidered as short when between six and twelve months.
fStep 4 is not shown because ‘the duration of OST’ variable correlated strongly (.61) with methadone dose producing a multicollinearity condition, and on a
theoretical basis it was excluded from the analyses.
*p < 0.05. #p < 0.10.
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significant predictors of verbal memory performance,
both of which were associated negatively with verbal
memory performance.
The full or reduced model predicting visual memory
showed only low and non-significant values for all pre-
dictors. Thus, the predictive power of the models
remained non-significant (p = 0.33 and p = 0.85,
respectively).
Discussion
The aim of the study was to examine the predictive
power of drug treatment variables on specific cognitive
Table 4 Hierarchical regression results for working memory (n = 102)
Predictors in the reduced model Step 1 Beta
(t-test)a
Step 2 Beta
(t-test)
Step 3 Beta
(t-test)
Step 4 Beta
(t-test)
Drug treatment variables
BZD treatment (yes vs. no) -.34 -.30 -.28 -.28
t(100) = 3.56 t(99) = 3.14 . t(98) = 2.83 t(97) = 2.81
p = 0.0006 *** p = 0.002 ** p = 0.006 * p = 0.006 *
Duration of OST (long vs. short)b .17 .17 .16
t(99) = 1.81 t(98) = 1.72 t(97) = 1.69
p = 0.074 # p = 0.088 # p = 0.094 #
The number of psychoactive drugs, other than opioid or BZD (high vs. low)c -.06 .07
OST drug type (buprenorphine vs. methadone) -.03
R2 (adjusted) .104 .124 .119 .100
Model (ANOVA)a F(1,100) = 12.68 F(2,99) = 8.12 F(3,98) = 5.52 F(4,97) = 4.12
p = 0.0006 *** p =0.0006 *** p = 0.002 ** p = 0.004 **
Change (ANOVA)a F (1,99) = 3.26
p = 0.074# p = 0.52 p = 0.76
aOnly p-value shown when p ≥ 0.10.
bConsidered as short when between six and twelve months.
cConsidered as low up to one drug.
***p < 0.00. **p < 0.01. *p < 0.05. #p < 0.10.
Table 5 Hierarchical regression results for verbal memory (n = 74)
Predictors in the reduced model Step 1 Beta
(t-test)a
Step 2 Beta
(t-test)
Step 3 Beta
(t-test)
Step 4 Beta
(t-test)
Step 5 Beta
(t-test)
Substance abuse variable
Frequency of the previous month substance
abuse (high vs. low)b
-.35 -.34 ** -.36 ** -.35 ** -.36 **
t(72) = 3.17 t(71) = 3.24 t(70) = 3.34 t(69) = 3.22 t(68) = 3.15
p = 0.002** p = 0.002** p = 0.0013** p = 0.002** p = 0.002**
Drug treatment variables
The number of psychoactive drugs, other than
opioid or BZD (high vs. low)c
-.32 -.35 -.35 -.35 **
t(71) = 3.06 t(70) = 3.15 t(69) = 3.13 t68) = 2.99
p = 0.003** p = 0.002** p = 0.003** p = 0.004**
BZD treatment (yes vs. no) .10 .10 10
OST drug type (buprenorphine vs. methadone) -.03 -.03
Duration of OST (long vs. short)d .01
R2 (adjusted) .110 .203 .199 .189 .177
Model (ANOVA) F(1,72) = 10.02 F(2,71) = 10.28 F(3,70) = 7.06 F(4,69) = 5.24 F(5,68) = 4.14
p = 0.002** p = 0.0001*** p = 0.0003 *** p =0.001*** p =0.002 *
Change (ANOVA)a F(1,71) = 9.37
p = 0.003 ** p = 0.40 p = 0.79 p = 0.91
aOnly p-value shown when p ≥ 0.10.
bConsidered as high when three or more days a week. Alcohol use was taken into account if it was at least mean weekly 16 portions (12 g) for females and
24 portions for males or binge drinking occurred on any day.
cConsidered as low up to one drug.
dConsidered as short when between six and twelve months.
***p <0.001. **p < 0. 01. *p < 0.05. #p < 0.10.
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performance measures in multidrug-treated opioid-
dependent patients. Also, we were interested in finding
out which of the possible significant associations turn
out as hypothesized. All patients had been in OST for at
least six months, and there were no major changes in
their drug regimen within the last week prior to the
study. Being on methadone-treatment predicted a rather
low, though statistically significant proportion (about
5%) of attention performance as measured by combined
reaction times in alertness tests. When opioid drug
groups were analyzed separately about 10% of attention
performance variance could be explained in both groups,
but the predictors were different. Being on BZD drug
treatment predicted about 10% of working memory per-
formance. Having more than one other psychoactive
drug (than an opioid or BZD drug) was negatively asso-
ciated with verbal memory performance. Also, recent
high-frequency substance abuse was negatively asso-
ciated with verbal memory performance. Together these
factors predicted about 20% of verbal memory perform-
ance variance.
Drug treatment variables as predictors of
attention performance
In buprenorphine patients co-treatment with a BZD
drug was negatively associated with attention perform-
ance, but buprenorphine dose had no significant effect.
This is in line with an experimental study showing
that BZD diazepam in combination with buprenorphine
affects negatively on reaction time, and the effect is
independent of the buprenorphine dose administered
[21]. In methadone patients the interpretation is more
complex. The highest predictor of slower reaction
time in methadone patients was treatment with more
than one other psychoactive drug than methadone or
BZD (beta .31). As hypothesized, there was a positive
slope between methadone dose and the combined reac-
tion time (.26) among methadone-treated patients. It is
known that rapid elevation of methadone dose reduces
peripheral blood oxygen saturation even among patients
highly tolerant to methadone [43]. Oxygen saturation
reduction has been associated with specific reaction
time deficit with relative sparing of other cognitive func-
tions [44]. Specific to methadone it has been shown by
Lintzeris et al. that when a higher than normal (150%)
dose of methadone is given to methadone-treated opioid-
dependent patients, reductions in oxygen saturation and
reaction time can be detected [21]. In sum, our results
give support to our hypotheses that among buprenor-
phine patients, co-treatment with a BZD drug is asso-
ciated negatively with attention performance. Methadone
treatment, especially when done together with other psy-
choactive drugs, can be negatively associated with atten-
tion performance. Of note here is the timing of the
possible opioid agonist effects: the drug plasma concen-
tration peaks between 0.5–4 h after the dose for bupre-
norphine and 2–6 h for methadone [31,45-47].
Drug treatment variables as predictors of working
memory performance
Our hypothesis of an advantage for buprenorphine in
working performance was not supported by the analyses.
Instead, treatment with a BZD drug was negatively asso-
ciated with working memory performance (Table 4).
When we analyzed the possible associations of BZD
drug type or dose, no significant associations were
found, and the model had very low predictive power.
Thus, we could not link the working performance with
BZD parameters. According to the meta-analysis, BZDs
in general have small or medium sized negative effects
on working memory functioning as measured by Cohen’s
d [24]. Although diazepam and oxazepam are probably
the most widely used BZDs, few studies have examined
their effects on a complex working memory measure like
Letter-Number Sequencing. One study found that 5 mg
of diazepam did not affect performance in the complex
working memory measure, the n-back task, although it
reduced frontal brain activation [48]. It is known that
high BZD doses have a general sedative effect and thus
have the potential to affect cognitive function, but the
development of tolerance may outweigh these effects
[49]. Notably, we observed that more than one year in
OST was positively, although weakly associated with
working memory performance (beta = .16). This obser-
vation is in line with our previous observation that
working memory improves in buprenorphine patients
between six and twelve months into OST [22].
Drug treatment variables as predictors of
memory performance
The high number of other psychoactive drugs (than opi-
oid and BZD) and recent high- frequency substance
abuse together predicted 20% of immediate verbal mem-
ory performance variance as measured by a story recall
task. There is some evidence that verbal memory is
more sensitive than other cognitive domains to the nega-
tive effects of multiple psychoactive drugs. This observa-
tion, however, may be specific to elderly patients and
anticholinergic drugs [50]. Even less is known about the
possible memory effects of psychoactive drug burden (as
measured by the number of drugs) in combination with
opioid agonists. In our recent longitudinal study, both
buprenorphine- and methadone-treated patients lagged
behind healthy controls in verbal memory performance
as measured by story recall [22]. Surprisingly, when we
extended the sample in the second part of our earlier
study, the difference to healthy controls disappeared.
Also, the correlation between the number of psychoactive
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drugs and verbal memory was positive, not negative, as in
the current study. In sum, although our finding of a nega-
tive verbal memory effect of more than one psychoactive
drug is in concert with our hypothesis, the specificity of
this finding cannot be shown with our data. The finding
that recent high-frequency substance abuse predicted
poor verbal memory is in accordance with studies show-
ing that recent frequent substance abuse impairs verbal
memory performance [51,52].
Implications
The results of this study suggest that cognitive impair-
ment in opioid-dependent patients is more common
when the patient is prescribed additional psychoactive
drugs. It is also likely, although not confirmed by our
study, that at least long-term BZD medication independ-
ently predicts cognitive impairment among multidrug-
treated opioid-dependent patients. Fortunately, during
OST many patients become more open to discussion
about medication side-effects. Patients may agree that
slower reaction times, associated in our study with co-
medication differently in buprenorphine- vs. methadone-
treated patients, can be disadvantageous in vehicle
driving and many sport activities. For instance there is
evidence OST patients being disproportionately involved
in road traffic crashes accidents [53,54]. Working
memory deficits, associated in our study with BZD co-
medication, are known to impair reading comprehen-
sion, learning, and reasoning [55]. BZDs interfere with
affective learning which is important in therapy [56].
Thus, combining BZD medication with psychological
treatment may actually be detrimental to the long-term
outcome of the treatment. The finding that one fifth of
story recall performance variance was explained by two
variables (high number of psychoactive drugs other than
opioid or BZD drug; and high-frequency substance abuse
in the previous month) is also relevant information. The
optimal functioning of verbal memory is a useful re-
source in everyday life, work, or education [57]. All these
facts may give the patient and prescriber a good reason
to consider non-pharmacological treatment choices in
place of polypharmacy. In some cases a realistic choice,
for the time being, is to change cognitively harmful drugs
like BZDs and tricyclic antidepressants for ones that are
less harmful to cognition [58,59].
Limitations
The distribution of the drug treatment variables, except
opioid drug groups, was unplanned, and turned out to
be highly skewed for some variables. As dichotomiza-
tions were used for these variables this reduces the stat-
istical power of the analyses [60]. Therefore our findings
about drug treatment effects are preliminary. Also, data
about opioid and BZD doses may not be fully accurate,
because drug screens do not detect extra doses of pre-
scription drugs. Thus, our results do not confirm a
causal association between drug treatment variables and
cognitive performance. Patients with a higher number of
prescribed drugs may have premorbid cognitive deficits
that explain the associations found. On the other hand,
longitudinal studies of patient groups other than OST
patients have shown that discontinuation of a BZD drug
regimen is followed by slow improvement in cognitive
function and quality of life but no negative effects on
sleep [61-64]. Our results support the idea that this
could also be possible in opioid-dependent patients
as well. There has been progress in the classification of
psychoactive drugs by their interaction potential with
buprenorphine or methadone [5,58] Alternatively, the
recently formed drug burden index could be a promising
tool for reducing the number of drug treatment variables
in clinical studies [65]. These tools were found, however,
to be unsuitable for our purposes. Negative cognitive
effects of psychoactive drugs usually diminish during
long-term use, and there may be differences in this
between attention and memory effects [22,59,66,67]. If
we had had data on length of drug use this would have
been an important variable in analysing drug treatment
effects. Our regression analyses were restricted only
to the main effects of variables. Perhaps interactions
between the variables could have explained more of the
variation in cognitive performance. This was not consid-
ered appropriate given the high number of variables.
Repeated testing of a third of patients is a potential con-
founder in the results, although after an interval of
six months between testing times, as was the case in
our study, the effects of repeated testing are trivial or
non-existent for most measures [68,69]. In our study
the verbal memory test, the Logical Memory test, was
an exception, and this was taken into account in the
analyses. Inclusion of psychiatric control variables, as
used by Loeber et al. or Prosser et al. when studying
cognitive performance in opioid-dependent patients,
would probably have raised the predictive power of the
analyses [70,71], and consequently the specificity of
the findings.
Conclusions
While the causal direction of effects cannot be assured
with these data, the results agree with the idea that spe-
cific prescription drug treatment variables may predict
poor cognitive performance in OST patients. Improve-
ment in quality of life, successful psychological treat-
ment, and work or education participation are common
goals in OST programs, each of which are associated
with good cognitive functioning. Our results suggest that
psychoactive polypharmacy may be contradictory to
these goals. This should give treatment practitioners and
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policy makers one more reason to monitor the rational-
ity of polypharmacy in OST.
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Introduction 
Opioid maintenance treatment, also known as opioid-substitution
treatment, with long-acting opioid like oral methadone or sublingual
buprenorphine is the standard treatment for opioid-dependence, if 
opioid withdrawal cannot be achieved [1]. While the OMT is effective in
reducing use of illegal opioids, psychosocial and psychiatric condition 
of the patients is often complicated, and the duration of the treatment 
is usually several years, or even decades. On the basis of systematic 
review, it has been concluded that short-term treatment with an opioid
drug is associated with cognitive deficits and reduces driving fitness [2].
Opioid-dependent patients, however, have high tolerance for opioid 
effects and many of them feel that they are competent to drive soon after 
a stable maintenance dose has been achieved. Yet, guidelines whether 
the patients are considered fit to drive vary a lot between countries, and
research knowledge of this issue is still showing inconsistent findings
between traffic crash data and experimental studies [3,4]. Statistics
show that opioid users have elevated risk of traffic accidents, while 
experimental evidence on effects of long-term OMT on driving is
limited [5].
Soon after initiation of OMT programs with methadone in 1965
the driving fitness of the patients became an issue of professional 
discussions and a research topic. Early studies concerning methadone 
treatment effects on driving ability were summarized by Vingilis in 2002 
by noting that the results are mixed, and firm conclusions cannot be
made [6]. One year later Fishbain reviewed the driving-related studies 
extensively and concluded that the majority of the studies indicate that 
either buprenorphine or methadone appears not to impair driving [7].
More recently some studies have shown that buprenorphine patients 
show slightly better performance than methadone patients in driving-
related cognitive tests [8,9]. However, an advantage of buprenorphine 
over methadone has not been seen in all studies [10,11]. A recent
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Abstract
Introduction: Patients in stable Opioid Maintenance Treatment (OMT) for opioid-dependence are, as a rule, 
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whom the majority were multidrug-treated patients.
Material and methods: The assessment included a standard on-road driving test, clinical neurological 
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impairment (n=10). This group included patients treated with opioid agonist alone or along with the second generation 
antidepressant or lithium. The second group included patients with probable drug-related driving impairment (n=12). 
All patients in this group were given at least one benzodiazepine (BZD) drug,
Results: In neurological evaluation all OMT patients met the basic requirements for driving. In the driving test, 
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than the improbable group (p=0.021, 0.001, and 0.028, respectively). Two cases with ‘probable drug-related driving 
impairment’ are described in detail.
Conclusions: The results of this case series give support for the notion that OMT patients in stable treatment, in 
?????????????????????????? ??????????????????????????????????????????????? ?????????????????????????????????????????
pharmacological and non-pharmacological information is essential, as shown by two case descriptions.
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review concluded that there are still several shortcomings for making 
a general recommendation about driving fitness of OMT patients [4]. 
These include lack of actual driving performance tests, great variability 
in driving-related cognitive tests, and the lack of inclusion of other 
prescription drugs commonly used by the patients. Further study taking 
these problems into consideration was called for. In order to reduce the 
gaps in current knowledge we made a study in which driving ability of a 
natural sample of OMT patients was comprehensively assessed. 
The present study had two major aims. First, driving fitness of 
opioid maintained patients was determined using comprehensive 
assessment methods including an on-road driving test. The result of the 
on-road driving test in a normal traffic was treated as the main variable 
of interest, because it is kept as the most valid assessment of the driving 
fitness [12,13]. Our second aim was to examine if co-medications given 
to OMT patients are associated with driving performance or driving-
related cognitive test results. 
Material and methods
The study participants were unpaid volunteer opioid-dependent 
patients admitted for OMT in the addiction clinics of Helsinki, Tampere 
or Jyväskylä area. Inclusion criteria were the following: age 18−50 
years, native Finnish speaker, opioid-dependence diagnosis, being at 
least of twelve months in OMT with buprenorphine, buprenorphine/
naloxone, or methadone, and a valid driver’s license. Exclusion criteria 
were the following: current polysubstance or alcohol abuse, acute axis 
I psychiatric morbidity other than substance abuse related, change in 
current drug doses or initiation of a new psychoactive drug within the 
past week, severe brain injury, chronic neurological disease, history of 
other than substance-induced psychoses, epileptic seizures, Human 
Immunodeficiency Virus (HIV) infection, pregnancy, or primary 
cognitive deficit. To ensure study eligibility, a clinical psychiatric 
interview was conducted for each participant using diagnostic criteria 
from the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV) [14]. Each patient was screened by a urine sample for substance 
abuse on the day of testing and at least once in the preceding month. 
Participants showing signs of current intoxication or binge on any 
substance of abuse, and those with any non-prescribed psychoactive 
drug dose within 24 h, were all excluded.   
Buprenorphine/naloxone was given to the majority (78%) of 
buprenorphine treated patients. Thus, they received a dose of naloxone 
in the ratio of 1:4 combined with their buprenorphine dose. When 
the tablet is given sublingually the absorption of naloxone is low and 
eliminates within the first hours [15]. It has been shown that naloxone 
has minimal, if any effect, on the bioavailability or pharmacokinetics 
of buprenorphine [16,17]. Therefore, patients using either one of the 
buprenorphine compounds were combined. 
Research ethics
The study was approved by the independent Hospital District of 
Helsinki and Uusimaa Ethical Committee (permission 90/2001). The 
study was conducted in accordance with the 1964 Declaration of 
Helsinki. All study participants were able to read and understand the 
patient information sheet, and signed the informed consent form. The 
participants were free to discontinue their participation in the study 
whenever they wanted. No information about individual assessment 
results were passed to the authorities. 
Procedure
The patients were tested with between 10 am and 2 pm, which 
means between two to seven hours after the administration of their 
opioid maintenance drug. They were divided into two groups (Table 
1) based on their co-medication related risk of impairment on driving. 
This was based on the assumption that opioid agonist pharmacotherapy 
with buprenorphine or methadone, as a single drug, has only minor, 
if any, negative effect on driving performance [7,18]. The first group 
included all patients with no co-medication or with one additional drug 
with a low risk for driving impairment. Additional drugs classified as 
having a low risk for driving-impairment included new generation 
antidepressants and lithium [19,20]. The second group included patients 
using drugs for which there is relatively high risk for impairment on 
driving like benzodiazepines [21,22]. Possibilities for drug interactions 
were taken into account when classifying patients into these groups [23-
26]. For the further analyses benzodiazepine doses of were converted to 
a diazepam equivalent using Bazire’s equivalence table [27].
Driving experience information and the patient’s own view about 
driving safety was asked by a questionnaire devised for the study. 
Variable
Group
Statistical
comparisons
between
groups1
Patients with 
improbable
drug-related
driving
impairment
(n=10)
Patients with 
probable
drug-related
driving
impairment
(n=12)
Age (years) 32 ± 8 38 ± 9 p=0.08
???
Female (%)
Male (%)
40%
60%
17%
83%
p=0.35
Opioid agonist drug
Buprenorphine (%)/
Methadone (%)
Buprenorphinedose (M ± SD)
Methadonedose (M ± SD)
80% / 20%
18 ± 7 mg
115 ± 21 mg
8% / 92%
24 mg
133 ± 30 mg
p=0.002 **
-
-
Time in OMT (years) 3 ± 1 3 ± 2 p=0.75
Other drugs than opioid 
agonist
Any drug (%)
Antihistamine (%)
BZD (%)2
Dose (M ± SD)
Mood stabilizer (%)3
Neuroleptic (%)
Non-BZD hypnotic (%)
Second generation 
antidepressant (%)
Tricyclic antidepressant (%)
40%
0%
0%
-
10%
0%
0%
30%
0%
100%
10%
100%
24 ± 22 mg
17%
25%
25%
8%
10%
p=0.09
p=1.00
p=0.0001 ***
-
p=1.00
p=0.22
p=0.22
p=0.29
p=1.00
Patients reporting opioid 
overdose (%) 10% 17% p=1.00
Patients reporting minor 
head injury (%) 40% 42% p=1.00
1???????????????????????????????
2BZD equivalent doses [28].
3These included anticonvulsants and lithium.
Table 1: Group comparisons on demographic and treatment variables.
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In addition the patients evaluated distressing effects of 22 driving 
situations by choosing one out of four alternatives (not at all, somewhat, 
quite, or very distressing); and reported frequency of 22 driving errors 
by choosing one out of four alternatives (never, occasionally, quite 
often, almost every time while driving) [28]. More information about 
the topics covered by the questionnaires are presented in connection 
with case descriptions. 
On-road driving assessment
On-road driving assessment was done by the same licensed driving 
instructor for each participant. The one-hour driving test using a car 
took place in city traffic during normal day- time instead of rush hours. 
The test included various car driving tasks typically done in driving 
evaluations devised for neurological patients [28]. This evaluation was 
meant for driving a car for non-professional purposes [29]. The driving 
instructor completed two formal evaluation sheets. Driving errors were 
classified as nonhazardous vs. hazardous errors. An error was classified 
as a hazardous one, if it exposed anyone on the road to a potential 
risk. The marking of the errors was done according to the manual 
developed by the Finnish Vehicle Administration [30]. In addition 
driving instructor gave a performance score for 11 driving domains. 
The scoring was done as follows: 5=definitely strong, 4=strong, 3=either 
strong or weak, 2=weak and 1=definitely weak [27]. Driving domains 
which were evaluated included the following: awareness of other 
vehicles and road users, appropriate adjustment of speed, signaling one’s 
intentions, predictability, correctness of driving lines, understanding 
correct driving order, e.g., at intersections, junctions, roundabouts, 
ability to follow traffic lights and traffic signs, distance to other vehicles 
and obstacles , vehicle handling and vehicle control, independence and 
ability to map out one’s driving, ability to anticipate events in traffic, and 
concentration on driving. Finally, an overall safety assessment was done 
using four levels [31]. The highest level of safety was ‘safe driver in all 
conditions’ meaning that she/he was considered as being a safe driver in 
all places and any road conditions. The next best level was ‘safe driver in 
normal conditions’ meaning that she/he was considered as a safe driver 
in all places but good road conditions were essential for safe driving. 
Third level was ‘safe driver only in the best conditions’ meaning that 
she/he was considered as a safe drive only in familiar places and in good 
road conditions. The last level was ‘unsafe driver’ meaning that driving 
was considered unsafe in all places and road conditions. According to 
the Finnish driving regulations drivers belonging to the classes ‘safe 
drivers in all conditions’ or ‘in normal conditions’ are considered fit to 
drive a car.
Medical examinations 
Medical examinations included a clinical neurological status and 
a traffic vision evaluation done by a neurologist. In addition, a clinical 
psychiatric interview, based on DSM-IV axis 1 criteria, was done as 
described earlier. Psychiatric drug regimen of patients was not changed, 
and the severity of psychiatric disorder was used only as an exclusion 
criterion. Thus the groups were not compared in regards to psychiatric 
comorbidity. 
Driving-related cognitive tests 
Cognitive examinations done by a neuropsychologist included 
the Determination, Peripheral Perception, Signal Detection, Stroop 
Interference, and Tachistoscopic Traffic Perception tests from the 
computer-aided Vienna Test System [32-36]. The purpose of the 
Determination test is to measure ‘Resilience of Attention and reaction 
speed under conditions of sensory stress’. The examinee is instructed to 
identify color or sound stimuli and react to them pressing correspondent 
response button using a response panel. Adaptive version S1 was used. 
The number of correct reactions was chosen as the variable of interest 
as it has been shown to have specific predictive value for driving ability 
[37]. 
The purpose of the Peripheral Perception test is to assess the 
perception and processing of peripheral visual information. The 
examinee is instructed to focus on a simple visual tracking task 
presented on the computer screen. Simultaneously, she/he should 
react by pressing a pedal whenever they notice critical visual stimuli 
presented at their left or right periphery. ‘Tracking deviation’, a measure 
of divided attention, was used as a score [37]. 
The purpose of the Signal test is to test long-term selective attention, 
namely differentiation of relevant visual signals from the irrelevant 
ones. The score variables for the Signal test were median reaction time 
and the number of correct or delayed reactions. Test form S1 was used. 
The purpose of the Stroop test is to evaluate inhibition of overlearned 
responses instead of consciously controlled ones. Poor performance 
in the Stroop interference condition has been shown to be associated 
with inappropriate reactions in critical traffic situations [38]. Therefore, 
variable ‘median reaction time in interference condition’ was used as a 
score. Version S4 (light pen) was used. 
The purpose of the Traffic Perception Test is to evaluate visual 
observation ability and skill in obtaining an overview, and also of visual 
orientation ability and speed of perception. The examinee is shown 
20 pictures of traffic scenes, for one second each. Then she/he has to 
select from a list that contains five different items those ones that she/
he remembers to have seen in the picture. The number of correctly 
answered lists constitutes the main variable ‘Overview’. This was chosen 
as a score of interest [37, 39]. Version S1 was used. 
In evaluating the cognitive results age-independent norms were 
used, whenever possible, and scores that were not above the 16th 
percentile were considered to indicate problems in driving ability 
similarly to the ‘passed test’ methodology developed by Gaertner et 
al. [40]. Test norms from the norm sample were used except in the 
Peripheral Perception and Stroop tests where general adult norms were 
used for determining performance percentiles. Driving instructor was 
not informed about the results of the medical or cognitive examinations.
Statistical analyses
Group comparisons between patient groups were performed using 
the non-parametric Mann-Whitney U tests or Fisher’s exact test. 
Correlations between driving test scores and drug doses were analyzed 
by the non-parametric Spearman’s rho. In all analyses alpha-level was 
set to 0.05. Two-tailed tests from the Statistical Package for Social 
Sciences (SPSS) version 20.0 were used. 
Results 
Sample characteristics
Twenty –six volunteer patients met all the inclusion criteria. Four 
volunteer patients were excluded on the basis of a positive drug screen 
for illicit drug use. The mean age of included patients was 35 ± 9 
years. Two thirds (68%) of them were male. The mean duration since 
obtaining a driver’s license was 13 ± 9 years. One fifth of the patients 
(19 %) had professional car driving in their driving history. All patients 
had driven a car during the last year. Group-wise statistics of driving 
variables is shown in table 2. The mean time in OMT was 3 ± 2 years. 
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Forty-one percent of the patients were treated with buprenorphine and 
59% with methadone. However, after the patients were divided into two 
groups on the basis of probability of drug-related driving impairment, 
nearly all buprenorphine patients were in the improbable group and 
nearly all methadone patients in the probable group. This difference was 
statistically significant (Table 1). Two thirds of the patients, as a whole, 
(67%) were treated with other psychoactive drug than opioid agonist 
drug. About half of them (55%) were given any BZD drug (including 
both anxiolytic and hypnotic prescriptions). In fact, having a BZD 
drug became the variable which showed precise 0/100% distribution 
between improbable vs. probable drug-related driving impairment 
(respectively). As shown in table 1 nearly all patients with ‘improbable 
drug-related driving impairment’ were treated with buprenorphine and 
had no BZD co- medication whereas the patients with ‘probable drug-
related driving impairment’ were almost all treated with methadone 
along with a BZD drug. Case-wise listing of all drugs given to the 
two drug groups can be seen in tables 3 and 4. (Of note here, is the 
observation that all four patients with positive drug screen would have 
been in the group ‘probable drug-related driving impairment’ because 
of their BZD drug prescriptions). Patients with ‘probable drug-related 
driving impairment’ tended to be elder than the ones in the ‘improbable’ 
group, but this difference only approached significance. 
On-road driving 
In the on-road test the patients scored mean 49 ± 5 points out of 55 
points. According to the driving instructor’s overall safety assessment 
83% of the patients belonged to highest safety class, ‘safe drivers in all 
conditions’ and 11% were ‘safe drivers in normal conditions’. Thus, in 
total 94% of them were considered fit to drive a car for non-professional 
purposes (all except one patient). Forty-one percent of them drove the 
route without any driving error and 83% without any hazardous error. 
As shown in table 2 significant between groups differences favoring the 
‘improbable’ group were seen in total score of the on-road driving test 
and domains evaluated as ‘weak’ or ‘either weak or strong’. Also, it can 
be noted that 5 out of 6 patients treated with opioid agonist only drove 
the test route without committing any error in the route (cases 1-5 in 
table 3). On the contrary, all three patients that made any hazardous 
error in the driving test belonged to the group with ‘probable drug-
related driving impairment’ (cases A, B and 21 in table 4).
Patients with ‘probable drug-related driving impairment’ scored 
statistically significantly lower in the on-road driving test (U=25.5, 
p=0.021). Figure 1 shows the group means and the individual data 
for scores for both groups in the on-road driving test. As can be seen 
in figure 1 there was much more variance in the driving test score 
among the patients with ‘probable drug-related driving impairment’. 
Both buprenorphine and methadone dose negatively correlated with 
the driving test score (-.21, ns and -.68, p = .01, respectively). Figure 2 
shows the correlation between methadone dose and driving test score. 
When the correlation between BZD equivalent dose and driving test 
was analyzed in the methadone patients, also that was negative (-0.40), 
but a non-significant one. 
Medical examinations and cognitive-driving related tests
All patients (n=22) showed normal visual fields and were 
considered neurologically fit to drive. In driving-related cognitive tests, 
which are not mandatory in Finnish driving assessment for special 
populations such as OMT patients, about half of the patients (48%) 
passed every test above the 16th percentile criterion. As shown in table 
2 the group with ‘probable drug-related driving impairment’ had more 
non-passed cognitive tests than the improbable group (78% vs. 25%). 
Figure 3 shows test-wise comparisons between the groups on cognitive 
tests. In group-wise raw score comparisons of cognitive driving-related 
tests two significant between groups differences were seen. Patients 
with ‘probable drug-related driving impairment’ scored significantly 
55
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* = p < 0.05
*
Figure 1: The relationship between medication groups and on-road driving test 
score.
Test
Group
Statistical
comparisons
between groups1
Patients with 
improbable drug-
related driving
impairment
(n=10)
Patients with 
probable drug-
related driving
impairment
(n=12)
Years since 
obtaining a driver’s 
license
10 ± 9 14 ± 10 p = .25
Driven kilometers 
within the last year, 
participants with 
more than 5000 
km (%)
50% 25% p=0.38
Patients with 
professional driving 
??????????????
17% 20% p=1.00
Driving test score
?????????????????? 51 ± 3 46 ± 5 p=0.021 *
Safe drivers in 
all conditions 
according to 
driving instructor’s 
assessment (%)
90% 83% p=1.00
Participants driving 
the test route with 
no errors (%)
60% 55% p=1.00
Participants
showing no ‘weak’ 
or ‘either weak 
or strong’ driving 
domains (%)
0 % 58 % p=0.005 **
Participants
passing all driving-
related cognitive 
tests above ‘pass 
level’ (%)2
78% 25% p=0.024 *
1???????????????????????????????
2n=9
Table 2: Group comparisons on driving variables.
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worse than the improbable group in the Determination test measuring 
‘resilience of attention under conditions of sensory stress’ (number of 
correct reactions, respectively 429 ± 97 vs. 512 ± 56; U=23.0, p=0.028). 
In the Stroop interference test, the mean of median reaction time was 
significantly slower in patients with ‘probable drug-related driving 
impairment’ in relation to other patients (1.35 ± 0.55 sec vs. 0.88 ± 0.11 
sec; U=97.5 p=0.001, respectively).
Finally, in order to elucidate the individual variance of driving 
fitness and potential factors affecting on it, two cases from the group 
‘probable drug-related driving impairment’ are described. 
Case A: When A came to driving test he was 47 years old. He had 
been in methadone maintenance treatment for 4 years, current dose 
150 mg. In addition he was prescribed BZD oxazepam 90 mg a day (30 
mg every 8 h) as an anxiolytic. In the evening he took a third prescribed 
medicine, tricyclic antidepressant doxepine 100 mg, as a somnolent 
and antidepressant. His depression, however, was considered as being 
in partial remission. A had obtained a driver’s license 20 years ago, and 
he said that he had driven since then ‘a huge amount of kilometers both 
home and abroad’, all non-professional driving. In a medical inspection 
he was considered fit to drive. During the four years in MMT, A had 
gained 35 kg weight. His BMI index was 36.2, which is considered as 
obese according to the World Health Organization classification, but 
this was not considered as health problem affecting driving fitness. 
Case A admitted that earlier his driver’s license had been cancelled 
by the police for driving under influence of drugs. He got back his driver’s 
license a year ago. He estimated that since then he has driven around 
50000 km. He admitted that occasionally he is very tired when driving 
and that is very distressing for him. He reported that occasionally he 
finds himself making some driving errors like driving too fast or slow, 
or drives too close to the middle line. He considered that these never 
cause sudden danger on the road. Overall, A considered himself as a 
safe driver in all conditions. 
In driving test A made two errors. He almost drove against red 
lights, and this was considered as a hazardous error. He made a second 
error in noticing a traffic sign telling to change a lane a little bit late, 
but he handled the situation very smoothly. In the driving test his 
total score was 44. This was below the mean of the all patients. Yet, 
driving instructor’s overall assessment of driving safety was ‘safe in all 
conditions’. This was motivated by his excellent vehicle handling and 
smooth and calm handling of problems encountered. Problems were 
found to be related to minor slowing of initial reactions. A’s slowness 
was evident in cognitive tests as well. His performances were below 
critical values in the Determination and Stroop interference tests (Table 
3). 
Case B: When B came to driving test he was 26 years old. He had 
been in methadone maintenance treatment for 3 years, current dose 
105 mg. In addition he was prescribed BZD clonazepam 6 mg as an 
anxiolytic, valproate 1000 mg for controlling borderline personality 
disorder related mood swings and neuroleptic levomepromazine 100 
mg and zopiclone 7.5 mg for sleeping. B had suffered a minor head 
injury about 5 years ago when he had been intoxicated. He reported 
a black out and confusion period of few minutes. He was taken into 
hospital for a medical check-up and because he was orientated and in 
a good condition, he was soon released. B had obtained driver’s license 
9 years ago. He estimated that he had driven during the last year about 
20000 kilometers. He felt none of the driving conditions given in 
the questionnaire would be quite or very distressing for him. He did 
report that he hardly ever notices vehicles that drive behind him, and 
occasionally makes some other driving errors. Yet, he considered that 
his driving errors never cause sudden danger on the road, and he is a 
safe driver in all conditions. 
In driving test he made ten errors. Five of his driving errors were 
classified as hazardous ones (three in keeping safe distance to other 
road-users, one in perception, and one driving order). Another five 
were classified as non-hazardous. His overall score in the driving test 
(43 points) was below the mean of all patients, and his performance 
was evaluated as poor in two driving components, namely ‘distance to 
other road users’ and ‘concentration on driving’. The driving instructor’s 
overall assessment of driving safety was ‘safe only in the best conditions’. 
This was motivated by his impulsive driving style and violations in 
keeping within speed limitations or safe distances to other road-users. 
His vehicle handling, however, was considered excellent. In cognitive 
testing B passed only three out of six tests above the critical value of 16th 
percentile. Non-passed tests included the Determination, Peripheral 
perception, and the Stroop tests (Table 3). 
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Figure 3: Percentage of passed driving-related cognitive tests by group.
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Figure 2: Correlation between methadone dose and driving test score.
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Discussion 
This study was planned to examine driving fitness of stable OMT 
patients. All included patients had been at least one year in treatment 
and were tested negative in drug screens for substance abuse at least for 
one month. As expected more than half of the patients in the sample 
were currently using some other psychoactive prescription drug too. 
The main finding in our case-series of 22 OMT patients is that all expect 
one of the patients was found fit to drive according to an on-road driving 
test which followed official guidelines used for all drivers in Finland. 
In order to assess the association between co-medications and driving 
fitness, the patients were divided into two groups according to their 
probability of drug-related driving impairment. The analyses showed 
that the patients with ‘probable drug-related driving impairment’ 
scored lower than other patients in the sum of on-road driving tests 
and in two out of six driving-related cognitive tests. 
Patients with improbable drug-related driving impairment
The sample included five patients using only buprenorphine (cases 
1-4 and 6) and one methadone (case 5). Five of them (except one 
Case code
 Age / Sex
Minor head injuries
or opioid overdoses
Drugs:
OMT drug
BZD drugs
Other drugs
Driving safety:
Instructors overall 
assessment based 
on on-road driving 
test
On-road driving test 
score?????????????
Errors in on-road 
driving test (number 
??????????????????
Domain-wise
evaluation
of driving
performance
(number of either
strong or weak
driving domains/ 
number of weak 
driving domains)
Driving-related
cognitive tests
(non-passed test; 
percentile)
Driving experience: 
Driver’s license 
Professional driving 
???????????
 The last year driving
Case 1
27 years / male
Minor head injury +
Buprenorphine 24 mg
  -
  -
Safe   driver in all 
conditions
????????????????? ???
score)
No errors in the on-road 
driving test
All driving domains  
evaluated as 
strong2
All cognitive tests 
above pass level 3
Nine years since driver’s 
license
One  year of professional 
driving
20000 km of driving during the 
last year
Case 2
28 years / male
-
Buprenorphine 16 mg 
–
Safe driver in all 
conditions’
53 points
No errors in the on-road 
driving test
All driving domains  
evaluated as strong
All cognitive tests 
above pass level
10 years since driver’s license
No professional driving 
1000 km of driving during the 
last year
 Case 3 
32 years / male 
–
Buprenorphine 10 mg
 –
Safe  driver  in all 
conditions
53 points
No errors in the on-road 
driving test
All driving domains  
evaluated as strong
All cognitive tests
above pass level
Two years since driver’s 
license
No professional driving 
15000 km of driving during the 
last year
Case 4 
38 years /male 
Minor head injury +
Buprenorphine 24 mg
–
Safe  driver in all 
conditions
53 points
No errors in the on-road 
driving test
All driving domains  
evaluated as strong
All cognitive tests 
above pass level
19 years since driver’s license 
No professional driving 
30000 km of driving during the 
last year
Case 5 
33 years / female 
Opioid overdose +
Methadone 130 mg
–
Safe driver in all 
conditions
51 points
No errors in the on-road 
driving test
All driving domains  
evaluated as strong
All cognitive tests 
above pass level
One year since driver’s 
license
No professional driving 
5000 km of driving during the 
last year
 Case 6
 28 years / female 
–
Buprenorphine 12 mg
 –
Safe driver in all 
conditions
53 points
Three non-hazardous 
errors
All driving domains  
evaluated as strong
All cognitive tests 
above pass level 
Two  years since driver’s 
license
No professional driving 
12000 km of driving during the 
last year
Case 7
28 years /  male 
–
Buprenorphine 16 mg
–
Mirtatzapine 30 mg
Safe driver in all 
conditions
50 points
No errors in the on-road 
driving test
All driving domains  
evaluated as strong
Signal test (number 
of correct or 
delayed reactions ;  
percentile 10)
Nine years since driver’s 
license
No of professional driving
3000 km of driving during the 
last year
Case 8 
49 years / male 
Minor head injury +
Methadone 100 mg
–
Lithium 600 mg 
Safe driver in all 
conditions
51 points
One non-hazardous 
error
All driving domains  
evaluated as strong
Signal Test below 
pass level (reaction 
times; percentile 
10)
32 years since driver’s license 
5 years  of professional driving
5000 km of driving during the 
last year
Case 9 
30 years / female 
–
Buprenorphine 28 mg
–
?????????????????
Safe  driver in all 
conditions
47 points
 Two non-hazardous 
errors
All driving domains  
evaluated as strong
All cognitive tests 
above pass level
10 years since driver’s license 
No professional driving
5000 km of driving during the 
last year
Case 10 
 28 years / female 
Minor head injury +
Buprenorphine 12 mg
–
Essitalopram10 mg
Safe driver in normal 
conditions
47  points
Three non-hazardous 
errors
All driving domains  
evaluated as strong
All cognitive tests 
above pass level
 6 years since driver’s license 
No professional driving
3000 km of driving during the 
last year
1??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????-
phine before methadone.
2?????????????????????????????????
3Determination and Stroop tests are missing.
Table 3: Summary of cases with improbable drug-related driving impairment1.
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Case
Age / Sex
Minor head injuries
opioid overdoses
Drugs:
OMT drug
BZD drugs
Other drugs
Driving safety:
Instructors overall 
assessment based 
on on-road driving 
test
On-road driving test 
score??????????
Errors in on-road 
driving test (number 
??????????????????
Domain-wise evaluation 
of driving  performance
(number of either strong 
or weak driving domains/ 
number of weak driving 
domains)
Driving-related
cognitive tests
(non-passed test; 
percentile)
Driving experience:
Driver’s license
Professional driving 
??????????
The last year driving
Case 11
32 years / male
—
—
Methadone 105 mg
??????????????
Valproate 100 mg
Zopiclone 7.5 mg d
Safe driver in all 
conditions
??????????????? ???
score)
No errors in the on-
road driving test
All driving domains
evaluated as strong2
Stroop test below 
pass level  (percentile 
12)
Nine years since driver’s 
license
Two years of 
professional driving
30000 km of driving 
during the last year
Case 12
50 years male
Minor head injury +
Opioid overdose +
Buprenorphine 24 mg
Temazepam 20 mg as-needed 
taken in the night before the 
testing.  Diazepam 10 mg as-
needed. Reports no Diazepam 
use within the last 24 h
–
Safe driver in all 
conditions
52  points
No errors in the on-
road driving test
All driving domains
evaluated as strong no 
errors in the on-road driving 
test
Signal test (reaction 
time) and  Stroop 
tests below pass level 
(percentiles 10 and 
11, respectively)
29 years since driver’s 
license
No professional driving
40000 km of driving 
during the last year
Case 13
31 years / male
–
Methadone 120 mg
Clonazepam 5.5 mg
??????????????????
Quetiapine 25 mg
Safe driver in all 
conditions
51 points
No errors in the on-
road driving test
All driving domains
evaluated as strong
Stroop test below 
pass level  (reaction 
time; percentile 1)
Five years since driver’s 
license
No professional driving
20000 km of driving 
during the last year
case 14
42 years / female
–
Methadone 130 mg
Diazepam 10 mg
Zopiclone 7.5 mg
safe driver in all 
conditions
48 points
no errors in the on-
road driving test
One driving domain 
evaluated as either strong 
or weak
All cognitive tests 
above pass level
20 years since driver’s 
license
No professional driving
10000 km of driving 
during the last year
Case 15
37 years /& male
–
Methadone 110 mg
Temazepam 10 mg
Risperidone 2 mg
safe driver in all 
conditions’
48 points in the driving 
test
no errors in the driving 
test
All driving domains
evaluated as strong
Signal Test below 
pass level (number 
of correct or delayed 
reactions:
percentile 1)
15 years since driver’s 
license
No professional driving
15000 km of driving 
during the last year
Case 16
24 years/ male
–
Methadone 85 mg
??????????????
Safe driver in all 
conditions’
47 points in the driving 
test
No errors in the driving 
test
All driving domains
evaluated as strong
All cognitive tests 
above pass level
6 years since driver’s 
license
No professional driving
20000 km of driving 
during the last year
Case 17
50 years / female
–
Methadone 135 mg
??????????????
??????????????????
Safe driver in all 
conditions
48 points in the driving 
test
Two non-hazardous 
errors in the driving 
test
One driving domain 
evaluated as either strong 
or weak
Stroop test below 
pass level (percentile 
5)
32 years since driver’s 
license
No professional driving
5000 km of driving 
during the last year
Case A3
47 years / male
–
Methadone 150 mg
??????????????
??????????????
Safe driver  in all 
conditions
44 points in the driving test
One non-hazardous 
error and 
onehazardous error in 
the driving test
Two driving domains 
evaluated as either strong 
or weak
Determination
and Stroop tests 
below pass level
(percentiles  4 and 1, 
respectively)
20 years since driver’s 
license
No professional driving
5000 km of driving 
during the last year
Case 19
female
39 years
Minor head injury +
Methadone 140 mg
Clonazepam 6 mg
—
Safe driver in all 
conditions
42 points in the driving 
test
Five non-hazardous 
errors in the driving 
test
Five  driving domains 
evaluated as either strong 
or weak
Signal (reaction time) 
and Stroop tests 
below pass level (; 
percentiles 16 and 8, 
respectively)
17 years since driver’s 
license
No professional driving
2500 km of driving 
during the last year
Case 20
37 years / male
Minor head injury +
Opioid overdose +
Methadone 125 mg
??????????????
–
Safe driver in all 
conditions
43 points in the driving 
test
Eight non-hazardous 
errors in the driving 
test
Three  driving domains 
evaluated as either strong 
or weak
All cognitive tests 
above pass level
19 years since driver’s 
license
10 years of professional 
driving
1000 km of driving 
during the last year
Case 21
50 years/ male
Minor head injury +
Methadone 190 mg
??????????????
Diazepam 20 mg as-needed 
(Reports no Diazepam use within 
the last 24 h)
Safe driver  in 
normal conditions
37 points in the driving 
test
Five non-
hazardouserrors and 
onehazardous error in 
the driving test
Seven  driving domains 
evaluated as either strong 
or weak
Stroop  test below 
pass level (percentile 
6)
Two years since driver’s 
license
No professional driving
15000 km of driving 
during the last year
case B
27 years /male
Minor head injury +
Methadone 170 mg
Clonazepam 6 mg
Levomepromatzine 100 mg
Valproate 1000 mg
Zopiclone 7.5 mg
Safe driver only in 
best conditions
38 points in the driving 
test
Five non-hazardous 
???????????????
hazardous errors
Three  driving domains 
evaluated as either strong 
or weak and two as weak
Determination , 
Peripheral perception, 
and  Stroop tests 
below pass level (
percentiles 5, 13 and 
1, respectively)
Nine years since driver’s 
license
No professional driving
20000 km of driving 
during the last year
1??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
buprenorphine before methadone.
2?????????????????????????????????
3?????????????????????????????????????????????????
Table 4: Summary of cases with probable drug-related impairment on driving1.
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buprenorphine-only patient) drove the test route without any error. 
Also, they performed every driving-related cognitive test above critical 
values (one buprenorphine patient missed data from two cognitive 
tests). The excellent driving-related performance of these patients is 
a one more piece of evidence for the notion that long-term treatment 
with long-acting opioid agonist drug, as a single drug, has only minor if 
any effect on driving fitness [7,41,42]. 
Four of the patients were considered to belong to the group with 
‘improbable drug-related driving impairment’ although they had one 
additional psychoactive drug in their drug regimen. All of them were 
considered fit to drive, and none of them made any hazardous errors 
while driving although one of them scored below the critical value in 
one driving-related cognitive test. Three of them used buprenorphine 
along with a second-generation antidepressant. According to the 
current knowledge second-generation antidepressant do not cause 
of driving impairment, or interact with buprenorphine [19,24]. One 
methadone-treated patient used lithium. Although the issue of driving-
related cognitive effects of long-term lithium therapy is not fully 
resolved, controlled studies or traffic crash data do not show significant 
driving impairment among lithium users [21,43,44]. Pharmacokinetic 
interaction between methadone and lithium is unlikely [26]. 
Pharmocodynamic interaction is possible in some conditions like 
in pain behaviour [44,45]. Yet, there is no evidence that long-term 
treatment with methadone and lithium would show significant 
interaction in other areas of behaviour [24,26].
Patients with probable drug-related driving impairment
All patients in this group used a BZD drug along with methadone 
and in one case with buprenorphine. It is known that a BZD drug as such 
may affect negatively on driving fitness [46,47]. Moreover, the effects of 
opioid agonist drugs like methadone or buprenorphine are amplified by 
BZD co-drugs which promote GABA in the brain [48]. Thus, combined 
effects of these are possible, and this may show dose-effect as suggested 
by the figure 2. The association is, however, is not well evidenced by 
our data, because some patients in this group were also given a third 
or fourth drug with probable negative effect on driving. These included 
BZD-like hypnotic zopiclone, antihistamine hydroxyzine and first 
generation antidepressant doxepin [49,50]. Thus, it is not surprising 
that that patients with ‘probable drug-related driving impairment’, as 
a group, performed worse in driving test and in the determination test 
and the Stroop test. There was, however, a large within-group variation 
in performance in these measures. This may indicate that some of the 
patients had developed full tolerance to the negative drug effects. 
Individual assessment of driving fitness: Combining 
pharmacological and non-pharmacological information
The European research-based recommendation of driving 
assessment for patients treated with drugs states that each OMT patient’s 
driving fitness should be individually evaluated, and in cases of other 
prescription drugs, tests of cognitive performance are recommended, 
especially for elder patients [51]. Although significant information about 
driving fitness of the patient can be inferred from her/his medication 
and cognitive performance, also other information needs to be taken 
into account. To illustrate this detailed information of two cases were 
reported in the results section. The first case (middle-aged patient A) 
has methadone 150 mg, oxazepam 90 mg, and doxepin 100 mg in his 
drug regimen. The driving impairing effect of each of these drugs is 
well-known for drug naïve individuals [52,53]. Yet, individual variation 
of drug effects is large and most of the patients using these drugs will 
eventually become tolerant for the negative effects on driving [54]. In 
the case of A it can be noted that his doses for all drugs were relatively 
high, and it is possible that full tolerance for the day-time sedative 
effects of these may not have developed. In accordance with this idea 
two studies have reported that higher methadone dose is associated 
with longer reaction times in tasks measuring alertness or vigilance 
[55,56]. Furthermore, tricyclic antidepressant doxepin has potential for 
long-term negative effects on driving-related cognitive testing [50]. In 
medical examination of A nothing was found that would be make him 
unfit to drive. A, however, belongs to the minority of methadone-treated 
patients that had gained a lot of weight during the MMT. There is no 
consensus if this is a pharmacological side-effect of methadone or solely 
related to life-style changes among patients [57,58]. Case A complained 
daytime drowsiness as well, which is a common side effect of full opioid 
agonists [59]. It is known that methadone shows large interindividual 
variability both in pharmacokinetics and pharmacodynamics [60-62]. 
Thus, it is possible that A gets more side-effects from his drug regimen 
than OMT patients in general. In spite of this, A was considered fit 
to drive. It is likely that his long driving experience gave him some 
advantage in on-road assessment. Anyhow, his case illustrates that a 
methadone patient who is treated with three psychotropic medications 
can be considered fit to drive a car for non-professional purposes. 
The second case description (young patient B) illustrates the 
common problem of weighing the effects of psychiatric comorbidity 
on driving. His drug regimen included methadone 105 mg, BZD 
valproate 1000 mg, levomepromazine 100 mg, and non-benzodiazepine 
zopiclone 7.5 mg. Driving impairment caused by clonazepam and 
levomepromazine, or zopiclone are well-known when any of these are 
given to drug naïve individuals [63]. On the other hand, individual 
variation in drug effects on driving-related functioning is large, and 
impairment caused by the long-term use of drugs cannot be reliable 
determined in individual cases [64]. In regards to valproate, there is no 
firm evidence for driving impairment [20,42]. B has been diagnosed 
a borderline personality disorder, and has sustained a probable mild 
head injury, although the latter has not been formally diagnosed. Both 
of these conditions are known to be associated with impulsive driving 
behavior [65,66], which was the main problem in B’s driving. Notably, 
in cognitive driving-related testing B passed only three out of six 
tests above the critical value of 16th percentile. In sum, a case like B 
shows that the current state of the patient’s comorbidity may be more 
important for assessing her/his driving fitness than are drugs used to 
treat it.
Strengths and limitations of the current study 
A case-series study, like the current study, is useful in situations in 
which randomization of variables is not possible for ethical reasons, 
such as giving a patient long-term drug treatment that is not necessary 
for her/him [67]. Another strength of case-series approach is the 
possibility of taken the extreme cases into consideration, whom are in 
randomized studies often treated as outliers [68]. However, a case-series 
is not useful in in discovering causal relationship between variables. For 
instance, our case-series is skewed in regards of distribution between 
buprenorphine, methadone, and co-medications. Although we found 
dose effect for methadone on driving (Figure 2), there also was a 
negative association between BZD equivalent dose and driving test 
score. Although these results fit well with the idea that methadone and 
BZDs have combined negative effects on driving, our case series should 
be seen as hypothesis generating, but not as hypothesis confirming. 
Controlled comparisons between buprenorphine- vs. methadone-
treated patients need to follow our results. Further limitations include 
the following. Psychiatric comorbidity could not be taken into account 
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in our statistical analyses, and this should be taken into account when 
interpreting our results. Comorbid conditions, age and sex also are 
important factors for driving safety [69]. A case has been reported in 
which, astabile long-term OMT patient apparently lost his tolerance 
for the sedative effects of methadone dose of 130 mg at the age of 66 
without any concomitant health deterioration; and the patient returned 
to normal after reduction of the dose to 60 mg [70]. Keeping this in 
mind, our results may be best applicable to the OMT patients up to 
early middle-age. Finally, our study dealt with driving performance 
more than with driving behavior, and both should be taken into 
accounting in assessing driving safety [71]. However, on-road driving 
test gives some information about driving behavior as well; and cases 
like B show that it is often the driving behavior in real-life traffic which 
determines driving safety. 
Conclusions
The results of this case series agree with earlier studies in showing 
that OMT patients in stable treatment, as group, can be considered 
fit to drive. On the other hand, for OMT patients with long-term 
psychiatric or neurological comorbidity, or probable problematic 
polypharmacy, individual assessment combing pharmacological and 
non-pharmacological factors is still essential. For this purpose multi-
professional team-work like described in this study is an ideal solution. 
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